


**CUMULATIVE
SUPPLEMENT 3
MARCH 2023**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

43rd EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2023

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

43rd EDITION

**Cumulative Supplement 3
March 2023**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi
DRUG PRODUCT LISTS		
	Prescription Drug Product List	1-1
	OTC Drug Product List	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
	Orphan Products Designations and Approvals List	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Lists	A-1
B.	Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

43rd EDITION

**CUMULATIVE SUPPLEMENT 3
MARCH 2023**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOB/PRA) of any changes or corrections. The DOB/PRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ALLERGAN (ALLERGAN)	ABBVIE INC (ABBVIE)
ALLERGAN HOLDINGS UNLTD CO (ALLERGAN HOLDINGS)	ABBVIE INC (ABBVIE)
ALLERGAN INC (ALLERGAN)	ABBVIE INC (ABBVIE)
ALLERGAN SALES LLC (ALLERGAN)	ABBIE (ABBVIE)
ALLERGAN SALES LLC (ALLERGAN)	ABBVIE INC (ABBVIE)

ALEOR DERMACEUTICALS LTD (ALEOR DERMACEUTICALS)	ALEMBIC PHARMACEUTICALS LTD (ALEMBIC PHARMS)
EMCURE PHARMACEUTICALS LTD (EMCURE PHARMS)	AVET LIFESCIENCES LTD (AVET LIFESCIENCES)
EMCURE PHARMACEUTICALS LTD (EMCURE PHARMS LTD)	AVET LIFESCIENCES LTD (AVET LIFESCIENCES)
HERITAGE PHARMA LABS INC (HERITAGE PHARMA)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
HERITAGE PHARMA LABS INC DBA AVET PHARMACEUTICALS LABS INC (HERITAGE PHARMA AVET)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

² Please consult the Active Section of the Orange Book for information on other strengths.

therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucml29689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2022</u>	<u>MAR</u> <u>2023</u>	<u>JUN</u> <u>2023</u>	<u>SEP</u> <u>2023</u>	<u>DEC</u> <u>2024</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	21983 (12.4%)	22398 (12.3%)			
MULTISOURCE	19265 (87.6%)	19639 (87.7%)			
THERAPEUTICALLY EQUIVALENT	19165 (87.2%)	19554 (87.3%)			
NOT THERAPEUTICALLY EQUIVALENT	100 (0.5%)	85 (0.4%)			
EXCEPTIONS ⁴	46 (0.2%)	46 (0.2%)			
NEW MOLECULAR ENTITIES APPROVED	8	19			
NUMBER OF APPLICANTS	1211	1222			

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABIRATERONE ACETATE

TABLET;ORAL
ABIRATERONE ACETATE

>A>	AB	FLORIDA	500MG	A215086	001	Mar 23, 2023	Mar	NEWA
	AB	TEVA PHARMS USA	500MG	A210726	001	Jan 26, 2023	Jan	NEWA

ACARBOSE

TABLET;ORAL
ACARBOSE

	@	DASH PHARMS	25MG	A091053	001	Jan 06, 2011	Feb	CAHN
	@		50MG	A091053	002	Jan 06, 2011	Feb	CAHN
	@		100MG	A091053	003	Jan 06, 2011	Feb	CAHN

ACETAMINOPHEN

SOLUTION;INTRAVENOUS
ACETAMINOPHEN

>D>	AP	ZYDUS PHARMS	1GM/100ML (10MG/ML)	A216467	001	Oct 25, 2022	Mar	DISC
>A>	@		1GM/100ML (10MG/ML)	A216467	001	Oct 25, 2022	Mar	DISC

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL
APADAZ

>D>	+	KVK TECH INC	325MG;EQ 4.08MG BASE	N208653	002	Jan 04, 2019	Mar	DISC
>A>	+ @		325MG;EQ 4.08MG BASE	N208653	002	Jan 04, 2019	Mar	DISC
>D>	+		325MG;EQ 6.12MG BASE	N208653	001	Feb 23, 2018	Mar	DISC
>A>	+ @		325MG;EQ 6.12MG BASE	N208653	001	Feb 23, 2018	Mar	DISC
>D>	+		325MG;EQ 8.16MG BASE	N208653	003	Jan 04, 2019	Mar	DISC
>A>	+ @		325MG;EQ 8.16MG BASE	N208653	003	Jan 04, 2019	Mar	DISC

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL
BUTALBITAL AND ACETAMINOPHEN

AA		SENORES PHARMS	300MG;50MG	A214088	001	Apr 07, 2022	Jan	CAHN
AA			325MG;25MG	A214088	002	Apr 07, 2022	Jan	CAHN
AA			325MG;50MG	A214088	003	Apr 07, 2022	Jan	CAHN

ACETAMINOPHEN; IBUPROFEN

>A>								
>A>								
>A>	+	AFT PHARMS LTD	325MG;97.5MG	N209471	001	Mar 01, 2023	Mar	NEWA

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

>D>	AB	AMNEAL PHARMS	325MG;37.5MG	A090485	001	Dec 09, 2009	Mar	CHRS	
>A>	AB	!	325MG;37.5MG	A090485	001	Dec 09, 2009	Mar	CHRS	
>D>		ULTRACET							
>D>	AB	+	JANSSEN PHARMS	325MG;37.5MG	N021123	001	Aug 15, 2001	Mar	DISC
>A>		+ @		325MG;37.5MG	N021123	001	Aug 15, 2001	Mar	DISC

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL
ACETAZOLAMIDE

AB		INDICUS PHARMA	500MG	A090779	001	Jul 14, 2011	Feb	CMFD
>A>	AB		125MG	A207503	001	Apr 30, 2020	Jan	DISC
			250MG	A207503	002	Apr 30, 2020	Jan	DISC
>A>	AB	ZYDUS	125MG	A211069	001	Apr 04, 2023	Mar	NEWA
>A>	AB		250MG	A211069	002	Apr 04, 2023	Mar	NEWA

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC
ACETIC ACID

	@	CHARTWELL RX	2%	A040166	001	Jul 26, 1996	Jan	CAHN
--	---	--------------	----	---------	-----	--------------	-----	------

ACYCLOVIR

	CREAM; TOPICAL							
	ACYCLOVIR							
AB	ZYDUS LIFESCIENCES	5%		A206770	001	Feb 28, 2023	Feb	NEWA
	SUSPENSION; ORAL							
	ACYCLOVIR							
>A> AB	MSN	200MG/5ML		A217393	001	Mar 09, 2023	Mar	NEWA

ALBUTEROL SULFATE

	TABLET; ORAL							
	ALBUTEROL SULFATE							
AB	DASH PHARMS NATCO	EQ 2MG BASE		A072894	002	Jan 17, 1991	Feb	CAHN
AB	!	EQ 4MG BASE		A072894	001	Jan 17, 1991	Feb	CAHN

ALBUTEROL SULFATE; BUDESONIDE

	AEROSOL, METERED; INHALATION							
	AIRSUPRA							
+	! ASTRAZENECA	EQ 90MCG BASE/INH; 80MCG/INH		N214070	001	Jan 10, 2023	Feb	CAHN
+	! BOND	EQ 90MCG BASE/INH; 80MCG/INH		N214070	001	Jan 10, 2023	Jan	NEWA

ALVIMOPAN

	CAPSULE; ORAL							
	ALVIMOPAN							
AB	PAR PHARM	12MG		A216843	001	Jan 24, 2023	Jan	NEWA

AMANTADINE HYDROCHLORIDE

	CAPSULE; ORAL							
	AMANTADINE HYDROCHLORIDE							
AB	STRIDES PHARMA	100MG		A209047	001	Jun 07, 2017	Feb	CTEC
	TABLET; ORAL							
	AMANTADINE HYDROCHLORIDE							
AB	STRIDES PHARMA	100MG		A209035	001	Jun 09, 2017	Feb	CTEC

AMIKACIN SULFATE

	INJECTABLE; INJECTION							
	AMIKACIN SULFATE							
@	FRESENIUS KABI USA	EQ 50MG BASE/ML		A205605	001	Dec 09, 2015	Feb	DISC
!	HIKMA	EQ 50MG BASE/ML		A063313	001	Apr 11, 1994	Feb	CTEC

AMINO ACIDS

	INJECTABLE; INJECTION							
	FREAMINE HBC 6.9%							
@	B BRAUN	6.9% (6.9GM/100ML)		N016822	006	May 17, 1983	Jan	DISC
	FREAMINE III 10%							
@	B BRAUN	10% (10GM/100ML)		N016822	005		Jan	DISC
	FREAMINE III 8.5%							
@	B BRAUN	8.5% (8.5GM/100ML)		N016822	004		Jan	DISC
	HEPATAMINE 8%							
@	B BRAUN	8% (8GM/100ML)		N018676	001	Aug 03, 1982	Jan	DISC

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

	INJECTABLE; INJECTION							
	PROCALAMINE							
@	B BRAUN	3%; 26MG/100ML; 3GM/100ML; 54MG/100ML; 41MG/100ML; 150MG/100ML; 200MG/100ML; 120MG/100ML		N018582	001	May 08, 1982	Jan	DISC

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

	INJECTABLE; INJECTION							
	FREAMINE III 8.5% W/ ELECTROLYTES							
@	B BRAUN	8.5%; 110MG/100ML; 230MG/100ML; 10MG/100ML; 440MG/100ML; 690MG/100ML		N016822	007	Jul 01, 1988	Jan	DISC

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

	INJECTABLE; INJECTION							
	FREAMINE III 3% W/ ELECTROLYTES							
@	B BRAUN	3%; 54MG/100ML; 40MG/100ML; 150MG/100ML; 200MG/100ML; 120MG/100ML		N016822	003		Jan	DISC

AMINOCAPROIC ACID

SOLUTION; ORAL

AMINOCAPROIC ACID

>A>	AA	TARO PHARMS	0.25GM/ML	A214458	001	Mar 24, 2023	Mar	NEWA
>D>	AA	VISTAPHARM	0.25GM/ML	A212814	001	Feb 26, 2020	Mar	DISC
>A>		@	0.25GM/ML	A212814	001	Feb 26, 2020	Mar	DISC

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPoxide

TABLET; ORAL

LIMBITROL

>A>		+ @ CHARTWELL RX	EQ 12.5MG BASE;5MG	N016949	001		Mar	CAHN
>D>		+ @ HERITAGE PHARMS INC	EQ 12.5MG BASE;5MG	N016949	001		Mar	CAHN
			LIMBITROL DS					
>A>		+ @ CHARTWELL RX	EQ 25MG BASE;10MG	N016949	002		Mar	CAHN
>D>		+ @ HERITAGE PHARMS INC	EQ 25MG BASE;10MG	N016949	002		Mar	CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB		COREPHARMA	EQ 2.5MG BASE	A076719	001	May 23, 2007	Feb	CAHN
AB			EQ 5MG BASE	A076719	002	May 23, 2007	Feb	CAHN
AB			EQ 10MG BASE	A076719	003	May 23, 2007	Feb	CAHN

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

@ WISCONSIN

3.75mCi-260mCi/ML

A204356 001 Dec 18, 2014 Feb DISC

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

@ CHARTWELL RX

125MG/5ML

A062059 001

Jan CAHN

@

250MG/5ML

A062059 002

Jan CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		ANI PHARMS	2.5MG; 2.5MG; 2.5MG; 2.5MG	A205401	002	Jan 22, 2019	Feb	CMFD
AB		ASCENT PHARMS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A214959	001	Sep 29, 2021	Feb	CTNA
AB			2.5MG; 2.5MG; 2.5MG; 2.5MG	A214959	002	Sep 29, 2021	Feb	CTNA
AB			3.75MG; 3.75MG; 3.75MG; 3.75MG	A214959	003	Sep 29, 2021	Feb	CTNA
AB			5MG; 5MG; 5MG; 5MG	A214959	004	Sep 29, 2021	Feb	CTNA
AB			6.25MG; 6.25MG; 6.25MG; 6.25MG	A214959	005	Sep 29, 2021	Feb	CTNA
AB			7.5MG; 7.5MG; 7.5MG; 7.5MG	A214959	006	Sep 29, 2021	Feb	CTNA
AB		GRANULES	1.25MG; 1.25MG; 1.25MG; 1.25MG	A217027	001	Jan 23, 2023	Feb	CTNA
AB			1.25MG; 1.25MG; 1.25MG; 1.25MG	A217027	001	Jan 23, 2023	Jan	NEWA
AB			2.5MG; 2.5MG; 2.5MG; 2.5MG	A217027	002	Jan 23, 2023	Feb	CTNA
AB			2.5MG; 2.5MG; 2.5MG; 2.5MG	A217027	002	Jan 23, 2023	Jan	NEWA
AB			3.75MG; 3.75MG; 3.75MG; 3.75MG	A217027	003	Jan 23, 2023	Feb	CTNA
AB			3.75MG; 3.75MG; 3.75MG; 3.75MG	A217027	003	Jan 23, 2023	Jan	NEWA
AB			5MG; 5MG; 5MG; 5MG	A217027	004	Jan 23, 2023	Feb	CTNA
AB			5MG; 5MG; 5MG; 5MG	A217027	004	Jan 23, 2023	Jan	NEWA
AB			6.25MG; 6.25MG; 6.25MG; 6.25MG	A217027	005	Jan 23, 2023	Feb	CTNA
AB			6.25MG; 6.25MG; 6.25MG; 6.25MG	A217027	005	Jan 23, 2023	Jan	NEWA
AB			7.5MG; 7.5MG; 7.5MG; 7.5MG	A217027	006	Jan 23, 2023	Jan	NEWA
AB		LANNETT CO INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A214403	001	Nov 26, 2021	Feb	CMFD
AB		@	1.25MG; 1.25MG; 1.25MG; 1.25MG	A214403	001	Nov 26, 2021	Feb	CTNA
AB			2.5MG; 2.5MG; 2.5MG; 2.5MG	A214403	002	Nov 26, 2021	Feb	CMFD
AB		@	2.5MG; 2.5MG; 2.5MG; 2.5MG	A214403	002	Nov 26, 2021	Feb	CTNA
AB			3.75MG; 3.75MG; 3.75MG; 3.75MG	A214403	003	Nov 26, 2021	Feb	CMFD
AB		@	3.75MG; 3.75MG; 3.75MG; 3.75MG	A214403	003	Nov 26, 2021	Feb	CTNA
AB			5MG; 5MG; 5MG; 5MG	A214403	004	Nov 26, 2021	Feb	CMFD
AB		@	5MG; 5MG; 5MG; 5MG	A214403	004	Nov 26, 2021	Feb	CTNA
AB			6.25MG; 6.25MG; 6.25MG; 6.25MG	A214403	005	Nov 26, 2021	Feb	CMFD
AB		@	6.25MG; 6.25MG; 6.25MG; 6.25MG	A214403	005	Nov 26, 2021	Feb	CTNA
AB			7.5MG; 7.5MG; 7.5MG; 7.5MG	A214403	006	Nov 26, 2021	Feb	CMFD
AB		@	7.5MG; 7.5MG; 7.5MG; 7.5MG	A214403	006	Nov 26, 2021	Feb	CTNA

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		LANNETT CO INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A215565	001	Jul 08, 2022	Feb	CMFD
AB			1.875MG; 1.875MG; 1.875MG; 1.875MG	A215565	002	Jul 08, 2022	Feb	CMFD
AB			2.5MG; 2.5MG; 2.5MG; 2.5MG	A215565	003	Jul 08, 2022	Feb	CMFD

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		3.125MG;3.125MG;3.125MG;3.125MG	A215565	004	Jul 08, 2022	Feb	CMFD
AB		3.75MG;3.75MG;3.75MG;3.75MG	A215565	005	Jul 08, 2022	Feb	CMFD
AB		5MG;5MG;5MG;5MG	A215565	006	Jul 08, 2022	Feb	CMFD
AB		7.5MG;7.5MG;7.5MG;7.5MG	A215565	007	Jul 08, 2022	Feb	CMFD

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

	@ STERISCIENCE	EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Jan	CAHN
	@	EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A201025	003	Apr 09, 2014	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A201025	004	Apr 09, 2014	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A202198	001	Apr 07, 2014	Jan	CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

AP	STERISCIENCE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A201024	001	Apr 07, 2014	Jan	CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A201024	002	Apr 07, 2014	Jan	CAHN
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A202197	001	Apr 07, 2014	Jan	CAHN

APALUTAMIDE

TABLET;ORAL

ERLEADA

	+ JANSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018	Feb	CHRS
	+!	240MG	N210951	002	Feb 17, 2023	Feb	NEWA

APIXABAN

TABLET;ORAL

APIXABAN

AB	ZYDUS PHARMS	2.5MG	A210185	001	Feb 27, 2023	Feb	NEWA
AB		5MG	A210185	002	Feb 27, 2023	Feb	NEWA

APREMILAST

TABLET;ORAL

APREMILAST

>A>	AB	SHILPA	10MG	A211774	001	Apr 07, 2023	Mar	NEWA
>A>	AB		20MG	A211774	002	Apr 07, 2023	Mar	NEWA
>A>	AB		30MG	A211774	003	Apr 07, 2023	Mar	NEWA
	@ TEVA PHARMS USA INC	10MG	A211897	001	Aug 18, 2022	Feb	DISC	
	@	20MG	A211897	002	Aug 18, 2022	Feb	DISC	
	@	30MG	A211897	003	Aug 18, 2022	Feb	DISC	

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION

ARFORMOTEROL TARTRATE

AN	RITEDOSE CORP	EQ 0.015MG BASE/2ML	A214736	001	Mar 02, 2022	Feb	CMFD
----	---------------	---------------------	---------	-----	--------------	-----	------

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

	@ COREPHARMA	50MG	A201514	001	Mar 25, 2019	Feb	CAHN
	@	150MG	A201514	002	Mar 25, 2019	Feb	CAHN
	@	250MG	A201514	003	Mar 25, 2019	Feb	CAHN

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN

>A>	@ CHARTWELL RX	325MG;200MG	A089594	001	Mar 31, 1989	Mar	CAHN
>D>	@ HERITAGE PHARMS	325MG;200MG	A089594	001	Mar 31, 1989	Mar	CAHN

ASPIRIN; METHOCARBAMOL

TABLET;ORAL

ROBAXISAL

>D>	@ ROBINS AH	325MG;400MG	N012281	001		Mar	CRLD
>A>	+ @	325MG;400MG	N012281	001		Mar	CRLD

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

>A>	AB	ZYDUS PHARMS USA INC	10MG	A079017	007	Apr 05, 2023	Mar	NEWA
-----	----	----------------------	------	---------	-----	--------------	-----	------

ATORVASTATIN CALCIUM

SUSPENSION;ORAL

ATORVALIQ

+!	CMP DEV LLC	20MG/5ML	N213260	001	Feb 01, 2023	Feb	NEWA
----	-------------	----------	---------	-----	--------------	-----	------

AZELAIC ACID

AEROSOL, FOAM;TOPICAL

FINACEA

+!	LEO PHARMA AS	15%	N207071	001	Jul 29, 2015	Feb	CTEC
----	---------------	-----	---------	-----	--------------	-----	------

AZITHROMYCIN

TABLET;ORAL

AZITHROMYCIN

@ ACI

EQ 250MG BASE

A215772	001	Jul 15, 2022	Jan	DISC
---------	-----	--------------	-----	------

@

EQ 500MG BASE

A215773	001	Jul 12, 2022	Jan	DISC
---------	-----	--------------	-----	------

>A>	AB	ZYDUS PHARMS	EQ 250MG BASE	A213275	001	Apr 11, 2023	Mar	NEWA
-----	----	--------------	---------------	---------	-----	--------------	-----	------

>A>	AB		EQ 500MG BASE	A213056	001	Apr 07, 2023	Mar	NEWA
-----	----	--	---------------	---------	-----	--------------	-----	------

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

@ AKORN

400 UNITS/GM;1%;EQ 3.5MG

A065213	001	Jul 25, 2012	Jan	DISC
---------	-----	--------------	-----	------

BASE/GM;10,000 UNITS/GM

! BAUSCH AND LOMB

400 UNITS/GM;1%;EQ 3.5MG

A064068	001	Oct 30, 1995	Jan	CTEC
---------	-----	--------------	-----	------

BASE/GM;10,000 UNITS/GM

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

@ AKORN

400 UNITS/GM;EQ 3.5MG

A065088	001	Feb 06, 2004	Jan	DISC
---------	-----	--------------	-----	------

BASE/GM;10,000 UNITS/GM

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

AP	RUBICON	0.5MG/ML	A217324	001	Feb 22, 2023	Feb	NEWA
----	---------	----------	---------	-----	--------------	-----	------

AP		1MG/ML	A217324	002	Feb 22, 2023	Feb	NEWA
----	--	--------	---------	-----	--------------	-----	------

AP		2MG/ML	A217324	003	Feb 22, 2023	Feb	NEWA
----	--	--------	---------	-----	--------------	-----	------

TABLET;ORAL

BACLOFEN

>A>	AB	UNICHEM	5MG	A212067	003	Mar 09, 2023	Mar	NEWA
-----	----	---------	-----	---------	-----	--------------	-----	------

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

@ DASH PHARMS NATCO 750MG

A077807	001	Dec 28, 2007	Feb	CAHN
---------	-----	--------------	-----	------

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

>D>	AB	ANNORA PHARMA	5MG	A077128	001	Mar 08, 2006	Mar	CAHN
-----	----	---------------	-----	---------	-----	--------------	-----	------

>D>	AB		10MG	A077128	002	Mar 08, 2006	Mar	CAHN
-----	----	--	------	---------	-----	--------------	-----	------

>D>	AB		20MG	A077128	003	Mar 08, 2006	Mar	CAHN
-----	----	--	------	---------	-----	--------------	-----	------

>D>	AB		40MG	A077128	004	Mar 08, 2006	Mar	CAHN
-----	----	--	------	---------	-----	--------------	-----	------

>A>	AB	COREPHARMA	5MG	A077128	001	Mar 08, 2006	Mar	CAHN
-----	----	------------	-----	---------	-----	--------------	-----	------

>A>	AB		10MG	A077128	002	Mar 08, 2006	Mar	CAHN
-----	----	--	------	---------	-----	--------------	-----	------

>A>	AB		20MG	A077128	003	Mar 08, 2006	Mar	CAHN
-----	----	--	------	---------	-----	--------------	-----	------

>A>	AB		40MG	A077128	004	Mar 08, 2006	Mar	CAHN
-----	----	--	------	---------	-----	--------------	-----	------

BENDAMUSTINE HYDROCHLORIDE

POWDER;IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP	BRECKENRIDGE	25MG/VIAL	A205447	001	Feb 14, 2023	Feb	NEWA
----	--------------	-----------	---------	-----	--------------	-----	------

AP		100MG/VIAL	A205447	002	Feb 14, 2023	Feb	NEWA
----	--	------------	---------	-----	--------------	-----	------

SOLUTION;INTRAVENOUS

BENDAMUSTINE HYDROCHLORIDE

	+ @ HOSPIRA	25MG/ML (25MG/ML)	N211530	001	Dec 15, 2022	Jan DISC
	+ @	100MG/4ML (25MG/ML)	N211530	002	Dec 15, 2022	Jan DISC
	+ @	200MG/8ML (25MG/ML)	N211530	003	Dec 15, 2022	Jan DISC

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA	CHARTWELL RX	100MG	A040682	001	Jul 30, 2007	Feb CAHN
AA		200MG	A040682	002	Jul 30, 2007	Feb CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

BENZACLIN

	+ @ BAUSCH	5%;EQ 1% BASE	N050756	001	Dec 21, 2000	Feb DISC
	CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE					
AB	! GLENMARK PHARMS	5%;EQ 1% BASE	A209252	001	Mar 14, 2019	Feb CHRS

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC

BEPOTASTINE BESILATE

>A>	AT	ALEMBIC	1.5%	A214588	001	Apr 05, 2023	Mar NEWA
-----	----	---------	------	---------	-----	--------------	----------

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

AB	HIKMA	3MG/ML;EQ 3MG BASE/ML	A077838	001	Jan 17, 2023	Jan NEWA
----	-------	-----------------------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

>A>	AB	GLENMARK PHARMS LTD	0.064%;0.005%	A214688	001	Mar 21, 2023	Mar NFTG
		ENSTILAR					
>D>	+	LEO PHARMA AS	0.064%;0.005%	N207589	001	Oct 16, 2015	Mar CFTG
>A>	AB	+	0.064%;0.005%	N207589	001	Oct 16, 2015	Mar CFTG

OINTMENT;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

@ TOLMAR

A201615 001 Jan 14, 2013 Feb DISC

SUSPENSION;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB	COSETTE	0.064%;0.005%	A210765	001	May 11, 2020	Feb CAHN
----	---------	---------------	---------	-----	--------------	----------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

@ AKORN

A075386 001 Jun 30, 2000 Feb DISC

BEXAGLIFLOZIN

TABLET;ORAL

BRENZAVVY

	+	THERACOSBIO	20MG	N214373	001	Jan 20, 2023	Jan NEWA
--	---	-------------	------	---------	-----	--------------	----------

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB	PINNACLE LIFE SCI	50MG	A079089	001	Jul 06, 2009	Jan CAHN
----	-------------------	------	---------	-----	--------------	----------

BIMATOPROST

IMPLANT;OPHTHALMIC

DURYSTA

	+	ABBVIE	10MCG	N211911	001	Mar 04, 2020	Jan CAHN
--	---	--------	-------	---------	-----	--------------	----------

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

AB	PAR PHARM	140MG;125MG;125MG	A205770	001	Mar 06, 2023	Feb NFTG	
		PYLERA					
>A>	AB	+	ABBVIE	N050786	001	Sep 28, 2006	Mar CAHN
>D>	AB	+	ALLERGAN	N050786	001	Sep 28, 2006	Mar CAHN
AB	+			N050786	001	Sep 28, 2006	Feb CFTG

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

AB	ALEMIC	5MG	A204891	001	Jan 11, 2017	Feb CAHN
AB		10MG	A204891	002	Jan 11, 2017	Feb CAHN
	@ DASH PHARMS NATCO	5MG	A075831	001	Dec 14, 2005	Feb CAHN
	@	10MG	A075831	002	Dec 14, 2005	Feb CAHN

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

SOLUTION; INTRAVENOUS

BORTEZOMIB

@ ACCORD HLHCARE	3.5MG/VIAL	A204405	001	Jul 26, 2022	Feb DISC
+ @ ACCORD HLHCARE	2.5MG/ML (2.5MG/ML)	N215441	001	Jul 26, 2022	Feb DISC
+ @	3.5MG/1.4ML (2.5MG/ML)	N215441	002	Jul 26, 2022	Feb DISC

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

@ BRECKENRIDGE 50MG/ML

A204386 001 Dec 21, 2018 Feb DISC

BREXPIPIRAZOLE

TABLET; ORAL

BREXPIPIRAZOLE

AB	AJANTA PHARMA LTD	0.25MG	A213718	001	Feb 03, 2023	Jan NEWA
AB		0.5MG	A213718	002	Feb 03, 2023	Jan NEWA
AB		1MG	A213718	003	Feb 03, 2023	Jan NEWA
AB		2MG	A213718	004	Feb 03, 2023	Jan NEWA
AB		3MG	A213718	005	Feb 03, 2023	Jan NEWA
AB		4MG	A213718	006	Feb 03, 2023	Jan NEWA
>D> AB	AMNEAL	0.25MG	A213562	001	Jan 31, 2023	Mar DISC
>A>	@	0.25MG	A213562	001	Jan 31, 2023	Mar DISC
AB		0.25MG	A213562	001	Jan 31, 2023	Jan NEWA
>D> AB		0.5MG	A213562	002	Jan 31, 2023	Mar DISC
>A>	@	0.5MG	A213562	002	Jan 31, 2023	Mar DISC
AB		0.5MG	A213562	002	Jan 31, 2023	Jan NEWA
>D> AB		1MG	A213562	003	Jan 31, 2023	Mar DISC
>A>	@	1MG	A213562	003	Jan 31, 2023	Mar DISC
AB		1MG	A213562	003	Jan 31, 2023	Jan NEWA
>D> AB		2MG	A213562	004	Jan 31, 2023	Mar DISC
>A>	@	2MG	A213562	004	Jan 31, 2023	Mar DISC
AB		2MG	A213562	004	Jan 31, 2023	Jan NEWA
>D> AB		3MG	A213562	005	Jan 31, 2023	Mar DISC
>A>	@	3MG	A213562	005	Jan 31, 2023	Mar DISC
AB		3MG	A213562	005	Jan 31, 2023	Jan NEWA
>D> AB		4MG	A213562	006	Jan 31, 2023	Mar DISC
>A>	@	4MG	A213562	006	Jan 31, 2023	Mar DISC
AB		4MG	A213562	006	Jan 31, 2023	Jan NEWA
>A> AB	LUPIN LTD	0.25MG	A213512	001	Mar 17, 2023	Mar NEWA
>A> AB		0.5MG	A213512	002	Mar 17, 2023	Mar NEWA
>A> AB		1MG	A213512	003	Mar 17, 2023	Mar NEWA
>A> AB		2MG	A213512	004	Mar 17, 2023	Mar NEWA
>A> AB		3MG	A213512	005	Mar 17, 2023	Mar NEWA
>A> AB		4MG	A213512	006	Mar 17, 2023	Mar NEWA
	@ TEVA PHARMS USA INC	0.25MG	A213692	001	Aug 11, 2022	Feb DISC
	@	0.5MG	A213692	002	Aug 11, 2022	Feb DISC
	@	1MG	A213692	003	Aug 11, 2022	Feb DISC
	@	2MG	A213692	004	Aug 11, 2022	Feb DISC
	@	3MG	A213692	005	Aug 11, 2022	Feb DISC
	@	4MG	A213692	006	Aug 11, 2022	Feb DISC

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE

>A> AT	ALEMIC	0.15%	A215225	001	Mar 29, 2023	Mar NEWA
--------	--------	-------	---------	-----	--------------	----------

BRIVARACETAM

TABLET; ORAL

>D>		BRIVARACETAM							
>D>	AB	AUROBINDO PHARMA LTD	50MG	A214848	001	Jan 06, 2023	Mar	DISC	
>A>		@	50MG	A214848	001	Jan 06, 2023	Mar	DISC	
>D>	AB		100MG	A214848	002	Jan 06, 2023	Mar	DISC	
>A>		@	100MG	A214848	002	Jan 06, 2023	Mar	DISC	
>D>	AB	LUPIN LTD	10MG	A214918	001	Dec 20, 2022	Mar	DISC	
>A>		@	10MG	A214918	001	Dec 20, 2022	Mar	DISC	
>D>	AB		25MG	A214918	002	Dec 20, 2022	Mar	DISC	
>A>		@	25MG	A214918	002	Dec 20, 2022	Mar	DISC	
>D>	AB		50MG	A214918	003	Dec 20, 2022	Mar	DISC	
>A>		@	50MG	A214918	003	Dec 20, 2022	Mar	DISC	
>D>	AB		75MG	A214918	004	Dec 20, 2022	Mar	DISC	
>A>		@	75MG	A214918	004	Dec 20, 2022	Mar	DISC	
>D>	AB		100MG	A214918	005	Dec 20, 2022	Mar	DISC	
>A>		@	100MG	A214918	005	Dec 20, 2022	Mar	DISC	
		BRIVIACT							
>D>	AB	+ UCB INC	10MG	N205836	001	May 12, 2016	Mar	CTEC	
>A>		+	10MG	N205836	001	May 12, 2016	Mar	CTEC	
>D>	AB	+	25MG	N205836	002	May 12, 2016	Mar	CTEC	
>A>		+	25MG	N205836	002	May 12, 2016	Mar	CTEC	
>D>	AB	+	50MG	N205836	003	May 12, 2016	Mar	CTEC	
>A>		+	50MG	N205836	003	May 12, 2016	Mar	CTEC	
>D>	AB	+	75MG	N205836	004	May 12, 2016	Mar	CTEC	
>A>		+	75MG	N205836	004	May 12, 2016	Mar	CTEC	
>D>	AB	+!	100MG	N205836	005	May 12, 2016	Mar	CTEC	
>A>		+!	100MG	N205836	005	May 12, 2016	Mar	CTEC	

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

@ BRECKENRIDGE 2MG/5ML; 10MG/5ML; 30MG/5ML A203997 001 Sep 30, 2020 Jan DISC

BUDESONIDE

AEROSOL, FOAM; RECTAL

BUDESONIDE

>A>	AB	PADAGIS ISRAEL	2MG/ACTUATION	A215328	001	Apr 12, 2023	Mar	NFTG	
		UCERIS							
>D>		+! SALIX	2MG/ACTUATION	N205613	001	Oct 07, 2014	Mar	CFTG	
>A>	AB	+	2MG/ACTUATION	N205613	001	Oct 07, 2014	Mar	CFTG	

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUPRENORPHINE

>A>	AB	ALVOGEN	7.5MCG/HR	A207490	005	Mar 21, 2023	Mar	NEWA	
-----	----	---------	-----------	---------	-----	--------------	-----	------	--

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

		@ GRAVITI PHARMS	5MG	A075413	001	Mar 19, 2002	Feb	CAHN	
		@	10MG	A075413	002	Mar 19, 2002	Feb	CAHN	
		@	15MG	A075413	003	Mar 19, 2002	Feb	CAHN	
>A>	AB	ZYDUS PHARMS	7.5MG	A078888	005	Mar 21, 2023	Mar	NEWA	

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

		@ AM REGENT	6MG/ML	A202259	001	Dec 22, 2015	Jan	DISC	
>D>	AP	ARTHUR GRP	6MG/ML	A205106	001	Sep 21, 2018	Mar	DISC	
>A>		@	6MG/ML	A205106	001	Sep 21, 2018	Mar	DISC	

CABAZITAXEL

SOLUTION; INTRAVENOUS

CABAZITAXEL

		+! ACCORD HLTHCARE	60MG/3ML (20MG/ML)	N207949	001	Dec 29, 2021	Feb	CMFD	
AP		APOTEX	60MG/1.5ML (40MG/ML)	A207736	001	Feb 10, 2023	Feb	NEWA	
AP		DR REDDYS	60MG/1.5ML (40MG/ML)	A207718	001	Feb 10, 2023	Feb	NEWA	
		+! SANDOZ INC	45MG/4.5ML (10MG/ML)	N208715	001	Jan 05, 2023	Jan	NEWA	
		+!	60MG/6ML (10MG/ML)	N208715	002	Jan 05, 2023	Jan	NEWA	

CALCIPOTRIENE

		CREAM; TOPICAL							
		CALCIPOTRIENE							
		@ TOLMAR	0.005%	A200935	001	May 30, 2012	Feb	DISC	
		SOLUTION; TOPICAL							
		CALCIPOTRIENE							
AT	!	COSETTE	0.005%	A078468	001	Mar 24, 2011	Feb	CHRS	
		@ TOLMAR	0.005%	A077029	001	Nov 20, 2009	Feb	DISC	

CALCIUM ACETATE

		CAPSULE; ORAL							
		CALCIUM ACETATE							
>A>	AB	SQUARE PHARMS	667MG	A217205	001	Mar 13, 2023	Mar	NEWA	

CAPTOPRIL

		TABLET; ORAL							
		CAPTOPRIL							
>D>	AB	ANNORA PHARMA	12.5MG	A074737	001	Oct 28, 1998	Mar	CAHN	
>D>	AB		25MG	A074737	002	Oct 28, 1998	Mar	CAHN	
>D>	AB		50MG	A074737	003	Oct 28, 1998	Mar	CAHN	
>D>	AB		100MG	A074737	004	Oct 28, 1998	Mar	CAHN	
	AB	CHANGZHOU PHARM	12.5MG	A214442	001	Jan 27, 2023	Jan	NEWA	
	AB		25MG	A214442	002	Jan 27, 2023	Jan	NEWA	
	AB		50MG	A214442	003	Jan 27, 2023	Jan	NEWA	
	AB		100MG	A214442	004	Jan 27, 2023	Jan	NEWA	
>A>	AB	COREPHARMA	12.5MG	A074737	001	Oct 28, 1998	Mar	CAHN	
>A>	AB		25MG	A074737	002	Oct 28, 1998	Mar	CAHN	
>A>	AB		50MG	A074737	003	Oct 28, 1998	Mar	CAHN	
>A>	AB		100MG	A074737	004	Oct 28, 1998	Mar	CAHN	

CARBAMAZEPINE

		SUSPENSION; ORAL							
		CARBAMAZEPINE							
AB		CHARTWELL RX	100MG/5ML	A075714	001	Jun 05, 2002	Jan	CAHN	
		TABLET, EXTENDED RELEASE; ORAL							
		CARBAMAZEPINE							
>A>	AB	AJANTA PHARMA LTD	100MG	A216193	001	Mar 24, 2023	Mar	NEWA	
>A>	AB		200MG	A216193	002	Mar 24, 2023	Mar	NEWA	
>A>	AB		400MG	A216193	003	Mar 24, 2023	Mar	NEWA	
	AB	SCIECURE PHARMA INC	100MG	A216235	001	Mar 02, 2023	Feb	NEWA	
	AB		200MG	A216235	002	Mar 02, 2023	Feb	NEWA	
	AB		400MG	A216235	003	Mar 02, 2023	Feb	NEWA	

CARBIDOPA; LEVODOPA

		TABLET; ORAL							
		CARBIDOPA AND LEVODOPA							
>A>	AB	ZYDUS PHARMS	10MG;100MG	A215999	001	Apr 04, 2023	Mar	NEWA	
>A>	AB		25MG;100MG	A215999	002	Apr 04, 2023	Mar	NEWA	
>A>	AB		25MG;250MG	A215999	003	Apr 04, 2023	Mar	NEWA	

CARBOPROST TROMETHAMINE

		INJECTABLE; INJECTION							
		CARBOPROST TROMETHAMINE							
AP		CAPLIN	EQ 0.25MG BASE/ML	A216882	001	Feb 13, 2023	Feb	NEWA	

CARIPRAZINE HYDROCHLORIDE

		CAPSULE; ORAL							
		VRAYLAR							
	+!	ABBVIE	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Jan	CAHN	
	+		EQ 3MG BASE	N204370	002	Sep 17, 2015	Jan	CAHN	
	+		EQ 4.5MG BASE	N204370	003	Sep 17, 2015	Jan	CAHN	
	+		EQ 6MG BASE	N204370	004	Sep 17, 2015	Jan	CAHN	

CARMUSTINE

		INJECTABLE; INJECTION							
		CARMUSTINE							
>A>									
>A>	AP	ACCORD HLTHCARE	100MG/VIAL	A214117	001	Dec 27, 2022	Mar	CTNA	
>D>	AP	MYLAN LABS LTD	100MG/VIAL	A215368	001	Mar 03, 2023	Mar	DISC	
>A>		@	100MG/VIAL	A215368	001	Mar 03, 2023	Mar	DISC	
	AP		100MG/VIAL	A215368	001	Mar 03, 2023	Feb	NEWA	

	INJECTABLE; INJECTION						
>D>	Carmustine						
>D>	AP	ACCORD HLTHCARE	100MG/VIAL	A214117	001	Dec 27, 2022	Mar CTNA
>D>	<u>CEFOTAXIME SODIUM</u>						
>D>	INJECTABLE; INJECTION						
>D>	CEFOTAXIME						
>D>	!	HIKMA	EQ 500MG BASE/VIAL	A065072	001	Nov 20, 2002	Mar DISC
>A>	@		EQ 500MG BASE/VIAL	A065072	001	Nov 20, 2002	Mar DISC
>D>	!		EQ 1GM BASE/VIAL	A065072	002	Nov 20, 2002	Mar DISC
>A>	@		EQ 1GM BASE/VIAL	A065072	002	Nov 20, 2002	Mar DISC
>D>	!		EQ 2GM BASE/VIAL	A065072	003	Nov 20, 2002	Mar DISC
>A>	@		EQ 2GM BASE/VIAL	A065072	003	Nov 20, 2002	Mar DISC
>D>	!		EQ 10GM BASE/VIAL	A065071	001	Nov 20, 2002	Mar DISC
>A>	@		EQ 10GM BASE/VIAL	A065071	001	Nov 20, 2002	Mar DISC
	<u>CELECOXIB</u>						
	CAPSULE; ORAL						
	CELECOXIB						
>D>	AB	MYLAN	100MG	A078857	002	Feb 11, 2015	Mar DISC
>A>	@		100MG	A078857	002	Feb 11, 2015	Mar DISC
>A>	AB	YABAO PHARM	100MG	A212564	001	Apr 10, 2023	Mar NEWA
>A>	AB		200MG	A212564	002	Apr 10, 2023	Mar NEWA
>A>	AB		400MG	A212564	003	Apr 10, 2023	Mar NEWA
	SOLUTION; ORAL						
	ELYXYB						
	+	@ SCILEX HLDG	25MG/ML	N212157	001	May 05, 2020	Feb CAHN
	<u>CEVIMELINE HYDROCHLORIDE</u>						
	CAPSULE; ORAL						
	CEVIMELINE HYDROCHLORIDE						
>A>	AB	RUBICON	30MG	A216682	001	Apr 06, 2023	Mar NEWA
	<u>CHLORHEXIDINE GLUCONATE</u>						
	SOLUTION; DENTAL						
	CHLORHEXIDINE GLUCONATE						
AT		CHARTWELL RX	0.12%	A075006	001	Mar 03, 2004	Jan CAHN
	<u>CHLORZOXAZONE</u>						
	TABLET; ORAL						
	CHLORZOXAZONE						
AB		APPCO	375MG	A212047	001	Jan 27, 2023	Jan NEWA
AB			750MG	A212047	002	Jan 27, 2023	Jan NEWA
AA		BELCHER	250MG	A215540	001	Jan 24, 2023	Jan NEWA
>A>	AA	COREPHARMA	250MG	A214702	001	Apr 10, 2023	Mar NEWA
	<u>CICLOPIROX</u>						
	SOLUTION; TOPICAL						
	CICLOPIROX						
AT	!	PADAGIS US	8%	A077623	001	Sep 18, 2007	Jan CHRS
		PENLAC					
	+	@ VALEANT BERMUDA	8%	N021022	001	Dec 17, 1999	Jan DISC
	<u>CIMETIDINE HYDROCHLORIDE</u>						
	SOLUTION; ORAL						
	CIMETIDINE HYDROCHLORIDE						
>D>	AA	WOCKHARDT BIO AG	EQ 300MG BASE/5ML	A074757	001	Oct 17, 1997	Mar CAHN
>A>	AA	XTTRIUM LABS INC	EQ 300MG BASE/5ML	A074757	001	Oct 17, 1997	Mar CAHN
	<u>CIPROFLOXACIN</u>						
	INJECTABLE, SUSPENSION; OTIC						
	OTIPRIO						
	+	@ ALK ABELLO	6% (60MG/ML)	N207986	001	Dec 10, 2015	Jan DISC
	<u>CIPROFLOXACIN HYDROCHLORIDE</u>						
	SOLUTION/DROPS; OPHTHALMIC						
	CIPROFLOXACIN HYDROCHLORIDE						
	@	AKORN	EQ 0.3% BASE	A076555	001	Dec 11, 2008	Feb DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CELEXA

AB	+	ABBVIE	EQ 10MG BASE	N020822	001	Apr 27, 2000	Feb CAHN
AB	+		EQ 20MG BASE	N020822	002	Jul 17, 1998	Feb CAHN
AB	+	!	EQ 40MG BASE	N020822	003	Jul 17, 1998	Feb CAHN
		@	EQ 60MG BASE	N020822	004	Jul 17, 1998	Feb CAHN

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

>A>	AB	GLENMARK PHARMS LTD	EQ 75MG BASE	A216957	001	Mar 10, 2023	Mar NEWA
>A>	AB		EQ 150MG BASE	A216957	002	Mar 10, 2023	Mar NEWA
>A>	AB		EQ 300MG BASE	A216957	003	Mar 10, 2023	Mar NEWA

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA		CHARTWELL RX	EQ 75MG BASE/5ML	A206958	001	May 05, 2017	Feb CAHN
----	--	--------------	------------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

>A>	AP	HIKMA	EQ 6MG BASE/ML	A214401	001	Apr 05, 2023	Mar NEWA
>A>	AP		EQ 12MG BASE/ML	A214401	002	Apr 05, 2023	Mar NEWA
>A>	AP		EQ 18MG BASE/ML	A214401	003	Apr 05, 2023	Mar NEWA

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

@ XTTRIUM LABS INC EQ 1% BASE

A063304	001	Jul 15, 1997	Jan CAHN
---------	-----	--------------	----------

CLOBAZAM

SUSPENSION; ORAL

CLOBAZAM

>D>	AB	ACCORD HLTHCARE	2.5MG/ML	A216008	001	Sep 06, 2022	Mar DISC
>A>		@	2.5MG/ML	A216008	001	Sep 06, 2022	Mar DISC
>D>	AB	UPSHER SMITH LABS	2.5MG/ML	A210569	001	Oct 22, 2018	Mar DISC
>A>		@	2.5MG/ML	A210569	001	Oct 22, 2018	Mar DISC

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

@ TORRENT 0.05%

A211836	001	Dec 30, 2019	Feb DISC
---------	-----	--------------	----------

CLOFARABINE

SOLUTION; INTRAVENOUS

CLOFARABINE

>D>	AP	EUGIA PHARMA	20MG/20ML (1MG/ML)	A212457	001	Oct 03, 2022	Mar DISC
>A>		@	20MG/20ML (1MG/ML)	A212457	001	Oct 03, 2022	Mar DISC

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HYDROCHLORIDE

>A>	AB	AUROBINDO PHARMA	25MG	A216440	001	Mar 20, 2023	Mar NEWA
>A>	AB		50MG	A216440	002	Mar 20, 2023	Mar NEWA
>A>	AB		75MG	A216440	003	Mar 20, 2023	Mar NEWA

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

AB		AUROBINDO PHARMA USA	0.5MG	A075150	001	Oct 05, 1998	Jan CMFD
AB			1MG	A075150	002	Oct 05, 1998	Jan CMFD
AB			2MG	A075150	003	Oct 05, 1998	Jan CMFD

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

@ DASH PHARMS 3.75MG

@ 7.5MG

@ 15MG

A071509	001	Oct 19, 1987	Feb CAHN
A071510	001	Oct 19, 1987	Feb CAHN
A071511	001	Oct 19, 1987	Feb CAHN

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
TRIACIN-C

>A>	!	ANIMA	10MG/5ML; 30MG/5ML; 1.25MG/5ML	A 088704	001	Mar 22, 1985	Mar CAHN
>D>	!	STI PHARMA LLC	10MG/5ML; 30MG/5ML; 1.25MG/5ML	A 088704	001	Mar 22, 1985	Mar CAHN

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION; ORAL
COLESEVELAM HYDROCHLORIDE

AB		IMPAX	3.75GM/PACKET	A 212886	001	Jan 18, 2023	Jan NEWA
----	--	-------	---------------	----------	-----	--------------	----------

COLESTIPOL HYDROCHLORIDE

TABLET; ORAL
COLESTIPOL HYDROCHLORIDE

>A>	AB		PRAXGEN	1GM	A 216517	001	Mar 10, 2023	Mar NEWA
-----	----	--	---------	-----	----------	-----	--------------	----------

CROMOLYN SODIUM

SOLUTION/DROPS; OPHTHALMIC
CROMOLYN SODIUM

		@	AKORN	4%	A 074706	001	Apr 29, 1998	Feb DISC
		!	SANDOZ INC	4%	A 075282	001	Jun 16, 1999	Feb CTEC
AT		!		4%	A 075282	001	Jun 16, 1999	Feb CHRS

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

>D>	AB		APOTEX	15MG	A 206703	001	Jul 24, 2018	Mar DISC
>A>		@		15MG	A 206703	001	Jul 24, 2018	Mar DISC
>D>	AB			30MG	A 206703	002	Jul 24, 2018	Mar DISC
>A>		@		30MG	A 206703	002	Jul 24, 2018	Mar DISC

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB			CHARTWELL RX	5MG	A 078218	002	Jun 19, 2015	Feb CAHN
AB				7.5MG	A 078218	003	Nov 03, 2020	Feb CAHN
AB				10MG	A 078218	001	Apr 18, 2008	Feb CAHN

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
CYCLOGYL

		+	ALCON LABS INC	0.5%	A 084109	001		Feb CTEC
		@	AKORN	0.5%	A 205937	001	Dec 09, 2015	Feb DISC

CYCLOSPORINE

EMULSION; OPHTHALMIC
CYCLOSPORINE

AB			APOTEX	0.05%	A 207606	001	Jan 12, 2023	Jan NEWA
----	--	--	--------	-------	----------	-----	--------------	----------

SOLUTION; ORAL
CYCLOSPORINE

AB2			XTTRIUM LABS INC	100MG/ML	A 065133	001	Sep 17, 2004	Jan CAHN
-----	--	--	------------------	----------	----------	-----	--------------	----------

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

>D>		@	CHARTWELL RX	4MG	A 088212	001	May 26, 1983	Mar CMFD
>A>	AA			4MG	A 088212	001	May 26, 1983	Mar CMFD

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION
CYSTEINE HYDROCHLORIDE

			NIVAGEN PHARMS INC	7.25%	A 213073	001	Jan 26, 2023	Jan NFTG
--	--	--	--------------------	-------	----------	-----	--------------	----------

DABRAFENIB MESYLATE

TABLET, FOR SUSPENSION; ORAL

TAFINLAR

>A>		+	NOVARTIS	EQ 10MG BASE	N 217514	001	Mar 16, 2023	Mar NEWA
-----	--	---	----------	--------------	----------	-----	--------------	----------

DAPRODUSTATTABLET; ORAL
JESDUVROQ

+	GLAXOSMITHKLINE	1MG	N216951	001	Feb 01, 2023	Feb	NEWA
+		2MG	N216951	002	Feb 01, 2023	Feb	NEWA
+		4MG	N216951	003	Feb 01, 2023	Feb	NEWA
+		6MG	N216951	004	Feb 01, 2023	Feb	NEWA
+!		8MG	N216951	005	Feb 01, 2023	Feb	NEWA

DAPTOMYCINPOWDER; INTRAVENOUS
DAPTOMYCIN

@	HAINAN POLY PHARM	500MG/VIAL	A215890	001	Aug 18, 2022	Feb	DISC
+!	XELLIA PHARMS APS	350MG/VIAL	N217415	001	Jan 30, 2023	Jan	NEWA
+!		500MG/VIAL	N217415	002	Jan 30, 2023	Jan	NEWA

SOLUTION; INTRAVENOUS

>A>		DAPTOMYCIN IN 0.9% SODIUM CHLORIDE						
>A>	+!	BAXTER HLTHCARE CORP	350MG/50ML (7MG/ML)	N213645	002	Feb 27, 2023	Mar	NEWA
>A>	+!		500MG/50ML (10MG/ML)	N213645	003	Feb 27, 2023	Mar	NEWA
>A>	+!		700MG/100ML (7MG/ML)	N213645	004	Feb 27, 2023	Mar	NEWA
>A>	+!		1GM/100ML (10MG/ML)	N213645	005	Feb 27, 2023	Mar	NEWA

DEFERASIROXGRANULE; ORAL
DEFERASIROX

>A>	AB	ANNORA PHARMA	90MG	A216229	003	Mar 16, 2023	Mar	NEWA
-----	----	---------------	------	---------	-----	--------------	-----	------

TABLET; ORAL
DEFERASIROX

>D>	AB	CELLTRION	90MG	A212669	001	May 27, 2021	Mar	CAHN
>D>	AB		180MG	A212669	002	May 27, 2021	Mar	CAHN
>D>	AB		360MG	A212669	003	May 27, 2021	Mar	CAHN
>A>	AB	CHARTWELL RX	90MG	A212669	001	May 27, 2021	Mar	CAHN
>A>	AB		180MG	A212669	002	May 27, 2021	Mar	CAHN
>A>	AB		360MG	A212669	003	May 27, 2021	Mar	CAHN
>D>	AB	CIPLA	90MG	A211852	001	Feb 11, 2020	Mar	DISC
>A>	@		90MG	A211852	001	Feb 11, 2020	Mar	DISC
>D>	AB		180MG	A211852	003	Jun 15, 2020	Mar	DISC
>A>	@		180MG	A211852	003	Jun 15, 2020	Mar	DISC
>D>	AB		360MG	A211852	002	Feb 11, 2020	Mar	DISC
>A>	@		360MG	A211852	002	Feb 11, 2020	Mar	DISC

TABLET, FOR SUSPENSION; ORAL
DEFERASIROX

>D>	AB	TEVA PHARMS USA	125MG	A207124	001	Sep 23, 2022	Mar	DISC
>A>	@		125MG	A207124	001	Sep 23, 2022	Mar	DISC
>D>	AB		250MG	A207124	002	Sep 23, 2022	Mar	DISC
>A>	@		250MG	A207124	002	Sep 23, 2022	Mar	DISC
>D>	AB		500MG	A207124	003	Sep 23, 2022	Mar	DISC
>A>	@		500MG	A207124	003	Sep 23, 2022	Mar	DISC

DESLORATADINETABLET; ORAL
DESLORATADINE
@ DASH PHARMS

		5MG	A078351	001	Feb 10, 2012	Feb	CAHN
--	--	-----	---------	-----	--------------	-----	------

DESMOPRESSIN ACETATEINJECTABLE; INJECTION
DESMOPRESSIN ACETATE

>A>	AP	GLAND	0.004MG/ML	A216904	001	Mar 20, 2023	Mar	NEWA
-----	----	-------	------------	---------	-----	--------------	-----	------

DEUTETRABENAZINETABLET, EXTENDED RELEASE; ORAL
AUSTEDO XR

+	TEVA	6MG	N216354	001	Feb 17, 2023	Feb	NEWA
+		12MG	N216354	002	Feb 17, 2023	Feb	NEWA
+!		24MG	N216354	003	Feb 17, 2023	Feb	NEWA

DEXAMETHASONE

ELIXIR;ORAL

DEXAMETHASONE

+ @ XTTRIUM LABS INC 0.5MG/5ML A088254 001 Jul 27, 1983 Jan CAHN

TABLET;ORAL

DEXAMETHASONE

@ PRASCO 4MG A080399 002 Apr 20, 2022 Feb DISC

DEXTROAMPHETAMINE SULFATE

SOLUTION;ORAL

DEXTROAMPHETAMINE SULFATE

>D> AA ! OUTLOOK PHARMS 5MG/5ML A040776 001 Jan 29, 2008 Mar CAHN

>A> AA ! PRASCO 5MG/5ML A040776 001 Jan 29, 2008 Mar CAHN

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA ARBOR PHARMS LLC 2.5MG A090533 001 Oct 25, 2011 Jan CTEC

AA 7.5MG A090533 003 Oct 25, 2011 Jan CTEC

AA 15MG A090533 005 Oct 25, 2011 Jan CTEC

AA 20MG A090533 006 Oct 25, 2011 Jan CTEC

AA 30MG A090533 007 Oct 25, 2011 Jan CTEC

AA WINDER LABS LLC 2.5MG A212160 001 Jun 07, 2021 Jan CMFD

AA 5MG A212160 002 Jun 07, 2021 Jan CMFD

AA 7.5MG A212160 003 Jun 07, 2021 Jan CMFD

AA 10MG A212160 004 Jun 07, 2021 Jan CMFD

AA 15MG A212160 005 Jun 07, 2021 Jan CMFD

AA 20MG A212160 006 Jun 07, 2021 Jan CMFD

AA 30MG A212160 007 Jun 07, 2021 Jan CMFD

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

>D> @ FRESENIUS KABI USA 5GM/100ML;149MG/100ML;225MG/100ML A212348 001 Jul 30, 2021 Mar CMFD

>A> AP 5GM/100ML;149MG/100ML;225MG/100ML A212348 001 Jul 30, 2021 Mar CMFD

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

>D> @ FRESENIUS KABI USA 5GM/100ML;74.5MG/100ML;450MG/100ML A213523 001 Mar 09, 2021 Mar CMFD

>A> AP 5GM/100ML;74.5MG/100ML;450MG/100ML A213523 001 Mar 09, 2021 Mar CMFD

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

>D> @ FRESENIUS KABI USA 5GM/100ML;149MG/100ML;225MG/100ML A212348 002 Jul 30, 2021 Mar CMFD

>A> AP 5GM/100ML;149MG/100ML;225MG/100ML A212348 002 Jul 30, 2021 Mar CMFD

>D> + ICU MEDICAL INC 5GM/100ML;149MG/100ML;225MG/100ML N018365 001 Mar CHRS

>A> AP +! 5GM/100ML;149MG/100ML;225MG/100ML N018365 001 Mar CHRS

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

>D> @ FRESENIUS KABI USA 5GM/100ML;149MG/100ML;450MG/100ML A213523 002 Mar 09, 2021 Mar CMFD

>A> AP 5GM/100ML;149MG/100ML;450MG/100ML A213523 002 Mar 09, 2021 Mar CMFD

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%

>D> @ FRESENIUS KABI USA 5GM/100ML;149MG/100ML;900MG/100ML A213445 001 Mar 09, 2021 Mar CMFD

>A> AP 5GM/100ML;149MG/100ML;900MG/100ML A213445 001 Mar 09, 2021 Mar CMFD

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

>D> @ FRESENIUS KABI USA 5GM/100ML;224MG/100ML;450MG/100ML A213523 003 Mar 09, 2021 Mar CMFD

>A> AP 5GM/100ML;224MG/100ML;450MG/100ML A213523 003 Mar 09, 2021 Mar CMFD

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

>D> @ FRESENIUS KABI USA 5GM/100ML;298MG/100ML;450MG/100ML A213523 004 Mar 09, 2021 Mar CMFD

>A> AP 5GM/100ML;298MG/100ML;450MG/100ML A213523 004 Mar 09, 2021 Mar CMFD

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%

>D> @ FRESENIUS KABI USA 5GM/100ML;298MG/100ML;900MG/100ML A213445 002 Mar 09, 2021 Mar CMFD

>A> AP 5GM/100ML;298MG/100ML;900MG/100ML A213445 002 Mar 09, 2021 Mar CMFD

DICLOFENAC POTASSIUM

TABLET;ORAL

DICLOFENAC POTASSIUM

>A> AB SENORES PHARMS 50MG A215787 001 Mar 15, 2023 Mar NEWA

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

AB AMNEAL 3% A200936 001 Oct 28, 2013 Feb CAHN

SOLUTION;TOPICAL

DICLOFENAC SODIUM

AB AUROLIFE PHARMA LLC 2% A213040 001 Feb 03, 2023 Jan NEWA

DICYCLOMINE HYDROCHLORIDE

		CAPSULE; ORAL							
		DICYCLOMINE HYDROCHLORIDE							
>A>	AB	COREPHARMA	10MG	A216639	001	Mar 24, 2023	Mar	NEWA	
		INJECTABLE; INJECTION							
		BENTYL							
AP	+!	ABBVIE	10MG/ML	N008370	001	Oct 15, 1984	Feb	CAHN	
		BENTYL PRESERVATIVE FREE							
AP	+!	ABBVIE	10MG/ML	N008370	002	Oct 15, 1984	Feb	CAHN	
		TABLET; ORAL							
		DICYCLOMINE HYDROCHLORIDE							
AB		AUROBINDO PHARMA USA	20MG	A040317	001	Sep 07, 1999	Feb	CMFD	

DIETHYLPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
DIETHYLPROPION HYDROCHLORIDE
! LANNETT CO INC 75MG

A091680 001 Oct 24, 2011 Feb CTEC

DILTIAZEM HYDROCHLORIDE

		CAPSULE, EXTENDED RELEASE; ORAL							
		DILTIAZEM HYDROCHLORIDE							
AB1		TWI PHARMS	60MG	A217377	001	Mar 01, 2023	Feb	NEWA	
AB1			90MG	A217377	002	Mar 01, 2023	Feb	NEWA	
AB1			120MG	A217377	003	Mar 01, 2023	Feb	NEWA	
		INJECTABLE; INJECTION							
		DILTIAZEM HYDROCHLORIDE							
>A>	AP	EUGIA PHARMA	5MG/ML	A216552	001	Mar 29, 2023	Mar	NEWA	
		TABLET, EXTENDED RELEASE; ORAL							
		DILTIAZEM HYDROCHLORIDE							
AB		AMTA	120MG	A216439	001	Mar 07, 2023	Feb	NEWA	
AB			180MG	A216439	002	Mar 07, 2023	Feb	NEWA	
AB			240MG	A216439	003	Mar 07, 2023	Feb	NEWA	
AB			300MG	A216439	004	Mar 07, 2023	Feb	NEWA	
AB			360MG	A216439	005	Mar 07, 2023	Feb	NEWA	
AB			420MG	A216439	006	Mar 07, 2023	Feb	NEWA	
>A>	AB	SCIEGEN PHARMS INC	120MG	A216327	001	Apr 06, 2023	Mar	NEWA	
>A>	AB		180MG	A216327	002	Apr 06, 2023	Mar	NEWA	
>A>	AB		240MG	A216327	003	Apr 06, 2023	Mar	NEWA	
>A>	AB		300MG	A216327	004	Apr 06, 2023	Mar	NEWA	
>A>	AB		360MG	A216327	005	Apr 06, 2023	Mar	NEWA	
>A>	AB		420MG	A216327	006	Apr 06, 2023	Mar	NEWA	

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL
DIMETHYL FUMARATE

AB		SOLA PHARMS	120MG	A210436	001	Mar 26, 2021	Feb	CMFD	
AB			240MG	A210436	002	Mar 26, 2021	Feb	CMFD	

DISULFIRAM

TABLET; ORAL
DISULFIRAM

@	DASH PHARMS	250MG	A203916	001	Mar 04, 2015	Feb	CAHN	
@		500MG	A203916	002	Mar 04, 2015	Feb	CAHN	

DOCETAXEL

INJECTABLE; INJECTION
DOCETAXEL

AP		ALEMbic	20MG/2ML (10MG/ML)	A215744	001	Feb 28, 2023	Feb	NEWA	
AP			80MG/8ML (10MG/ML)	A215744	002	Feb 28, 2023	Feb	NEWA	
AP			160MG/16ML (10MG/ML)	A215744	003	Feb 28, 2023	Feb	NEWA	

DOXEpin HYDROCHLORIDE

CAPSULE; ORAL
DOXEpin HYDROCHLORIDE

>A>	AB	ZYDUS LIFESCIENCES	EQ 10MG BASE	A210700	001	Mar 23, 2023	Mar	CAHN	
>A>	AB		EQ 25MG BASE	A210700	002	Mar 23, 2023	Mar	CAHN	
>A>	AB		EQ 50MG BASE	A210700	003	Mar 23, 2023	Mar	CAHN	
>A>	AB		EQ 75MG BASE	A210700	004	Mar 23, 2023	Mar	CAHN	
>A>	AB		EQ 100MG BASE	A210700	005	Mar 23, 2023	Mar	CAHN	
>A>	AB		EQ 150MG BASE	A210140	001	Mar 21, 2023	Mar	CAHN	

		CREAM; TOPICAL							
		DOXEPIN HYDROCHLORIDE							
AB		TEVA PHARMS	5%		A215408	001	Feb 17, 2023	Feb	NFTG
		ZONALON							
AB	+!	MYLAN	5%		N020126	001	Apr 01, 1994	Feb	CFTG
		TABLET; ORAL							
		DOXEPIN HYDROCHLORIDE							
>A>	AB	MSN	EQ 3MG BASE		A214823	001	Apr 03, 2023	Mar	NEWA
>A>	AB		EQ 6MG BASE		A214823	002	Apr 03, 2023	Mar	NEWA
		<u>DOXYCYCLINE HYCLATE</u>							
		INJECTABLE; INJECTION							
		DOXYCYCLINE HYCLATE							
>A>	AP	GLAND PHARMA LTD	EQ 100MG BASE/VIAL		A215583	001	Apr 12, 2023	Mar	NEWA
		TABLET; ORAL							
		DOXYCYCLINE HYCLATE							
		@ ORYZA PHARMS SHENZHN	EQ 100MG BASE		A213475	001	Mar 10, 2021	Feb	CAHN
		<u>DULOXETINE HYDROCHLORIDE</u>							
		CAPSULE, DELAYED REL PELLETS; ORAL							
>D>		DRIZALMA SPRINKLE							
>D>	+	SUN PHARM	EQ 30MG BASE		N212516	002	Jul 19, 2019	Mar	DISC
>A>	+	@	EQ 30MG BASE		N212516	002	Jul 19, 2019	Mar	DISC
		@	EQ 40MG BASE		N212516	003	Jul 19, 2019	Jan	DISC
>D>	+	!	EQ 60MG BASE		N212516	004	Jul 19, 2019	Mar	DISC
>A>	+	@	EQ 60MG BASE		N212516	004	Jul 19, 2019	Mar	DISC
		<u>EDETATE CALCIUM DISODIUM</u>							
>D>		INJECTABLE; INJECTION							
>D>		CALCIUM DISODIUM VERSENATE							
>D>	+	BAUSCH	200MG/ML		N008922	001		Mar	DISC
>A>	+	@	200MG/ML		N008922	001		Mar	DISC
		<u>EFAVIRENZ</u>							
		CAPSULE; ORAL							
		EFAVIRENZ							
>D>	AB	AUROBINDO PHARMA	50MG		A078064	001	Dec 15, 2017	Mar	CTEC
>A>			50MG		A078064	001	Dec 15, 2017	Mar	CTEC
>D>	AB		200MG		A078064	003	Dec 15, 2017	Mar	CHRS
>A>	!		200MG		A078064	003	Dec 15, 2017	Mar	CHRS
>D>		SUSTIVA							
>D>	AB	+ BRISTOL MYERS SQUIBB	50MG		N020972	001	Sep 17, 1998	Mar	DISC
>A>	+	@	50MG		N020972	001	Sep 17, 1998	Mar	DISC
>D>	AB	+	200MG		N020972	003	Sep 17, 1998	Mar	DISC
>A>	+	@	200MG		N020972	003	Sep 17, 1998	Mar	DISC
		<u>ELACESTRANT DIHYDROCHLORIDE</u>							
		TABLET; ORAL							
		ORSERDU							
	+	STEMLINE THERAP	EQ 86MG BASE		N217639	001	Jan 27, 2023	Jan	NEWA
	+	!	EQ 345MG BASE		N217639	002	Jan 27, 2023	Jan	NEWA
		<u>EMPAGLIFLOZIN</u>							
		TABLET; ORAL							
		EMPAGLIFLOZIN							
		@ ZYDUS PHARMS	10MG		A212138	001	Aug 03, 2022	Jan	DISC
		@	25MG		A212138	002	Aug 03, 2022	Jan	DISC
		JARDIANCE							
	+	BOEHRINGER INGELHEIM	10MG		N204629	001	Aug 01, 2014	Jan	CTEC
	+	!	25MG		N204629	002	Aug 01, 2014	Jan	CTEC
		<u>EMTRICITABINE</u>							
		CAPSULE; ORAL							
		EMTRICITABINE							
>A>	AB	AUROBINDO PHARMA LTD	200MG		A079188	001	Mar 15, 2023	Mar	NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

>A>	AB	AUROBINDO PHARMA LTD	100MG;150MG	A211640	001	Mar 09, 2023	Mar	NEWA
>A>	AB		133MG;200MG	A211640	002	Mar 09, 2023	Mar	NEWA
>A>	AB		167MG;250MG	A211640	003	Mar 09, 2023	Mar	NEWA

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

>A>	AP	SHENZHEN TECHDOW	30MG/0.3ML (100MG/ML)	A205660	001	Mar 15, 2023	Mar	NEWA
>A>	AP		40MG/0.4ML (100MG/ML)	A205660	002	Mar 15, 2023	Mar	NEWA
>A>	AP		60MG/0.6ML (100MG/ML)	A205660	003	Mar 15, 2023	Mar	NEWA
>A>	AP		80MG/0.8ML (100MG/ML)	A205660	004	Mar 15, 2023	Mar	NEWA
>A>	AP		100MG/ML (100MG/ML)	A205660	005	Mar 15, 2023	Mar	NEWA
>A>	AP		120MG/0.8ML (150MG/ML)	A205660	006	Mar 15, 2023	Mar	NEWA
>A>	AP		150MG/ML (150MG/ML)	A205660	007	Mar 15, 2023	Mar	NEWA

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

EMERPHED

>A>	+	NEXUS PHARMS	25MG/5ML (5MG/ML)	N213407	002	Feb 28, 2023	Mar	NEWA
		EPHEDRINE SULFATE						
AP		SAGENT PHARMS INC	50MG/ML (50MG/ML)	A214528	001	Mar 09, 2023	Feb	NEWA

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

EPOPROSTENOL SODIUM

AP2	!	SUN PHARM	EQ 0.5MG BASE/VIAL	A210473	001	Jan 15, 2021	Feb	CHRS
		VELETRI						
AP2	+	ACTELION	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb	CHRS

ERGOCALCIFEROL

CAPSULE; ORAL

DRISDOL

AA	+	VALIDUS PHARMS	50,000 IU	N003444	001			Feb	CHRS
		ERGOCALCIFEROL							
AA		CHARTWELL RX	50,000 IU	A040833	001	May 20, 2009	Feb	CAHN	
AA	!	STRIDES PHARMA	50,000 IU	A090455	001	Aug 03, 2010	Feb	CHRS	

ERYTHROMYCIN

TABLET; ORAL

ERYTHROMYCIN

AB		ARBOR PHARMS LLC	500MG	A061621	002			Jan	CHRS
AB	!	CADILA PHARMS LTD	500MG	A213628	002	Jun 28, 2021	Jan	CHRS	
AB		ZYDUS	250MG	A212693	001	Mar 07, 2023	Feb	NEWA	
AB			500MG	A212693	002	Mar 07, 2023	Feb	NEWA	

ESCITALOPRAM OXALATE

SOLUTION; ORAL

LEXAPRO

+	@	ABBVIE	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Jan	CAHN
---	---	--------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL

ESCITALOPRAM OXALATE

	@	DASH PHARMS	EQ 5MG BASE	A077550	001	May 14, 2015	Feb	CAHN
	@		EQ 10MG BASE	A077550	002	May 14, 2015	Feb	CAHN
	@		EQ 20MG BASE	A077550	003	May 14, 2015	Feb	CAHN
		LEXAPRO						
AB	+	ABBVIE	EQ 5MG BASE	N021323	001	Aug 14, 2002	Jan	CAHN
AB	+		EQ 10MG BASE	N021323	002	Aug 14, 2002	Jan	CAHN
AB	+	!	EQ 20MG BASE	N021323	003	Aug 14, 2002	Jan	CAHN

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

AP	+	!	BAXTER HLTHCARE	2GM/100ML	N019386	005	Jan 27, 2003	Jan	CTEC
			BREVIBLOC IN PLASTIC CONTAINER						
AP	+	!	BAXTER HLTHCARE	1GM/100ML	N019386	004	Feb 16, 2001	Jan	CTEC
			ESMOLOL HYDROCHLORIDE						
AP		AMNEAL	1GM/100ML	A216603	001	Dec 13, 2022	Jan	CPOT	
AP			2GM/100ML	A216603	002	Dec 13, 2022	Jan	CPOT	

INJECTABLE; INJECTIONESMOLOL HYDROCHLORIDE

AP	EUGIA PHARMA	1GM/100ML	A216244	001	Mar 21, 2022	Jan CPOT
AP		2GM/100ML	A216244	002	Mar 21, 2022	Jan CPOT
AP	HQ SPCLT PHARMA	1GM/100ML	A214172	001	Dec 02, 2022	Jan CPOT
AP		2GM/100ML	A214172	002	Dec 02, 2022	Jan CPOT
AP	MYLAN LABS LTD	1GM/100ML	A206608	001	Jun 08, 2018	Jan CPOT
AP		2GM/100ML	A206608	002	Jun 08, 2018	Jan CPOT
AP	SAGENT PHARMS INC	1GM/100ML	A207107	001	Jun 08, 2018	Jan CPOT
AP		2GM/100ML	A207107	002	Jun 08, 2018	Jan CPOT

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

ESOMEPRAZOLE MAGNESIUM

>A>	AB	PRINSTON INC	EQ 20MG BASE	A214920	001	Mar 28, 2023	Mar NEWA
>A>	AB		EQ 40MG BASE	A214920	002	Mar 28, 2023	Mar NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE; ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

@ ACTAVIS LABS FL INC EQ 20MG BASE; 375MG

A204470 001 Aug 24, 2022 Feb DISC

@ EQ 20MG BASE; 500MG

A204470 002 Aug 24, 2022 Feb DISC

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP	EUGIA PHARMA	EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Jan CHRS
----	--------------	-------------------	---------	-----	--------------	----------

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ESTRADIOL

>A>	AB2	ZYDUS NOVELTECH INC	0.025MG/24HR	A202985	001	Mar 29, 2023	Mar NEWA
>A>	AB2		0.0375MG/24HR	A202985	002	Mar 29, 2023	Mar NEWA
>A>	AB2		0.05MG/24HR	A202985	003	Mar 29, 2023	Mar NEWA
>A>	AB		0.06MG/24HR	A202985	004	Mar 29, 2023	Mar NEWA
>A>	AB2		0.075MG/24HR	A202985	005	Mar 29, 2023	Mar NEWA
>A>	AB2		0.1MG/24HR	A202985	006	Mar 29, 2023	Mar NEWA

INSERT; VAGINAL

IMVEXXY

+	MAYNE PHARMA	0.004MG	N208564	001	May 29, 2018	Jan CAHN
+	!	0.01MG	N208564	002	May 29, 2018	Jan CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

@ AMNEAL PHARMS 0.02MG; 0.1MG

A201108 001 Feb 05, 2014 Jan DISC

@ 0.03MG; 0.15MG

A201095 001 Dec 08, 2014 Jan DISC

AB1	HETERO LABS	0.02MG; 0.1MG	A212298	001	Feb 13, 2023	Feb NEWA
-----	-------------	---------------	---------	-----	--------------	----------

AB	LUPIN LTD	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A200248	001	Nov 19, 2015	Jan CTEC
----	-----------	--	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

HAILEY 24 FE

AB	!	GLENMARK PHARMS LTD	0.02MG; 1MG	A204847	001	Nov 17, 2017	Feb CTNA
----	---	---------------------	-------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

@ AMNEAL PHARMS 0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG

A203870 001 Nov 12, 2015 Jan DISC

ETHINYL ESTRADIOL; SEGESTERONE ACETATE

RING; VAGINAL

ANNOVERA

+	!	MAYNE PHARMA	0.013MG/24HR; 0.15MG/24HR	N209627	001	Aug 10, 2018	Jan CAHN
---	---	--------------	---------------------------	---------	-----	--------------	----------

ETOPOSIDEINJECTABLE; INJECTION
ETOPOSIDE

>A>	@ DASH PHARMS	20MG/ML	A204927	001	Oct 31, 2017	Mar	CAHN
	@ DASH PHARMS NATCO	20MG/ML	A203507	001	Nov 20, 2017	Feb	CAHN
>D>	@ MYLAN LABS LTD	20MG/ML	A204927	001	Oct 31, 2017	Mar	CAHN

EXEMESTANETABLET; ORAL
EXEMESTANE

@ ALVOGEN	25MG	A200898	001	Jul 28, 2014	Feb	DISC
-----------	------	---------	-----	--------------	-----	------

EZETIMIBETABLET; ORAL
EZETIMIBE

>D> AB	ORIENT PHARMA	10MG	A215693	001	Sep 13, 2022	Mar	DISC
>A>	@	10MG	A215693	001	Sep 13, 2022	Mar	DISC

FAMOTIDINETABLET; ORAL
FAMOTIDINE

AB	VKT PHARMA	20MG	A215630	001	Jan 07, 2022	Jan	CAHN
AB		40MG	A215630	002	Jan 07, 2022	Jan	CAHN

FAMOTIDINE; IBUPROFENTABLET; ORAL
IBUPROFEN AND FAMOTIDINE

>A> AB	ASCENT PHARMS INC	26.6MG;800MG	A216814	001	Mar 15, 2023	Mar	NEWA
--------	-------------------	--------------	---------	-----	--------------	-----	------

FEBUXOSTATTABLET; ORAL
FEBUXOSTAT

AB	ZYDUS LIFESCIENCES	40MG	A205443	001	Jan 09, 2023	Jan	CAHN
AB		80MG	A205443	002	Jan 09, 2023	Jan	CAHN

FENOFIBRATETABLET; ORAL
FENOFIBRATE

AB	CHARTWELL RX	54MG	A209660	001	Feb 11, 2019	Feb	CAHN
AB		160MG	A209660	002	Feb 11, 2019	Feb	CAHN

FENTANYLFILM, EXTENDED RELEASE; TRANSDERMAL
FENTANYL-100

AB	ZYDUS NOVELTECH INC	100MCG/HR	A209655	008	Jan 24, 2023	Jan	NEWA
AB	ZYDUS NOVELTECH INC	12.5MCG/HR	A209655	001	Jan 24, 2023	Jan	NEWA
AB	ZYDUS NOVELTECH INC	25MCG/HR	A209655	002	Jan 24, 2023	Jan	NEWA
AB	ZYDUS NOVELTECH INC	37.5MCG/HR	A209655	003	Jan 24, 2023	Jan	NEWA
AB	ZYDUS NOVELTECH INC	50MCG/HR	A209655	004	Jan 24, 2023	Jan	NEWA
AB	ZYDUS NOVELTECH INC	62.5MCG/HR	A209655	005	Jan 24, 2023	Jan	NEWA
AB	ZYDUS NOVELTECH INC	75MCG/HR	A209655	006	Jan 24, 2023	Jan	NEWA
AB	MYLAN TECHNOLOGIES	87.5MCG/HR	A076258	008	Dec 29, 2014	Jan	CTEC
AB	ZYDUS NOVELTECH INC	87.5MCG/HR	A209655	007	Jan 24, 2023	Jan	NEWA

FENTANYL CITRATEINJECTABLE; INJECTION
FENTANYL CITRATE

AP	HIKMA	EQ 0.025MG BASE/0.5ML	N019101	002	Jan 20, 2023	Jan	NEWA
	+	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Jan	CTNA
	SOLUTION; INTRAVENOUS						
	FENTANYL CITRATE						
	EXELA PHARMA	EQ 2.5MG BASE/50ML (EQ 0.05MG BASE/ML)	N215870	001	Feb 08, 2023	Feb	NEWA
	+	EQ 5MG BASE/100ML (EQ 0.05MG	N215870	002	Feb 08, 2023	Feb	NEWA

SOLUTION; INTRAVENOUS
FENTANYL CITRATE

BASE/ML)

FESOTERODINE FUMARATETABLET, EXTENDED RELEASE; ORAL
FESOTERODINE FUMARATE

@ LUPIN LTD	4MG	A204983	001	Jan 05, 2023	Feb DISC
@	8MG	A204983	002	Jan 05, 2023	Feb DISC

FINAFLOXACINSUSPENSION/DROPS; OTIC
XTORO

+ @ FONSECA BIOSCIENCES	0.3%	N206307	001	Dec 17, 2014	Jan CAHN
-------------------------	------	---------	-----	--------------	----------

FINGOLIMOD HYDROCHLORIDECAPSULE; ORAL
FINGOLIMOD HYDROCHLORIDE

AB BIOCON LTD	EQ 0.5MG BASE	A207979	001	Dec 04, 2019	Jan CMFD
---------------	---------------	---------	-----	--------------	----------

FINGOLIMOD LAURYL SULFATETABLET, ORALLY DISINTEGRATING; ORAL
TASCENSO ODT

+ CYCLE	EQ 0.25MG BASE	N214962	001	Dec 23, 2021	Jan CAHN
+!	EQ 0.5MG BASE	N214962	002	Dec 09, 2022	Jan CAHN

FLUDARABINE PHOSPHATEINJECTABLE; INJECTION
FLUDARABINE PHOSPHATE

AP2 ACTAVIS LLC	50MG/2ML (25MG/ML)	A203738	001	Feb 28, 2017	Jan CTEC
AP1 AREVA PHARMS	50MG/2ML (25MG/ML)	A090724	001	Sep 27, 2010	Jan CTEC
AP1 FRESENIUS KABI USA	50MG/2ML (25MG/ML)	A078393	001	Oct 15, 2007	Jan CTEC
AP	50MG/2ML (25MG/ML)	A078393	001	Oct 15, 2007	Jan CHRS
AP1 SAGENT PHARMS INC	50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Jan CTEC
AP2 +! SANDOZ	50MG/2ML (25MG/ML)	N022137	001	Sep 21, 2007	Jan CTEC

FLUOCINOLONE ACETONIDECREAM; TOPICAL
FLUOCINOLONE ACETONIDE

>A> @ INVATECH	0.025%	A088045	001	Dec 16, 1982	Mar CAHN
>D> @ MLV	0.025%	A088045	001	Dec 16, 1982	Mar CAHN

FLUOCINONIDECREAM; TOPICAL
FLUOCINONIDE

AB1 ! AMNEAL	0.05%	A210554	001	Aug 21, 2018	Feb CHRS
+ @ TARO	0.05%	N019117	001	Jun 26, 1984	Feb DISC

FLUOROMETHOLONESUSPENSION/DROPS; OPHTHALMIC
FML

+! ABBVIE	0.1%	N016851	002	Jul 28, 1982	Jan CAHN
FML FORTE					
+! ABBVIE	0.25%	N019216	001	Apr 23, 1986	Jan CAHN

FLUOROURACILINJECTABLE; INJECTION
FLUOROURACIL

AP ALEMbic	2.5GM/50ML (50MG/ML)	A217295	001	Mar 03, 2023	Feb NEWA
------------	----------------------	---------	-----	--------------	----------

FLUOXETINE HYDROCHLORIDESOLUTION; ORAL
FLUOXETINE HYDROCHLORIDE

>D> @ NOSTRUM LABS INC	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002	Mar CMFD
>A> AA	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002	Mar CMFD
AA XTTRIUM LABS INC	EQ 20MG BASE/5ML	A075514	001	Aug 29, 2002	Jan CAHN

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

>D> AB PIRAMAL HLTHCARE UK	EQ 10MG BASE	A211444	001	Sep 13, 2022	Mar DISC
>A> @	EQ 10MG BASE	A211444	001	Sep 13, 2022	Mar DISC
>D> AB	EQ 20MG BASE	A211444	002	Sep 13, 2022	Mar DISC
>A> @	EQ 20MG BASE	A211444	002	Sep 13, 2022	Mar DISC

FLUPHENAZINE DECANOATEINJECTABLE; INJECTION
FLUPHENAZINE DECANOATE

>A>	AO	GLAND PHARMA LTD	25MG/ML	A215509	001	Mar 30, 2023	Mar	NEWA
-----	----	------------------	---------	---------	-----	--------------	-----	------

FLUVOXAMINE MALEATETABLET; ORAL
LUVOX

AB	+	ANI PHARMS	25MG	N021519	001	Dec 20, 2007	Jan	CRLD
AB	+		50MG	N021519	002	Dec 20, 2007	Jan	CRLD
AB	+		100MG	N021519	003	Dec 20, 2007	Jan	CRLD

FORMOTEROL FUMARATESOLUTION; INHALATION
FORMOTEROL FUMARATE

>A>	AN	MANKIND PHARMA	0.02MG/2ML	A215883	001	Mar 22, 2023	Mar	NEWA
-----	----	----------------	------------	---------	-----	--------------	-----	------

FUROSEMIDESOLUTION; ORAL
FUROSEMIDE

@ XTTRIUM LABS INC 10MG/ML

A070655 001 Oct 02, 1987 Jan CAHN

TABLET; ORAL
FUROSEMIDE

>D>	@	AVET	20MG	N018413	001	Nov 30, 1983	Mar	CAHN
>D>	@		40MG	N018413	002	Nov 30, 1983	Mar	CAHN
>A>	@	CHARTWELL RX	20MG	N018413	001	Nov 30, 1983	Mar	CAHN
>A>	@		40MG	N018413	002	Nov 30, 1983	Mar	CAHN

GABAPENTINSOLUTION; ORAL
GABAPENTIN

AA RUBICON 250MG/5ML

A216492 001 Jan 18, 2023 Jan NEWA

TABLET; ORAL
GABAPENTIN

>A>	AB	GRANULES	600MG	A217116	001	Mar 28, 2023	Mar	NEWA
>A>	AB		800MG	A217116	002	Mar 28, 2023	Mar	NEWA

GADOBUTROLSOLUTION; INTRAVENOUS
GADOBUTROL

>A>	AP	HAINAN POLY PHARM	4.5354GM/7.5ML (604.72MG/ML)	A217480	001	Mar 15, 2023	Mar	NEWA
>A>	AP		9.0708GM/15ML (604.72MG/ML)	A217480	002	Mar 15, 2023	Mar	NEWA

GADOTERATE MEGLUMINESOLUTION; INTRAVENOUS
GADOTERATE MEGLUMINE

AP HENGRUI PHARMA 37.69GM/100ML (376.9MG/ML)

A215304 005 Apr 15, 2022 Feb CMS1

GANIRELIX ACETATEINJECTABLE; INJECTION
GANIRELIX ACETATE

AP GLAND PHARMA LTD 250MCG/0.5ML

A215658 001 Feb 28, 2023 Feb NEWA

GATIFLOXACINSOLUTION/DROPS; OPHTHALMIC
ZYMAR

>D>	+	ALLERGAN	0.3%	N021493	001	Mar 28, 2003	Mar	DISC
>A>	+	@	0.3%	N021493	001	Mar 28, 2003	Mar	DISC
AT	+	ABBVIE	0.5%	N022548	001	May 18, 2010	Jan	CAHN

GEFITINIBTABLET; ORAL
GEFITINIB

AB QILU PHARM HAINAN 250MG

A211591 001 Feb 13, 2023 Feb NEWA

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

AP	HIKMA	200MG/5.26ML (38MG/ML)	A213175	001	Mar 07, 2023	Feb	NEWA
AP		1GM/26.3ML (38MG/ML)	A213175	002	Mar 07, 2023	Feb	NEWA
AP		2GM/52.6ML (38MG/ML)	A213175	003	Mar 07, 2023	Feb	NEWA

GENTAMICIN SULFATE

OINTMENT; OPHTHALMIC
GENTAMICIN SULFATE

	@ AKORN	EQ 0.3% BASE	A064093	001	Aug 31, 1995	Feb	DISC
!	FERA PHARMS LLC	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb	CTEC
AT	!	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb	CHRS

SOLUTION/DROPS; OPHTHALMIC
GENOPTIC

	@ ALLERGAN	EQ 0.3% BASE	A062452	001	Oct 10, 1984	Feb	DISC	
	GENTAK							
	@ AKORN	EQ 0.3% BASE	A064163	001	Oct 12, 2001	Feb	DISC	
	GENTAMICIN SULFATE							
AT	!	SANDOZ INC	EQ 0.3% BASE	A062196	001		Feb	CHRS

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC
PRED-G

+	@ ALLERGAN	EQ 0.3% BASE; 0.6%	N050612	001	Dec 01, 1989	Jan	DISC
---	------------	--------------------	---------	-----	--------------	-----	------

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

	@ DASH PHARMS	2.5MG; 250MG	A078083	001	Apr 12, 2007	Feb	CAHN
	@	2.5MG; 500MG	A078083	002	Apr 12, 2007	Feb	CAHN
	@	5MG; 500MG	A078083	003	Apr 12, 2007	Feb	CAHN

GLUCAGON

SOLUTION; SUBCUTANEOUS
GVOKE PFS

+	@ XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097	001	Sep 10, 2019	Jan	DISC
---	---------	---------------------------	---------	-----	--------------	-----	------

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL
RAVICTI

+	!	HORIZON THERAP US	1.1GM/ML	N203284	001	Feb 01, 2013	Jan	CAHN
---	---	-------------------	----------	---------	-----	--------------	-----	------

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE

AP	LUPIN LTD	0.2MG/ML	A213655	001	Feb 07, 2023	Jan	NEWA
AP	MANKIND PHARMA	0.2MG/ML	A217354	001	Feb 27, 2023	Feb	NEWA

TABLET; ORAL

GLYCOPYRROLATE

AA	ALEMBIC	1MG	A203657	001	Nov 30, 2018	Feb	CAHN
AA		2MG	A203657	002	Nov 30, 2018	Feb	CAHN
AA	AUROBINDO PHARMA	1MG	A202675	001	Apr 15, 2013	Jan	CAHN
AA		2MG	A202675	002	Oct 30, 2018	Jan	CAHN

GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS
PREVDUO

+	!	SLAYBACK PHARMA LLC	0.6MG/3ML (0.2MG/ML); 3MG/3ML (1MG/ML)	N216903	001	Feb 23, 2023	Feb	NEWA
---	---	---------------------	--	---------	-----	--------------	-----	------

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

	@ ACTAVIS GROUP	0.5MG	A200854	001	Jul 01, 2022	Jan	DISC
	@	1MG	A200854	002	Jul 01, 2022	Jan	DISC
	@	2MG	A200854	003	Jul 01, 2022	Jan	DISC
	@	5MG	A200854	004	Jul 01, 2022	Jan	DISC
	@	10MG	A200854	005	Jul 01, 2022	Jan	DISC
	@	20MG	A200854	006	Jul 01, 2022	Jan	DISC
AB	ZYDUS PHARMS USA	0.5MG	A077580	001	Jan 17, 2023	Jan	NEWA

<u>TABLET; ORAL</u>							
HALOPERIDOL							
AB		1MG		A077580	002	Jan 17, 2023	Jan NEWA
AB		2MG		A077580	006	Jan 17, 2023	Jan NEWA
<u>HEPARIN SODIUM</u>							
INJECTABLE; INJECTION							
HEPARIN SODIUM							
AP	NANJING KING-FRIEND	5,000 UNITS/ML		A212061	001	Jul 15, 2020	Feb CMFD
AP	HEPARIN SODIUM PRESERVATIVE FREE			A212060	001	Apr 02, 2020	Feb CMFD
AP	NANJING KING-FRIEND	10,000 UNITS/ML		A212060	001	Apr 02, 2020	Feb CMFD
<u>HYDRALAZINE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
HYDRALAZINE HYDROCHLORIDE							
AP	EUGIA PHARMA	20MG/ML		A215147	001	Feb 13, 2023	Feb NEWA
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL</u>							
TABLET; ORAL							
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE							
AB	ZYDUS PHARMS	12.5MG; 20MG		A206377	001	Feb 24, 2023	Feb NEWA
AB		12.5MG; 40MG		A206377	002	Feb 24, 2023	Feb NEWA
AB		25MG; 40MG		A206377	003	Feb 24, 2023	Feb NEWA
<u>HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE</u>							
TABLET; ORAL							
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE							
AB	APOTEX	12.5MG; EQ 10MG BASE		A091524	001	Mar 12, 2013	Jan CAHN
AB		12.5MG; EQ 20MG BASE		A091524	002	Mar 12, 2013	Jan CAHN
AB		25MG; EQ 20MG BASE		A091524	003	Mar 12, 2013	Jan CAHN
<u>HYDROMORPHONE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
HYDROMORPHONE HYDROCHLORIDE							
>A>	HOSPIRA INC	0.25MG/0.5ML		N200403	005	Mar 03, 2023	Mar NEWA
<u>HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE</u>							
SOLUTION/DROPS; OPHTHALMIC							
PAREMYD							
	+ @ AKORN	1%; 0.25%		N019261	001	Jan 30, 1992	Feb DISC
<u>HYDROXYPROPYL CELLULOSE</u>							
INSERT; OPHTHALMIC							
LACRISERT							
	+! BAUSCH	5MG		N018771	001		Jan CAHN
	+! BAUSCH AND LOMB INC	5MG		N018771	001		Jan CAHN
<u>HYDROXYZINE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
HYDROXYZINE HYDROCHLORIDE							
	+! AM REGENT	25MG/ML		A087408	001		Feb CRLD
	+!	50MG/ML		A087408	002		Feb CRLD
TABLET; ORAL							
HYDROXYZINE HYDROCHLORIDE							
AB	CHARTWELL RX	10MG		A040804	001	Jun 30, 2008	Jan CAHN
AB		25MG		A040804	002	Jun 30, 2008	Jan CAHN
AB		50MG		A040804	003	Jun 30, 2008	Jan CAHN
<u>HYDROXYZINE PAMOATE</u>							
CAPSULE; ORAL							
HYDROXYZINE PAMOATE							
>D>	BX	HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Mar CTEC
>A>	AB		EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Mar CTEC
>D>	BX		EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Mar CTEC
>A>	AB		EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Mar CTEC

ICOSAPENT ETHYLCAPSULE;ORAL
ICOSAPENT ETHYL

AB	DR REDDYS	500MG	A209499	002	Mar 08, 2023	Feb NEWA
AB	HIKMA	500MG	A209457	002	Mar 08, 2023	Feb NEWA

IMATINIB MESYLATETABLET;ORAL
IMATINIB MESYLATE

>D>	AB	BRECKENRIDGE	EQ 100MG BASE	A205990	001	Feb 08, 2019	Mar DISC
>A>		@	EQ 100MG BASE	A205990	001	Feb 08, 2019	Mar DISC
	AB	CHARTWELL RX	EQ 100MG BASE	A208429	001	Jan 17, 2019	Jan CAHN
	AB		EQ 400MG BASE	A208429	002	Jan 17, 2019	Jan CAHN

IMIQUIMODCREAM;TOPICAL
ALDARA

		+ @ BAUSCH	5%	N020723	001	Feb 27, 1997	Feb DISC
		IMIQUIMOD					
AB	!	GLENMARK GENERICS	5%	A201994	001	Mar 06, 2012	Feb CHRS

INDOMETHACINCAPSULE;ORAL
INDOMETHACIN

AB		CHARTWELL MOLECULES	25MG	N018829	002	Aug 06, 1984	Feb CMFD
AB			50MG	N018829	001	Aug 06, 1984	Feb CMFD

IOPAMIDOLINJECTABLE;INJECTION
IOPAMIDOL

AP		HAINAN POLY	41%	A215382	001	Feb 27, 2023	Feb NEWA
AP			61%	A215382	002	Feb 27, 2023	Feb NEWA
		ISOVUE-M 200					
AP	+	BRACCO	41%	N018735	001	Dec 31, 1985	Feb CTEC
		ISOVUE-M 300					
AP	+	BRACCO	61%	N018735	004	Dec 31, 1985	Feb CTEC

ISONIAZIDTABLET;ORAL
LANIAZID

		@ CHARTWELL MOLECULAR	50MG	A080140	001		Feb CAHN
		@	100MG	A080140	002		Feb CAHN

IVERMECTINCREAM;TOPICAL
IVERMECTIN

		@ ZYDUS	1%	A215210	001	Aug 02, 2022	Jan DISC
--	--	---------	----	---------	-----	--------------	----------

KETAMINE HYDROCHLORIDEINJECTABLE;INJECTION
KETAMINE HYDROCHLORIDE

AP		FRESENIUS KABI USA	EQ 10MG BASE/ML	A215808	001	Jan 13, 2023	Jan NEWA
AP			EQ 50MG BASE/ML	A215808	002	Jan 13, 2023	Jan NEWA
AP		GLAND PHARMA LTD	EQ 50MG BASE/ML	A216809	002	Jan 24, 2023	Jan NEWA
AP			EQ 100MG BASE/ML	A216809	003	Jan 24, 2023	Jan NEWA

KETOROLAC TROMETHAMINESOLUTION/DROPS;OPHTHALMIC
ACULAR

AT	+	ABBVIE	0.5%	N019700	001	Nov 09, 1992	Jan CAHN
		KETOROLAC TROMETHAMINE					
		@ AKORN	0.5%	A078434	001	Nov 05, 2009	Jan DISC

TABLET;ORAL

KETOROLAC TROMETHAMINE

AB		BIONPHARMA INC	10MG	A216759	001	Feb 23, 2023	Feb NEWA
AB		LEADING	10MG	A215745	001	Feb 23, 2023	Feb NEWA

LACOSAMIDE

		SOLUTION; INTRAVENOUS							
		LACOSAMIDE							
AP	MSN	200MG/20ML (10MG/ML)		A215979	001	Feb 09, 2023	Feb	NEWA	
		SOLUTION; ORAL							
		LACOSAMIDE							
AA	MEDLEY PHARMS	10MG/ML		A216461	001	Feb 06, 2023	Jan	NEWA	
		TABLET; ORAL							
		LACOSAMIDE							
	@ ACCORD HLTHCARE	50MG		A205011	001	Jul 12, 2022	Jan	DISC	
	@	100MG		A205011	002	Jul 12, 2022	Jan	DISC	
	@	150MG		A205011	003	Jul 12, 2022	Jan	DISC	
	@	200MG		A205011	004	Jul 12, 2022	Jan	DISC	
>D>	AB APOTEX	50MG		A214567	001	Sep 23, 2022	Mar	DISC	
>A>	@	50MG		A214567	001	Sep 23, 2022	Mar	DISC	
>D>	AB	100MG		A214567	002	Sep 23, 2022	Mar	DISC	
>A>	@	100MG		A214567	002	Sep 23, 2022	Mar	DISC	
>D>	AB	150MG		A214567	003	Sep 23, 2022	Mar	DISC	
>A>	@	150MG		A214567	003	Sep 23, 2022	Mar	DISC	
>D>	AB	200MG		A214567	004	Sep 23, 2022	Mar	DISC	
>A>	@	200MG		A214567	004	Sep 23, 2022	Mar	DISC	

LACTULOSE

		SOLUTION; ORAL							
		LACTULOSE							
>D>	@ XTTRIUM LABS INC	10GM/15ML		A075911	001	Feb 21, 2002	Mar	CMFD	
>A>	AA	10GM/15ML		A075911	001	Feb 21, 2002	Mar	CMFD	
		SOLUTION; ORAL, RECTAL							
		LACTULOSE							
AA	BAJAJ	10GM/15ML		A076645	001	Jul 28, 2003	Feb	CMFD	

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

		TABLET; ORAL							
		TEMIXYS							
>D>	+ @ CELLTRION	300MG; 300MG		N211284	001	Nov 16, 2018	Mar	CAHN	
>A>	+ @ CHARTWELL RX	300MG; 300MG		N211284	001	Nov 16, 2018	Mar	CAHN	

LAMOTRIGINE

		TABLET; ORAL							
		LAMOTRIGINE							
	@ CHARTWELL MOLECULAR	25MG		A077783	001	Nov 01, 2010	Jan	CAHN	
	@	100MG		A077783	002	Nov 01, 2010	Jan	CAHN	
	@	150MG		A077783	003	Nov 01, 2010	Jan	CAHN	
	@	200MG		A077783	004	Nov 01, 2010	Jan	CAHN	

LANSOPRAZOLE

		TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE; ORAL							
		LANSOPRAZOLE							
>A>	AB AUROBINDO PHARMA LTD	15MG		A207167	001	Mar 28, 2023	Mar	NEWA	
>A>	AB	30MG		A207167	002	Mar 28, 2023	Mar	NEWA	

LATANOPROST

		SOLUTION/DROPS; OPHTHALMIC							
		LATANOPROST							
	@ AKORN	0.005%		A090887	001	Jul 19, 2011	Jan	DISC	

LENALIDOMIDE

		CAPSULE; ORAL							
		LENALIDOMIDE							
AB	APOTEX	2.5MG		A211022	005	Mar 07, 2023	Feb	NEWA	
AB		20MG		A211022	006	Mar 07, 2023	Feb	NEWA	
AB	ARROW INTL	2.5MG		A201452	005	Mar 06, 2023	Feb	NEWA	
AB		20MG		A201452	006	Mar 06, 2023	Feb	NEWA	
AB	CIPLA	2.5MG		A214618	001	Mar 06, 2023	Feb	NEWA	
AB		20MG		A210435	005	Mar 06, 2023	Feb	NEWA	
AB	EUGIA PHARMA	2.5MG		A213885	001	Mar 06, 2023	Feb	NEWA	
AB		5MG		A213885	002	Mar 06, 2023	Feb	NEWA	
AB		10MG		A213885	003	Mar 06, 2023	Feb	NEWA	
AB		15MG		A213885	004	Mar 06, 2023	Feb	NEWA	
AB		20MG		A213885	005	Mar 06, 2023	Feb	NEWA	
AB		25MG		A213885	006	Mar 06, 2023	Feb	NEWA	

CAPSULE;ORAL

LENALIDOMIDE

AB	LOTUS PHARM CO LTD	2.5MG	A210480	005	Mar 06, 2023	Feb	NEWA
AB		20MG	A210480	006	Mar 06, 2023	Feb	NEWA
AB	MYLAN	2.5MG	A213912	005	Mar 06, 2023	Feb	NEWA
AB		20MG	A213912	006	Mar 06, 2023	Feb	NEWA
AB	SUN PHARM	2.5MG	A211846	005	Mar 06, 2023	Feb	NEWA
AB		5MG	A211846	001	Feb 08, 2023	Jan	NEWA
AB		10MG	A211846	002	Feb 08, 2023	Jan	NEWA
AB		15MG	A211846	003	Feb 08, 2023	Jan	NEWA
AB		20MG	A211846	006	Mar 06, 2023	Feb	NEWA
AB		25MG	A211846	004	Feb 08, 2023	Jan	NEWA
AB	TORRENT	10MG	A213405	001	Feb 17, 2023	Feb	NEWA
AB		25MG	A213405	002	Feb 17, 2023	Feb	NEWA
AB	ZYDUS PHARMS	2.5MG	A210154	005	Mar 06, 2023	Feb	NEWA
AB		20MG	A210154	006	Mar 06, 2023	Feb	NEWA

>A> LENIOLISIB PHOSPHATE

>A> TABLET;ORAL

>A> JOENJA

>A>	+!	PHARMING	EQ 70MG BASE	N217759	001	Mar 24, 2023	Mar	NEWA
-----	----	----------	--------------	---------	-----	--------------	-----	------

LETROZOLE

TABLET;ORAL

LETROZOLE

	@	CHARTWELL RX	2.5MG	A202716	001	May 16, 2013	Feb	CAHN
--	---	--------------	-------	---------	-----	--------------	-----	------

LEUPROLIDE ACETATE

POWDER;SUBCUTANEOUS

ELIGARD KIT

+!	TOLMAR	7.5MG	N021343	001	Jan 23, 2002	Feb	CAHN
+!		22.5MG	N021379	001	Jul 24, 2002	Feb	CAHN
+!		30MG	N021488	001	Feb 13, 2003	Feb	CAHN
+!		45MG	N021731	001	Dec 14, 2004	Feb	CAHN

LEVETIRACETAM

INJECTABLE;INTRAVENOUS

LEVETIRACETAM IN SODIUM CHLORIDE

AP	FRESENIUS KABI USA	500MG/100ML (5MG/ML)	A208619	001	Jan 31, 2023	Jan	NEWA
AP		1.5GM/100ML (15MG/ML)	A208619	003	Jan 31, 2023	Jan	NEWA

SOLUTION;ORAL

LEVETIRACETAM

AA	ALEMBIC	100MG/ML	A203067	001	May 09, 2013	Feb	CAHN	
AA	QUAGEN	100MG/ML	A090079	001	Apr 11, 2012	Feb	CAHN	
>D>	@	WOCKHARDT BIO AG	100MG/ML	A090028	001	Mar 03, 2010	Mar	CAHN
>A>	@	XTTRIUM LABS INC	100MG/ML	A090028	001	Mar 03, 2010	Mar	CAHN

LEVOFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

	@	AKORN	0.5%	A090268	001	Dec 20, 2010	Jan	DISC
	!	RISING	0.5%	A077700	001	Dec 20, 2010	Jan	CTEC

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

FETZIMA

>D>	AB	+	ABBVIE	EQ 20MG BASE	N204168	001	Jul 25, 2013	Mar	CTEC
>A>		+		EQ 20MG BASE	N204168	001	Jul 25, 2013	Mar	CTEC
	AB	+		EQ 20MG BASE	N204168	001	Jul 25, 2013	Jan	CAHN
>D>	AB	+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Mar	CTEC
>A>		+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Mar	CTEC
	AB	+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Jan	CAHN
>D>	AB	+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Mar	CTEC
>A>		+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Mar	CTEC
	AB	+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Jan	CAHN
>D>	AB	+!		EQ 120MG BASE	N204168	004	Jul 25, 2013	Mar	CTEC
>A>		+!		EQ 120MG BASE	N204168	004	Jul 25, 2013	Mar	CTEC
	AB	+!		EQ 120MG BASE	N204168	004	Jul 25, 2013	Jan	CAHN
>D>				LEVOMILNACIPRAN HYDROCHLORIDE					
>D>	AB		AUROBINDO PHARMA LTD	EQ 20MG BASE	A210826	001	Jan 06, 2023	Mar	DISC
>A>		@		EQ 20MG BASE	A210826	001	Jan 06, 2023	Mar	DISC
>D>	AB			EQ 40MG BASE	A210826	002	Jan 06, 2023	Mar	DISC

CAPSULE, EXTENDED RELEASE;ORAL
LEVOMILNACIPRAN HYDROCHLORIDE

>A>	@	EQ 40MG BASE	A210826	002	Jan 06, 2023	Mar	DISC
>D>	AB	EQ 80MG BASE	A210826	003	Jan 06, 2023	Mar	DISC
>A>	@	EQ 80MG BASE	A210826	003	Jan 06, 2023	Mar	DISC
>D>	AB	EQ 120MG BASE	A210826	004	Jan 06, 2023	Mar	DISC
>A>	@	EQ 120MG BASE	A210826	004	Jan 06, 2023	Mar	DISC
>A>	AB	PRINSTON INC EQ 20MG BASE	A210771	001	Mar 20, 2023	Mar	NEWA
>A>	AB	EQ 40MG BASE	A210771	002	Mar 20, 2023	Mar	NEWA
>A>	AB	EQ 80MG BASE	A210771	003	Mar 20, 2023	Mar	NEWA
>A>	AB	EQ 120MG BASE	A210771	004	Mar 20, 2023	Mar	NEWA

LEVORPHANOL TARTRATE

TABLET;ORAL
LEVORPHANOL TARTRATE

AB	HIKMA	2MG	A074278	001	Mar 31, 2000	Jan	CMFD
----	-------	-----	---------	-----	--------------	-----	------

LEVOTHYROXINE SODIUM

POWDER;INTRAVENOUS
LEVOTHYROXINE SODIUM

>A>	AP	ZYDUS PHARMS 100MCG/VIAL	A217066	001	Mar 24, 2023	Mar	NEWA
>A>	AP	200MCG/VIAL	A217066	002	Mar 24, 2023	Mar	NEWA
>A>	AP	500MCG/VIAL	A217066	003	Mar 24, 2023	Mar	NEWA

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL
LEVOTHYROXINE SODIUM

AB4	ASCENT PHARMS INC	0.025MG	A215259	001	Jan 18, 2023	Jan	NEWA
AB4		0.05MG	A215259	002	Jan 18, 2023	Jan	NEWA
AB4		0.075MG	A215259	003	Jan 18, 2023	Jan	NEWA
AB4		0.088MG	A215259	004	Jan 18, 2023	Jan	NEWA
AB4		0.1MG	A215259	005	Jan 18, 2023	Jan	NEWA
AB4		0.112MG	A215259	006	Jan 18, 2023	Jan	NEWA
AB4		0.125MG	A215259	007	Jan 18, 2023	Jan	NEWA
AB4		0.137MG	A215259	008	Jan 18, 2023	Jan	NEWA
AB4		0.15MG	A215259	009	Jan 18, 2023	Jan	NEWA
AB4		0.175MG	A215259	010	Jan 18, 2023	Jan	NEWA
AB4		0.2MG	A215259	011	Jan 18, 2023	Jan	NEWA
AB4		0.3MG	A215259	012	Jan 18, 2023	Jan	NEWA
AB2	MACLEODS PHARMS LTD	0.025MG	A211417	001	Dec 21, 2022	Jan	CTEC
AB2		0.05MG	A211417	002	Dec 21, 2022	Jan	CTEC
AB2		0.075MG	A211417	003	Dec 21, 2022	Jan	CTEC
AB2		0.088MG	A211417	004	Dec 21, 2022	Jan	CTEC
AB2		0.1MG	A211417	005	Dec 21, 2022	Jan	CTEC
AB2		0.112MG	A211417	006	Dec 21, 2022	Jan	CTEC
AB2		0.125MG	A211417	007	Dec 21, 2022	Jan	CTEC
AB2		0.137MG	A211417	008	Dec 21, 2022	Jan	CTEC
AB2		0.15MG	A211417	009	Dec 21, 2022	Jan	CTEC
AB2		0.175MG	A211417	010	Dec 21, 2022	Jan	CTEC
AB2		0.2MG	A211417	011	Dec 21, 2022	Jan	CTEC
AB2		0.3MG	A211417	012	Dec 21, 2022	Jan	CTEC

LIDOCAINE HYDROCHLORIDE

SOLUTION;ORAL
LIDOCAINE HYDROCHLORIDE

>A>	AT	RUBICON 2%	A216780	001	Mar 28, 2023	Mar	NEWA
-----	----	---------------	---------	-----	--------------	-----	------

LINACLOTIDE

CAPSULE;ORAL
LINACLOTIDE

>D>	AB	AUROBINDO PHARMA 145MCG	A209611	001	Feb 07, 2023	Mar	DISC
>A>	@	145MCG	A209611	001	Feb 07, 2023	Mar	DISC
	AB	145MCG	A209611	001	Feb 07, 2023	Jan	NEWA
>D>	AB	290MCG	A209611	002	Feb 07, 2023	Mar	DISC
>A>	@	290MCG	A209611	002	Feb 07, 2023	Mar	DISC
	AB	290MCG	A209611	002	Feb 07, 2023	Jan	NEWA
		LINZESS					
>D>	AB	+! ABBVIE 145MCG	N202811	001	Aug 30, 2012	Mar	CTEC
>A>	+!	145MCG	N202811	001	Aug 30, 2012	Mar	CTEC
>D>	AB	+ 290MCG	N202811	002	Aug 30, 2012	Mar	CTEC
>A>	+	290MCG	N202811	002	Aug 30, 2012	Mar	CTEC
	AB	+! ALLERGAN 145MCG	N202811	001	Aug 30, 2012	Jan	CTEC

		CAPSULE;ORAL							
		LINZESS							
AB	+		290MCG		N202811	002	Aug 30, 2012	Jan	CTEC
		<u>LINAGLIPTIN</u>							
		TABLET;ORAL							
		LINAGLIPTIN							
>A>	AB	ZYDUS PHARMS	5MG		A208448	001	Mar 30, 2023	Mar	NEWA
		<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE</u>							
		TABLET;ORAL							
		LINAGLIPTIN AND METFORMIN HYDROCHLORIDE							
>A>	AB	ZYDUS PHARMS	2.5MG;500MG		A208449	001	Mar 30, 2023	Mar	NEWA
>A>	AB		2.5MG;850MG		A208449	002	Mar 30, 2023	Mar	NEWA
>A>	AB		2.5MG;1GM		A208449	003	Mar 30, 2023	Mar	NEWA
		<u>LINEZOLID</u>							
		TABLET;ORAL							
		LINEZOLID							
>D>	AB	CELLTRION	600MG		A210702	001	Apr 25, 2019	Mar	CAHN
>A>	AB	CHARTWELL RX	600MG		A210702	001	Apr 25, 2019	Mar	CAHN
		<u>LISINOPRIL</u>							
		TABLET;ORAL							
		LISINOPRIL							
>D>		@ HERITAGE PHARMA	2.5MG		A075752	001	Jul 01, 2002	Mar	CMFD
>A>	AB		2.5MG		A075752	001	Jul 01, 2002	Mar	CMFD
>D>		@	5MG		A075752	002	Jul 01, 2002	Mar	CMFD
>A>	AB		5MG		A075752	002	Jul 01, 2002	Mar	CMFD
>D>		@	10MG		A075752	003	Jul 01, 2002	Mar	CMFD
>A>	AB		10MG		A075752	003	Jul 01, 2002	Mar	CMFD
>D>		@	20MG		A075752	004	Jul 01, 2002	Mar	CMFD
>A>	AB		20MG		A075752	004	Jul 01, 2002	Mar	CMFD
>D>		@	30MG		A075752	005	Jul 01, 2002	Mar	CMFD
>A>	AB		30MG		A075752	005	Jul 01, 2002	Mar	CMFD
>D>		@	40MG		A075752	006	Jul 01, 2002	Mar	CMFD
>A>	AB		40MG		A075752	006	Jul 01, 2002	Mar	CMFD
		<u>LOPERAMIDE HYDROCHLORIDE</u>							
		CAPSULE;ORAL							
		LOPERAMIDE HYDROCHLORIDE							
AB		RUBICON	2MG		A216876	001	Jan 26, 2023	Jan	NEWA
>A>	AB	ZYDUS PHARMS	2MG		A217471	001	Mar 23, 2023	Mar	NEWA
		<u>LOSARTAN POTASSIUM</u>							
		TABLET;ORAL							
		LOSARTAN POTASSIUM							
AB		GRANULES	25MG		A215959	001	Feb 23, 2023	Feb	NEWA
AB			50MG		A215959	002	Feb 23, 2023	Feb	NEWA
AB			100MG		A215959	003	Feb 23, 2023	Feb	NEWA
		<u>LOTEPREDNOL ETABONATE</u>							
		SUSPENSION/DROPS;OPHTHALMIC							
		ALREX							
>D>	+	BAUSCH AND LOMB	0.2%		N020803	001	Mar 09, 1998	Mar	CFTG
>A>	AB	+	0.2%		N020803	001	Mar 09, 1998	Mar	CFTG
		LOTEPREDNOL ETABONATE							
>A>	AB	AKORN	0.2%		A215933	001	Apr 12, 2023	Mar	NFTG
		<u>LUBIPROSTONE</u>							
		CAPSULE;ORAL							
		LUBIPROSTONE							
AB		AMNEAL	8MCG		A209450	001	Nov 30, 2021	Jan	CMFD
AB			24MCG		A209450	002	Nov 30, 2021	Jan	CMFD
>A>	AB	ZYDUS PHARMS	8MCG		A214131	001	Mar 23, 2023	Mar	NEWA
>A>	AB		24MCG		A214131	002	Mar 23, 2023	Mar	NEWA

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LURASIDONE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	20MG	A208002	001	Jan 03, 2019	Feb	CMFD
AB		40MG	A208002	002	Jan 03, 2019	Feb	CMFD
AB		60MG	A208002	003	Jan 03, 2019	Feb	CMFD
AB		80MG	A208002	004	Jan 03, 2019	Feb	CMFD
AB		120MG	A208002	005	Jan 03, 2019	Feb	CMFD
>A>	AUROBINDO PHARMA LTD	20MG	A208045	001	Mar 10, 2023	Mar	NEWA
>A>		40MG	A208045	002	Mar 10, 2023	Mar	NEWA
>A>		60MG	A208045	003	Mar 10, 2023	Mar	NEWA
>A>		80MG	A208045	004	Mar 10, 2023	Mar	NEWA
>A>		120MG	A208045	005	Mar 10, 2023	Mar	NEWA
>D>	AVET LIFESCIENCES	120MG	A208058	005	Feb 28, 2023	Mar	DISC
>A>	@	120MG	A208058	005	Feb 28, 2023	Mar	DISC
AB		120MG	A208058	005	Feb 28, 2023	Feb	NEWA
AB	LUPIN LTD	20MG	A208031	001	Jan 03, 2019	Feb	CMFD
AB		40MG	A208031	002	Jan 03, 2019	Feb	CMFD
AB		60MG	A208031	003	Jan 03, 2019	Feb	CMFD
AB		80MG	A208031	004	Jan 03, 2019	Feb	CMFD
AB		120MG	A208031	005	Jan 03, 2019	Feb	CMFD
AB	PIRAMAL HLTHCARE UK	20MG	A212091	001	Dec 28, 2020	Feb	CMFD
AB		40MG	A212091	002	Dec 28, 2020	Feb	CMFD
AB		60MG	A212091	003	Dec 28, 2020	Feb	CMFD
AB		80MG	A212091	004	Dec 28, 2020	Feb	CMFD
AB		120MG	A212091	005	Dec 28, 2020	Feb	CMFD
AB	TORRENT	20MG	A208055	001	Jan 03, 2019	Feb	CMFD
AB		40MG	A208055	002	Jan 03, 2019	Feb	CMFD
AB		80MG	A208055	003	Jan 03, 2019	Feb	CMFD
AB		120MG	A208055	004	Jan 03, 2019	Feb	CMFD

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5

>D>	@ FRESENIUS KABI USA	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	A215370	001	Jun 29, 2022	Mar	CMFD
>A>	AP	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	A215370	001	Jun 29, 2022	Mar	CMFD
>D>	@ FRESENIUS KABI USA	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	A215371	001	Jun 08, 2022	Mar	CMFD
>A>	AP	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	A215371	001	Jun 08, 2022	Mar	CMFD
>D>	+! BAXTER HLTHCARE	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017378	001		Mar	CTEC
>A>	AP	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017378	001		Mar	CTEC
>D>	+! BAXTER HLTHCARE	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017378	002	Nov 22, 1982	Mar	CTEC
>A>	AP	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017378	002	Nov 22, 1982	Mar	CTEC

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP	AMNEAL	2GM/50ML (40MG/ML)	A216597	001	Feb 15, 2023	Feb	NEWA
AP		4GM/100ML (40MG/ML)	A216597	002	Feb 15, 2023	Feb	NEWA

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

@ CHARTWELL RX

EQ 50MG BASE

A072262 001 Nov 29, 1988 Jan CAHN

@

EQ 100MG BASE

A072263 001 Nov 29, 1988 Jan CAHN

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

AB	@ BRECKENRIDGE	125MG/ML	A204688	001	Dec 01, 2017	Jan	DISC
	XTTRIUM LABS INC	40MG/ML	A076721	001	Nov 01, 2004	Jan	CAHN

MELOXICAM

	TABLET; ORAL						
	MELOXICAM						
AB	COREPHARMA	7.5MG	A077882	001	Jul 20, 2006	Feb	CAHN
AB		15MG	A077882	002	Jul 20, 2006	Feb	CAHN

MEMANTINE HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE; ORAL						
	MEMANTINE HYDROCHLORIDE						
	@ ANI PHARMS	28MG	A205365	004	Feb 28, 2020	Feb	DISC
	NAMENDA XR						
AB	+ ABBVIE	7MG	N022525	001	Jun 21, 2010	Feb	CAHN
AB	+	14MG	N022525	002	Jun 21, 2010	Feb	CAHN
AB	+	21MG	N022525	003	Jun 21, 2010	Feb	CAHN
AB	+!	28MG	N022525	004	Jun 21, 2010	Feb	CAHN
	TABLET; ORAL						
	MEMANTINE HYDROCHLORIDE						
>D>	@ NINGBO	5MG	A212947	001	Apr 03, 2020	Mar	CAHN
>D>	@	10MG	A212947	002	Apr 03, 2020	Mar	CAHN
>A>	@ YILING	5MG	A212947	001	Apr 03, 2020	Mar	CAHN
>A>	@	10MG	A212947	002	Apr 03, 2020	Mar	CAHN
	NAMENDA						
AB	+ ABBVIE	5MG	N021487	001	Oct 16, 2003	Feb	CAHN
AB	+!	10MG	N021487	002	Oct 16, 2003	Feb	CAHN

MEROPENEM

	INJECTABLE; INJECTION							
	MEROPENEM							
>D>	AP	BROOKS STERISCIENCE	500MG/VIAL	A216154	001	Aug 18, 2022	Mar	DISC
>A>		@	500MG/VIAL	A216154	001	Aug 18, 2022	Mar	DISC
>D>	AP		1GM/VIAL	A216154	002	Aug 18, 2022	Mar	DISC
>A>		@	1GM/VIAL	A216154	002	Aug 18, 2022	Mar	DISC

MESALAMINE

	CAPSULE, DELAYED RELEASE; ORAL							
	DELZICOL							
AB	+! ABBVIE	400MG	N204412	001	Feb 01, 2013	Feb	CAHN	
	CAPSULE, EXTENDED RELEASE; ORAL							
	MESALAMINE							
>A>	AB	AUROBINDO PHARMA LTD	375MG	A214477	001	Mar 31, 2023	Mar	NEWA
	SUPPOSITORY; RECTAL							
	CANASA							
	@ ABBVIE	500MG	N021252	001	Jan 05, 2001	Feb	CAHN	
AB	+!	1GM	N021252	002	Nov 05, 2004	Feb	CAHN	

METAXALONE

	TABLET; ORAL						
	METAXALONE						
	+! PRIMUS PHARMS	640MG	N022503	001	Jun 01, 2015	Feb	CMFD

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

	TABLET; ORAL							
	JANUMET							
>D>	+	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N022044	001	Mar 30, 2007	Mar	CAHN
>D>	+!		1GM;EQ 50MG BASE	N022044	002	Mar 30, 2007	Mar	CAHN
>A>	+	MSD SUB MERCK	500MG;EQ 50MG BASE	N022044	001	Mar 30, 2007	Mar	CAHN
>A>	+!		1GM;EQ 50MG BASE	N022044	002	Mar 30, 2007	Mar	CAHN

METHOCARBAMOL

	SOLUTION; IM-IV						
	METHOCARBAMOL						
	@ BAXTER HLTHCARE CORP	1GM/10ML (100MG/ML)	A215065	001	Jul 14, 2022	Feb	DISC
	TABLET; ORAL						
	METHOCARBAMOL						
AA	AUROBINDO PHARMA LTD	500MG	A213967	002	Feb 09, 2023	Feb	NEWA
AA		750MG	A213967	001	Aug 12, 2020	Feb	CMFD
AA	DBL PHARMS	500MG	A203550	001	Feb 08, 2017	Feb	CAHN
AA		750MG	A203550	002	Feb 08, 2017	Feb	CAHN

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA	!	XTTRIUM LABS INC	EQ 5MG BASE/5ML	A074703	001	Oct 31, 1997	Jan CAHN
----	---	------------------	-----------------	---------	-----	--------------	----------

METRONIDAZOLE

GEL; TOPICAL

METRONIDAZOLE

AB		COSETTE	1%	A216692	001	Jan 23, 2023	Jan NEWA
	@	TOLMAR	1%	A090903	001	Jul 22, 2011	Feb DISC

GEL; VAGINAL

METRONIDAZOLE

>A>		@ ENCUBE	0.75%	A077264	001	Oct 31, 2006	Mar CAHN
>D>		@ TOLMAR	0.75%	A077264	001	Oct 31, 2006	Mar CAHN

TABLET; ORAL

METRONIDAZOLE

AB		ALEMBIC	250MG	A208681	001	Jun 20, 2017	Feb CAHN
AB			500MG	A208681	002	Jun 20, 2017	Feb CAHN

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

AB		LEADING	150MG	A215876	001	Feb 27, 2023	Feb NEWA
AB			200MG	A215876	002	Feb 27, 2023	Feb NEWA
AB			250MG	A215876	003	Feb 27, 2023	Feb NEWA
AB		ZENARA	150MG	A215315	001	Aug 26, 2022	Feb CAHN
AB			200MG	A215315	002	Aug 26, 2022	Feb CAHN
AB			250MG	A215315	003	Aug 26, 2022	Feb CAHN

MICAFUNGIN SODIUM

INJECTABLE; INTRAVENOUS

MICAFUNGIN SODIUM

>D>	AP	ZYDUS PHARMS	EQ 50MG BASE/VIAL	A215241	001	Oct 24, 2022	Mar DISC
>A>		@	EQ 50MG BASE/VIAL	A215241	001	Oct 24, 2022	Mar DISC
>D>	AP		EQ 100MG BASE/VIAL	A215241	002	Oct 24, 2022	Mar DISC
>A>		@	EQ 100MG BASE/VIAL	A215241	002	Oct 24, 2022	Mar DISC

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

+	ABBVIE	12.5MG	N022256	001	Jan 14, 2009	Jan CAHN
+		25MG	N022256	002	Jan 14, 2009	Jan CAHN
+	!	50MG	N022256	003	Jan 14, 2009	Jan CAHN
+		100MG	N022256	004	Jan 14, 2009	Jan CAHN

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP		SHANDONG	EQ 1MG BASE/ML	A216373	001	Jan 23, 2023	Jan NEWA
----	--	----------	----------------	---------	-----	--------------	----------

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL

MIRABEGRON

>D>	AB	ZYDUS PHARMS	25MG	A209488	001	Sep 29, 2022	Mar DISC
>A>		@	25MG	A209488	001	Sep 29, 2022	Mar DISC
>D>	AB		50MG	A209488	002	Sep 29, 2022	Mar DISC
>A>		@	50MG	A209488	002	Sep 29, 2022	Mar DISC

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

AB		PRASCO	7.5MG	A216751	001	Jan 18, 2023	Jan NEWA
AB			15MG	A216751	002	Jan 18, 2023	Jan NEWA
AB			30MG	A216751	003	Jan 18, 2023	Jan NEWA
AB			45MG	A216751	004	Jan 18, 2023	Jan NEWA

MISOPROSTOL

TABLET; ORAL

MISOPROSTOL

@ NOVEL LABS INC

0.1MG

A 091667 001 Jul 25, 2012 Feb DISC

@

0.2MG

A 091667 002 Jul 25, 2012 Feb DISC

MOMETASONE FUROATE

LOTION; TOPICAL

ELOCON

>D>

>D> AB +! ORGANON

0.1%

N 019796 001 Mar 30, 1989 Mar DISC

>A>

+ @

0.1%

N 019796 001 Mar 30, 1989 Mar DISC

MOMETASONE FUROATE

>D> AB

PADAGIS ISRAEL

0.1%

A 077180 001 Apr 06, 2005 Mar CHRS

>A> AB

!

0.1%

A 077180 001 Apr 06, 2005 Mar CHRS

MONTELUKAST SODIUM

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

AB

CHARTWELL MOLECULAR

EQ 4MG BASE

A 207464 001 Dec 06, 2018 Jan CAHN

AB

EQ 5MG BASE

A 207464 002 Dec 06, 2018 Jan CAHN

MORPHINE SULFATE

INJECTABLE; INJECTION

MORPHINE SULFATE

AP

HIKMA

2MG/ML

A 211452 001 Jan 12, 2023 Jan NFTG

AP

4MG/ML

A 211452 002 Jan 12, 2023 Jan NEWA

AP

8MG/ML

A 211452 003 Jan 12, 2023 Jan NEWA

AP

10MG/ML

A 211452 004 Jan 12, 2023 Jan NEWA

AP

15MG/ML

A 211452 005 Jan 12, 2023 Jan NFTG

AP

+!

HOSPIRA INC

2MG/ML

N 202515 001 Nov 14, 2011 Jan CFTG

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

@ AKORN

EQ 0.5% BASE

A 202916 001 Nov 09, 2017 Jan DISC

TABLET; ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB

HETERO LABS LTD V

EQ 400MG BASE

A 204836 001 Mar 02, 2023 Feb NEWA

@ TORRENT

EQ 400MG BASE

A 200160 001 Apr 03, 2014 Feb DISC

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

AP

!

EUGIA PHARMA SPECLTS

EQ 1GM BASE/VIAL

A 091613 001 Dec 26, 2012 Jan CHRS

AP

!

EQ 2GM BASE/VIAL

A 091613 002 Dec 26, 2012 Jan CHRS

AP

!

EQ 10GM BASE/VIAL

A 091614 001 Dec 26, 2012 Jan CHRS

@ SANDOZ

EQ 1GM BASE/VIAL

A 062527 002 Aug 02, 1984 Jan DISC

@

EQ 1GM BASE/VIAL

A 062732 001 Dec 23, 1986 Jan DISC

@

EQ 2GM BASE/VIAL

A 062527 003 Aug 02, 1984 Jan DISC

@

EQ 2GM BASE/VIAL

A 062732 002 Dec 23, 1986 Jan DISC

@

EQ 10GM BASE/VIAL

A 062527 004 Aug 02, 1984 Jan DISC

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIFINE HYDROCHLORIDE

AB

AMNEAL

2%

A 206960 001 Apr 10, 2017 Feb CAHN

GEL; TOPICAL

NAFTIFINE HYDROCHLORIDE

AB

AMNEAL

1%

A 206165 001 Mar 20, 2019 Feb CAHN

>D>

@ TARO

2%

A 208201 001 Apr 10, 2019 Mar CMFD

>A> AB

2%

A 208201 001 Apr 10, 2019 Mar CMFD

NAFTIN

+!

SEBELA IRELAND LTD

2%

N 204286 001 Jun 27, 2013 Feb CTEC

NALOXEGOL OXALATE

TABLET; ORAL

MOVANTIK

+ VALINOR

EQ 12.5MG BASE

N 204760 001 Sep 16, 2014 Feb CAHN

+!

EQ 25MG BASE

N 204760 002 Sep 16, 2014 Feb CAHN

NALOXONE HYDROCHLORIDEINJECTABLE; INJECTION
NALOXONE HYDROCHLORIDE

@ PAR STERILE PRODUCTS 1MG/ML

A215964 001 Jul 29, 2022 Jan DISC

SPRAY, METERED; NASAL

NALOXONE HYDROCHLORIDE

>A> +! AMPHASTAR PHARMS INC 4MG/SPRAY N208969 001 Mar 07, 2023 Mar NEWA
NARCAN

>D> AB +! EMERGENT 4MG/SPRAY N208411 001 Nov 18, 2015 Mar CMKT

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

NEBIVOLOL HYDROCHLORIDE

>A> AB BEXIMCO PHARMS USA EQ 2.5MG BASE A216568 001 Mar 30, 2023 Mar NEWA

>A> AB EQ 5MG BASE A216568 002 Mar 30, 2023 Mar NEWA

>A> AB EQ 10MG BASE A216568 003 Mar 30, 2023 Mar NEWA

>A> AB EQ 20MG BASE A216568 004 Mar 30, 2023 Mar NEWA

NELARABINE

INJECTABLE; INTRAVENOUS

NELARABINE

>A> AP AMNEAL 250MG/50ML (5MG/ML) A216346 001 Apr 04, 2023 Mar NEWA

AP SHORLA 250MG/50ML (5MG/ML) A214809 001 Mar 03, 2023 Feb NEWA

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

AP SAGENT PHARMS INC 5MG/10ML (0.5MG/ML) A216542 001 Feb 17, 2023 Feb NEWA

AP 10MG/10ML (1MG/ML) A216542 002 Feb 17, 2023 Feb NEWA

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

NISOLDIPINE

>A> AB AMTA 8.5MG A216606 001 Apr 10, 2023 Mar NEWA

NITRIC OXIDE

GAS; INHALATION

GENOSYL

+! VERO BIOTECH INC 800PPM N202860 001 Dec 20, 2019 Jan CAHN

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

>A> AB MANKIND PHARMA 25MG A217272 001 Mar 21, 2023 Mar NEWA

>A> AB 50MG A217272 002 Mar 21, 2023 Mar NEWA

>A> AB 100MG A217272 003 Mar 21, 2023 Mar NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

@ ALVOGEN 75MG; 25MG

A215002 001 Jul 20, 2022 Jan DISC

>A> AB AUROBINDO PHARMA 75MG; 25MG A209225 001 Mar 30, 2023 Mar NEWA

NYSTATIN

OINTMENT; TOPICAL

NYSTATIN

>D> AT TORRENT 100,000 UNITS/GM A211838 001 Jan 28, 2019 Mar DISC

>A> @ 100,000 UNITS/GM A211838 001 Jan 28, 2019 Mar DISC

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

>A> AP ASPIRO 10MG/VIAL A217466 001 Mar 22, 2023 Mar NEWA

TABLET; ORAL

OLANZAPINE

AB CADILA PHARMS LTD 2.5MG A210022 001 Feb 24, 2023 Feb NEWA

AB 5MG A210022 002 Feb 24, 2023 Feb NEWA

AB 7.5MG A210022 003 Feb 24, 2023 Feb NEWA

AB 10MG A210022 004 Feb 24, 2023 Feb NEWA

AB 15MG A210022 005 Feb 24, 2023 Feb NEWA

AB 20MG A210022 006 Feb 24, 2023 Feb NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

>A>	AB	ZYDUS PHARMS	5MG	A202889	001	Mar 09, 2023	Mar	NEWA
>A>	AB		10MG	A202889	002	Mar 09, 2023	Mar	NEWA
>A>	AB		15MG	A202889	003	Mar 09, 2023	Mar	NEWA
>A>	AB		20MG	A202889	004	Mar 09, 2023	Mar	NEWA

OLMESARTAN MEDOXOMIL

TABLET;ORAL
OLMESARTAN MEDOXOMIL

AB	MSN		5MG	A217399	001	Jan 18, 2023	Jan	NEWA
AB			20MG	A217399	002	Jan 18, 2023	Jan	NEWA
AB			40MG	A217399	003	Jan 18, 2023	Jan	NEWA

OMAVELOXOLONE

CAPSULE;ORAL
SKYCLARYS

+!	REATA PHARMS		50MG	N216718	001	Feb 28, 2023	Feb	NEWA
----	--------------	--	------	---------	-----	--------------	-----	------

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL
ONDANSETRON

>D>		CHARTWELL MOLECULES	16MG	A077406	001	Dec 26, 2006	Mar	CHRS
>A>	!		16MG	A077406	001	Dec 26, 2006	Mar	CHRS
>D>			24MG	A077406	002	Dec 26, 2006	Mar	CHRS
>A>	!		24MG	A077406	002	Dec 26, 2006	Mar	CHRS

ONDANSETRON HYDROCHLORIDE

TABLET;ORAL
ONDANSETRON HYDROCHLORIDE
! CHARTWELL MOLECULES EQ 24MG BASE

A077303	004	Jun 25, 2007	Feb	CTEC
---------	-----	--------------	-----	------

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE;ORAL
ORPHENADRINE CITRATE

AB	RISING		100MG	A040249	001	Jan 29, 1999	Jan	CAHN
----	--------	--	-------	---------	-----	--------------	-----	------

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL
OSELTAMIVIR PHOSPHATE
@ ACCORD HLTHCARE EQ 30MG BASE
@ EQ 45MG BASE
@ EQ 75MG BASE

A214726	001	Jul 25, 2022	Feb	DISC
A214726	002	Jul 25, 2022	Feb	DISC
A214726	003	Jul 25, 2022	Feb	DISC

FOR SUSPENSION;ORAL
OSELTAMIVIR PHOSPHATE

AB	EPIC PHARMA LLC		EQ 6MG BASE/ML	A215538	001	Feb 14, 2023	Feb	NEWA
----	-----------------	--	----------------	---------	-----	--------------	-----	------

OXANDROLONE

TABLET;ORAL
OXANDROLONE
@ PAR PHARM 2.5MG
@ 10MG
@ UPSHER SMITH LABS 2.5MG
@ 10MG

A077827	001	Jun 22, 2007	Feb	DISC
A077827	002	Jun 22, 2007	Feb	DISC
A076761	001	Dec 01, 2006	Feb	DISC
A078033	001	Mar 22, 2007	Feb	DISC

OXYBUTYNIN CHLORIDE

SYRUP;ORAL
OXYBUTYNIN CHLORIDE

>D>		@ CHARTWELL RX	5MG/5ML	A075039	001	Jan 29, 1999	Mar	CMFD
>A>	AA		5MG/5ML	A075039	001	Jan 29, 1999	Mar	CMFD
>D>		@ WOCKHARDT BIO AG	5MG/5ML	A074868	001	Feb 12, 1997	Mar	CAHN
>A>		@ XTTRIUM LABS INC	5MG/5ML	A074868	001	Feb 12, 1997	Mar	CAHN

TABLET;ORAL
OXYBUTYNIN CHLORIDE

!	APPCO		2.5MG	A209025	002	Feb 07, 2023	Jan	NFTG
---	-------	--	-------	---------	-----	--------------	-----	------

PACLITAXELINJECTABLE; INJECTION
PACLITAXEL

@ DASH PHARMS	6MG/ML	A091540	001	Sep 29, 2011	Feb CAHN
---------------	--------	---------	-----	--------------	----------

PALONOSETRON HYDROCHLORIDEINJECTABLE; INTRAVENOUS
PALONOSETRON HYDROCHLORIDE

@ CIPLA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A206396	001	Sep 19, 2018	Feb DISC
@ INGENUS PHARMS LLC	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020	Feb DISC

PANTOPRAZOLE SODIUMFOR SUSPENSION, DELAYED RELEASE; ORAL
PANTOPRAZOLE SODIUM

AB	AJANTA PHARMA LTD	EQ 40MG BASE	A217416	001	Feb 09, 2023	Feb NEWA
----	-------------------	--------------	---------	-----	--------------	----------

PAROXETINE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
PAROXETINE HYDROCHLORIDE

@ EPIC PHARMA LLC	EQ 12.5MG BASE	A213612	001	Aug 11, 2021	Jan CAHN
@	EQ 25MG BASE	A213612	002	Aug 11, 2021	Jan CAHN
@	EQ 37.5MG BASE	A213612	003	May 26, 2022	Jan CAHN

PEGCETACOPLANSOLUTION; INTRAVITREAL
SYFOVRE

+!	APELLIS PHARMS	15MG/0.1ML (15MG/0.1ML)	N217171	001	Feb 17, 2023	Feb NEWA
----	----------------	-------------------------	---------	-----	--------------	----------

PEMETREXED DISODIUMPOWDER; INTRAVENOUS
PEMETREXED DISODIUM

AP	MEITHEAL	EQ 100MG BASE/VIAL	A215479	001	Dec 13, 2022	Jan CAHN
AP		EQ 500MG BASE/VIAL	A215479	002	Dec 13, 2022	Jan CAHN
AP		EQ 750MG BASE/VIAL	A215479	003	Dec 13, 2022	Jan CAHN
AP		EQ 1GM BASE/VIAL	A215479	004	Dec 13, 2022	Jan CAHN
>A>	@ MYLAN LABS LTD	EQ 500MG BASE/VIAL	A203628	001	Mar 10, 2023	Mar DISC

SOLUTION; INTRAVENOUS
PEMETREXED DISODIUM

+!	SANDOZ INC	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214657	001	May 26, 2022	Jan CMS1
----	------------	--	---------	-----	--------------	----------

PENTAMIDINE ISETHIONATEFOR SOLUTION; INHALATION
PENTAMIDINE ISETHIONATE

AN	X-GEN PHARMS INC	300MG/VIAL	A206983	001	Jan 20, 2023	Jan NEWA
----	------------------	------------	---------	-----	--------------	----------

PERAMPANELSUSPENSION; ORAL
FYCOMPA

+!	CATALYST PHARMS	0.5MG/ML	N208277	001	Apr 29, 2016	Feb CAHN
----	-----------------	----------	---------	-----	--------------	----------

TABLET; ORAL
FYCOMPA

+	CATALYST PHARMS	2MG	N202834	001	Oct 22, 2012	Feb CAHN
+		4MG	N202834	002	Oct 22, 2012	Feb CAHN
+		6MG	N202834	003	Oct 22, 2012	Feb CAHN
+		8MG	N202834	004	Oct 22, 2012	Feb CAHN
+		10MG	N202834	005	Oct 22, 2012	Feb CAHN
+!		12MG	N202834	006	Oct 22, 2012	Feb CAHN

PHENTERMINE HYDROCHLORIDECAPSULE; ORAL
PHENTERMINE HYDROCHLORIDE

@ LANNETT	15MG	A087022	002	Jan 20, 2012	Feb DISC
@	30MG	A087022	001	Feb 03, 1983	Feb DISC

PHENYLEPHRINE HYDROCHLORIDESOLUTION; INTRAVENOUS
IMMPHENTIV

>A>	+	HIKMA	0.5MG/5ML (0.1MG/ML)	N203826	004	Mar 09, 2023	Mar	NEWA
>A>	+		1MG/10ML (0.1MG/ML)	N203826	005	Mar 09, 2023	Mar	NEWA
		PHENYLEPHRINE HYDROCHLORIDE						
AP2		AVET LIFESCIENCES	10MG/ML (10MG/ML)	A209968	001	Feb 28, 2023	Feb	NEWA

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE VC PLAIN

@	XTTRIUM LABS INC	5MG/5ML; 6.25MG/5ML	A088897	001	Jan 04, 1985	Jan	CAHN
---	------------------	---------------------	---------	-----	--------------	-----	------

PHENYTOIN SODIUM

CAPSULE; ORAL

EXTENDED PHENYTOIN SODIUM

>D>	AB	MYLAN	100MG EXTENDED	A040298	001	Dec 28, 1998	Mar	DISC
>A>		@	100MG EXTENDED	A040298	001	Dec 28, 1998	Mar	DISC

PHYTONADIONE

TABLET; ORAL

MEPHYTON

+	@	BAUSCH	5MG	N010104	003		Feb	DISC
---	---	--------	-----	---------	-----	--	-----	------

PHYTONADIONE

AB	!	ZYDUS	5MG	A210189	001	Feb 20, 2019	Feb	CHRS
----	---	-------	-----	---------	-----	--------------	-----	------

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

ZOSYN IN PLASTIC CONTAINER

>A>	+	BAXTER HLTHCARE CORP	EQ 40MG BASE/ML; EQ 5MG BASE/ML	N050750	001	Feb 24, 1998	Mar	CAHN
>A>	+		EQ 60MG BASE/ML; EQ 7.5MG BASE/ML	N050750	002	Feb 24, 1998	Mar	CAHN
>A>	+		EQ 4GM BASE/100ML; EQ 500MG BASE/100ML	N050750	003	Feb 24, 1998	Mar	CAHN
>D>	+	WYETH PHARMS	EQ 40MG BASE/ML; EQ 5MG BASE/ML	N050750	001	Feb 24, 1998	Mar	CAHN
>D>	+		EQ 60MG BASE/ML; EQ 7.5MG BASE/ML	N050750	002	Feb 24, 1998	Mar	CAHN
>D>	+		EQ 4GM BASE/100ML; EQ 500MG BASE/100ML	N050750	003	Feb 24, 1998	Mar	CAHN

PIRTOBRUTINIB

TABLET; ORAL

JAYPIRCA

+	LOXO ONCOL	50MG	N216059	001	Jan 27, 2023	Jan	NEWA
+		100MG	N216059	002	Jan 27, 2023	Jan	NEWA

PITAVASTATIN CALCIUM

TABLET; ORAL

PITAVASTATIN CALCIUM

AB		ZYDUS PHARMS	EQ 1MG BASE	A206047	001	Feb 22, 2023	Feb	NEWA
AB			EQ 2MG BASE	A206047	002	Feb 22, 2023	Feb	NEWA
AB			EQ 4MG BASE	A206047	003	Feb 22, 2023	Feb	NEWA

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

POLYTRIM

+	@	ALLERGAN	10,000 UNITS/ML; EQ 1MG BASE/ML	N050567	001	Oct 20, 1988	Feb	DISC
		TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE						

AT	!	SANDOZ INC	10,000 UNITS/ML; EQ 1MG BASE/ML	A064211	001	Apr 13, 1998	Feb	CHRS
----	---	------------	---------------------------------	---------	-----	--------------	-----	------

POMALIDOMIDE

CAPSULE; ORAL

POMALYST

+	BRISTOL	1MG	N204026	001	Feb 08, 2013	Jan	CAHN
+		2MG	N204026	002	Feb 08, 2013	Jan	CAHN
+		3MG	N204026	003	Feb 08, 2013	Jan	CAHN
+	!	4MG	N204026	004	Feb 08, 2013	Jan	CAHN

POTASSIUM ACETATE

	INJECTABLE; INJECTION						
	POTASSIUM ACETATE						
AP	EXELA PHARMA	2MEQ/ML	A212692	001	Oct 20, 2021	Feb	CMFD

POTASSIUM CHLORIDE

	SOLUTION; ORAL						
	POTASSIUM CHLORIDE						
AA	BELCHER	20MEQ/15ML	A216156	001	Mar 07, 2023	Feb	NEWA
AA		40MEQ/15ML	A216156	002	Mar 07, 2023	Feb	NEWA
	TABLET, EXTENDED RELEASE; ORAL						
	K-TAB						
	+ @ ABBVIE	10MEQ	N018279	001		Feb	DISC
	+ @	20MEQ	N018279	003	Nov 25, 2013	Feb	DISC
	POTASSIUM CHLORIDE						
AB3	! VITRUVIAS THERAP	20MEQ	A209688	002	Jan 12, 2018	Feb	CHRS

PRASUGREL HYDROCHLORIDE

	TABLET; ORAL						
	PRASUGREL						
>D> BX	AMNEAL PHARMS	EQ 5MG BASE	A205913	001	Jun 19, 2018	Mar	CTEC
>A> AB		EQ 5MG BASE	A205913	001	Jun 19, 2018	Mar	CTEC
>D> BX		EQ 10MG BASE	A205913	002	Jun 19, 2018	Mar	CTEC
>A> AB		EQ 10MG BASE	A205913	002	Jun 19, 2018	Mar	CTEC
	@ LUPIN LTD	EQ 5MG BASE	A205930	001	Jan 09, 2023	Feb	DISC
	@	EQ 10MG BASE	A205930	002	Jan 09, 2023	Feb	DISC

PRAZOSIN HYDROCHLORIDE

	CAPSULE; ORAL						
	PRAZOSIN HYDROCHLORIDE						
AB	ALEMBIC	EQ 1MG BASE	A217268	001	Mar 06, 2023	Feb	NEWA
AB		EQ 2MG BASE	A217268	002	Mar 06, 2023	Feb	NEWA
AB		EQ 5MG BASE	A217268	003	Mar 06, 2023	Feb	NEWA
>A> AB	AUROBINDO PHARMA LTD	EQ 1MG BASE	A213052	001	Mar 31, 2023	Mar	NEWA
>A> AB		EQ 2MG BASE	A213052	002	Mar 31, 2023	Mar	NEWA
>A> AB		EQ 5MG BASE	A213052	003	Mar 31, 2023	Mar	NEWA

PREDNISOLONE

	SYRUP; ORAL						
	PREDNISOLONE						
AA	XTTRIUM LABS INC	15MG/5ML	A040313	001	Sep 10, 2003	Jan	CAHN
	TABLET; ORAL						
	PREDNISOLONE						
>A> AB	AUROBINDO PHARMA LTD	5MG	A215673	001	Mar 17, 2023	Mar	NEWA
>D>	+! WATSON LABS	5MG	A080354	001		Mar	CTEC
>A> AB	+!	5MG	A080354	001		Mar	CTEC

PREDNISOLONE ACETATE

	SUSPENSION/DROPS; OPHTHALMIC						
	PRED FORTE						
AB	+! ABBVIE	1%	N017011	001		Jan	CAHN
	PRED MILD						
	+! ABBVIE	0.12%	N017100	001		Feb	CAHN

PREDNISOLONE SODIUM PHOSPHATE

	SOLUTION; ORAL						
	PREDNISOLONE SODIUM PHOSPHATE						
AA	EDENBRIDGE PHARMS	EQ 15MG BASE/5ML	A203559	003	Feb 06, 2023	Jan	NEWA
AA		EQ 15MG BASE/5ML	A203559	003	Feb 06, 2023	Jan	NEWA
AA		EQ 25MG BASE/5ML	A203559	004	Feb 06, 2023	Jan	NEWA
AA		EQ 25MG BASE/5ML	A203559	004	Feb 06, 2023	Jan	NEWA
AA	! MISSION PHARMA	EQ 25MG BASE/5ML	A091396	001	Sep 13, 2010	Jan	CTEC
AA	! XTTRIUM LABS INC	EQ 5MG BASE/5ML	A075099	001	Jun 28, 2002	Jan	CAHN
AA	!	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Jan	CAHN

PREDNISONE

	SOLUTION; ORAL						
	PREDNISONE						
	@ XTTRIUM LABS INC	5MG/5ML	A089726	001	Aug 02, 1988	Jan	CAHN

TABLET;ORAL
PREDNISONE

AB	+	!	HIKMA	2.5MG	A087801	001	Apr 22, 1982	Jan	CRLD
AB	+	!		5MG	A080352	001		Jan	CRLD
AB	+	!		50MG	A084283	001		Jan	CRLD

PREGABALIN

CAPSULE;ORAL
PREGABALIN

>A>	AB		AUROBINDO PHARMA	25MG	A205321	001	Mar 29, 2023	Mar	NEWA
>A>	AB			50MG	A205321	002	Mar 29, 2023	Mar	NEWA
>A>	AB			75MG	A205321	003	Mar 29, 2023	Mar	NEWA
>A>	AB			100MG	A205321	004	Mar 29, 2023	Mar	NEWA
>A>	AB			150MG	A205321	005	Mar 29, 2023	Mar	NEWA
>A>	AB			200MG	A205321	006	Mar 29, 2023	Mar	NEWA
>A>	AB			225MG	A205321	007	Mar 29, 2023	Mar	NEWA
>A>	AB			300MG	A205321	008	Mar 29, 2023	Mar	NEWA
>D>	AB		CELLTRION	50MG	A212865	001	Mar 20, 2020	Mar	CAHN
>D>	AB			75MG	A212865	002	Mar 20, 2020	Mar	CAHN
>D>	AB			100MG	A212865	003	Mar 20, 2020	Mar	CAHN
>D>	AB			150MG	A212865	004	Mar 20, 2020	Mar	CAHN
>A>	AB		CHARTWELL RX	50MG	A212865	001	Mar 20, 2020	Mar	CAHN
>A>	AB			75MG	A212865	002	Mar 20, 2020	Mar	CAHN
>A>	AB			100MG	A212865	003	Mar 20, 2020	Mar	CAHN
>A>	AB			150MG	A212865	004	Mar 20, 2020	Mar	CAHN
>D>	AB		SHUANGCHENG	75MG	A210891	001	Sep 30, 2019	Mar	CAHN
>D>	AB			300MG	A210891	002	Sep 30, 2019	Mar	CAHN
>A>	AB		YILING	75MG	A210891	001	Sep 30, 2019	Mar	CAHN
>A>	AB			300MG	A210891	002	Sep 30, 2019	Mar	CAHN

SOLUTION;ORAL
PREGABALIN

AA			PATRIN	20MG/ML	A212604	001	Feb 18, 2022	Jan	CAHN
----	--	--	--------	---------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL
PREGABALIN

			@ ZYDUS PHARMS	82.5MG	A215577	001	Aug 26, 2022	Jan	DISC
			@	165MG	A215577	002	Aug 26, 2022	Jan	DISC
			@	330MG	A215577	003	Aug 26, 2022	Jan	DISC

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION
PROCAINAMIDE HYDROCHLORIDE

AP	!		HOSPIRA	500MG/ML	A089070	001	Feb 12, 1986	Feb	CTEC
----	---	--	---------	----------	---------	-----	--------------	-----	------

PROCHLORPERAZINE MALEATE

TABLET;ORAL
PROCHLORPERAZINE MALEATE

>A>	AB		BIONPHARMA INC	EQ 5MG BASE	A217478	001	Apr 04, 2023	Mar	NEWA
>A>	AB			EQ 10MG BASE	A217478	002	Apr 04, 2023	Mar	NEWA
>A>	AB		GLENMARK PHARMS LTD	EQ 5MG BASE	A216595	001	Mar 17, 2023	Mar	NEWA
>A>	AB			EQ 10MG BASE	A216595	002	Mar 17, 2023	Mar	NEWA

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
PROPAFENONE HYDROCHLORIDE

AB			AUROBINDO PHARMA LTD	225MG	A213096	001	Feb 21, 2023	Feb	NEWA
AB				325MG	A213096	002	Feb 21, 2023	Feb	NEWA
AB				425MG	A213096	003	Feb 21, 2023	Feb	NEWA

PROPOFOL

INJECTABLE;INJECTION
PROPOFOL

AB			AVET LIFESCIENCES	10MG/ML	A206408	001	Oct 12, 2021	Jan	CAHN
----	--	--	-------------------	---------	---------	-----	--------------	-----	------

RAMELTEON

TABLET;ORAL
RAMELTEON

>D>	AB		INNOGENIX	8MG	A215435	001	Aug 24, 2022	Mar	DISC
>A>			@	8MG	A215435	001	Aug 24, 2022	Mar	DISC
	AB			8MG	A215435	001	Aug 24, 2022	Jan	CAHN
	AB		MICRO LABS	8MG	A215243	001	Feb 09, 2023	Feb	NEWA

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

AB	COREPHARMA	1.25MG	A079116	001	Jun 20, 2008	Feb CAHN
AB		2.5MG	A079116	002	Jun 20, 2008	Feb CAHN
AB		5MG	A079116	003	Jun 20, 2008	Feb CAHN
AB		10MG	A079116	004	Jun 20, 2008	Feb CAHN

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANEXA

	+ @ GILEAD	500MG	N021526	002	Jan 27, 2006	Jan DISC
	+ @	1GM	N021526	001	Feb 12, 2007	Jan DISC
	RANOLAZINE					
AB	! SUN PHARM	1GM	A211707	002	May 28, 2019	Jan CHRS
>A>	AB UNICHEM	500MG	A213083	001	Mar 16, 2023	Mar NEWA
>A>	AB	1GM	A213083	002	Mar 16, 2023	Mar NEWA

REGADENOSON

SOLUTION;INTRAVENOUS

REGADENOSON

AP	HIKMA	0.4MG/5ML (0.08MG/ML)	A215827	001	Feb 02, 2023	Jan NEWA
>A>	AP MYLAN	0.4MG/5ML (0.08MG/ML)	A213856	001	Apr 04, 2023	Mar NEWA

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

>A>	AB MACLEODS PHARMS LTD	0.5MG	A207209	001	Mar 22, 2023	Mar NEWA
>A>	AB	1MG	A207209	002	Mar 22, 2023	Mar NEWA
>A>	AB	2MG	A207209	003	Mar 22, 2023	Mar NEWA

>A> REZAFUNGIN ACETATE

>A> POWDER;INTRAVENOUS

>A> REZZAYO

>A>	+! CIDARA THERAPS	EQ 200MG BASE/VIAL	N217417	001	Mar 22, 2023	Mar NEWA
-----	-------------------	--------------------	---------	-----	--------------	----------

RIMEGEPANT SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL

NURTEC ODT

	+! PFIZER	EQ 75MG BASE	N212728	001	Feb 27, 2020	Feb CAHN
--	-----------	--------------	---------	-----	--------------	----------

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

RYKINDO

+!	SHANDONG LUYE	12.5MG	N212849	001	Jan 13, 2023	Jan NEWA
+!		25MG	N212849	002	Jan 13, 2023	Jan NEWA
+!		37.5MG	N212849	003	Jan 13, 2023	Jan NEWA
+!		50MG	N212849	004	Jan 13, 2023	Jan NEWA

TABLET;ORAL

RISPERIDONE

@	DASH PHARMS	0.25MG	A076288	001	Sep 15, 2008	Feb CAHN
@		0.5MG	A076288	002	Sep 15, 2008	Feb CAHN
@		1MG	A076288	003	Sep 15, 2008	Feb CAHN
@		2MG	A076288	004	Sep 15, 2008	Feb CAHN
@		3MG	A076288	005	Sep 15, 2008	Feb CAHN
@		4MG	A076288	006	Sep 15, 2008	Feb CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

@	DASH PHARMS	0.25MG	A091537	006	Feb 12, 2013	Feb CAHN
@		0.5MG	A091537	001	Mar 30, 2011	Feb CAHN
@		1MG	A091537	002	Mar 30, 2011	Feb CAHN
@		2MG	A091537	003	Mar 30, 2011	Feb CAHN
@		3MG	A091537	004	Mar 30, 2011	Feb CAHN
@		4MG	A091537	005	Mar 30, 2011	Feb CAHN

RITONAVIR

SOLUTION;ORAL

NORVIR

+ @	ABBVIE	80MG/ML	N020659	001	Mar 01, 1996	Feb DISC
-----	--------	---------	---------	-----	--------------	----------

ROCURONIUM BROMIDEINJECTABLE; INJECTION
ROCURONIUM BROMIDE

AP	CAPLIN	50MG/5ML (10MG/ML)	A216234	001	Mar 02, 2023	Feb	NEWA
AP		100MG/10ML (10MG/ML)	A216234	002	Mar 02, 2023	Feb	NEWA

ROPINIROLE HYDROCHLORIDETABLET; ORAL
ROPINIROLE HYDROCHLORIDE

>D>	AB	MYLAN	EQ 5MG BASE	A078881	007	May 19, 2008	Mar	DISC
>A>		@	EQ 5MG BASE	A078881	007	May 19, 2008	Mar	DISC

ROPIVACAINE HYDROCHLORIDESOLUTION; INJECTION
ROPIVACAINE HYDROCHLORIDE

AP	AMNEAL	200MG/100ML (2MG/ML)	A216605	001	Mar 08, 2023	Feb	NEWA
AP		400MG/200ML (2MG/ML)	A216605	002	Mar 08, 2023	Feb	NEWA
AP		500MG/100ML (5MG/ML)	A216605	003	Mar 07, 2023	Feb	NEWA
AP		1GM/200ML (5MG/ML)	A216605	004	Mar 07, 2023	Feb	NEWA

SELEGILINE HYDROCHLORIDETABLET; ORAL
SELEGILINE HYDROCHLORIDE

>A>		@ DASH PHARMS NATCO	5MG	A074866	001	Nov 26, 1997	Mar	CAHN
>D>		@ MYLAN	5MG	A074866	001	Nov 26, 1997	Mar	CAHN

SELENIUM SULFIDELOTION; SHAMPOO; TOPICAL
SELENIUM SULFIDE

>D>		@ WOCKHARDT BIO AG	2.5%	A088228	001	Sep 01, 1983	Mar	CAHN
>A>		@ XTTRIUM LABS INC	2.5%	A088228	001	Sep 01, 1983	Mar	CAHN

SERTRALINE HYDROCHLORIDETABLET; ORAL
SERTRALINE HYDROCHLORIDE

>D>		@ HERITAGE PHARMA AVET	EQ 25MG BASE	A076465	001	Aug 11, 2006	Mar	CMFD
>A>	AB		EQ 25MG BASE	A076465	001	Aug 11, 2006	Mar	CMFD
>D>		@	EQ 50MG BASE	A076465	002	Aug 11, 2006	Mar	CMFD
>A>	AB		EQ 50MG BASE	A076465	002	Aug 11, 2006	Mar	CMFD
>D>		@	EQ 100MG BASE	A076465	003	Aug 11, 2006	Mar	CMFD
>A>	AB		EQ 100MG BASE	A076465	003	Aug 11, 2006	Mar	CMFD

SEVELAMER CARBONATEFOR SUSPENSION; ORAL
SEVELAMER CARBONATE

AB	HANGZHOU ANPRIME	800MG/PACKET	A217319	001	Mar 02, 2023	Feb	NEWA
AB		2.4GM/PACKET	A217319	002	Mar 02, 2023	Feb	NEWA

SIROLIMUSSOLUTION; ORAL
SIROLIMUS

AA	MSN	1MG/ML	A216728	001	Jan 19, 2023	Jan	NEWA
----	-----	--------	---------	-----	--------------	-----	------

TABLET; ORAL
SIROLIMUS

AB	ZYDUS PHARMS	1MG	A201676	001	Feb 15, 2023	Feb	NEWA
AB		2MG	A201676	002	Feb 15, 2023	Feb	NEWA

SODIUM CHLORIDEINJECTABLE; INJECTION
SODIUM CHLORIDE 0.9%

>D>	+	B BRAUN	9MG/10ML	N019635	005	Aug 08, 2016	Mar	CPOT
>A>	+		9MG/ML	N019635	005	Aug 08, 2016	Mar	CPOT

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	+	@ LIEBEL-FLARSHEIM	405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Mar	CPOT
>A>	+	@	450MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Mar	CPOT
>D>	+		1012.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Mar	CPOT
>A>	+		1.125GM/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Mar	CPOT

SODIUM PHENYLBUTYRATE

	POWDER; ORAL								
	BUPHENYL								
AB	+!	HORIZON THERAP US	3GM/TEASPOONFUL		N020573	001	Apr 30, 1996	Jan	CAHN
	TABLET; ORAL								
	BUPHENYL								
AB	+!	HORIZON THERAP US	500MG		N020572	001	May 13, 1996	Jan	CAHN

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

	INJECTABLE; INJECTION								
	SODIUM PHOSPHATES								
>D>	AP	FRESENIUS KABI USA	142MG/ML; 276MG/ML		A209997	001	Mar 30, 2022	Mar	CHRS
>A>	AP	!	142MG/ML; 276MG/ML		A209997	001	Mar 30, 2022	Mar	CHRS

SORAFENIB TOSYLATE

	TABLET; ORAL								
	SORAFENIB TOSYLATE								
>A>	AB	TORRENT	EQ 200MG BASE		A217095	001	Apr 12, 2023	Mar	NEWA

SOTORASIB

	TABLET; ORAL								
	LUMAKRAS								
>D>	+	AMGEN INC	120MG		N214665	001	May 28, 2021	Mar	CHRS
>A>	+		120MG		N214665	001	May 28, 2021	Mar	CHRS
>D>	+		320MG		N214665	002	Jan 20, 2023	Mar	CHRS
>A>	+		320MG		N214665	002	Jan 20, 2023	Mar	CHRS
	+		320MG		N214665	002	Jan 20, 2023	Feb	NEWA

SPARSENTAN

	TABLET; ORAL								
	FILSPARI								
	+	TRAVERE	200MG		N216403	001	Feb 17, 2023	Feb	NEWA
	+		400MG		N216403	002	Feb 17, 2023	Feb	NEWA

STERILE WATER FOR INJECTION

	LIQUID; N/A								
	STERILE WATER FOR INJECTION								
AP		HIKMA	100%		A212735	001	Jan 31, 2023	Jan	NEWA

SUCCINYLCHOLINE CHLORIDE

	INJECTABLE; INJECTION								
	SUCCINYLCHOLINE CHLORIDE								
AP		MANKIND PHARMA	20MG/ML		A216127	001	Feb 02, 2023	Jan	NEWA

SULFACETAMIDE SODIUM

	SOLUTION/DROPS; OPHTHALMIC								
	SULFACETAMIDE SODIUM								
	@	AKORN	10%		A040215	001	May 25, 1999	Jan	DISC

SULINDAC

	TABLET; ORAL								
	SULINDAC								
	@	CHARTWELL RX	150MG		A072712	001	Aug 30, 1991	Jan	CAHN
	@		200MG		A072713	001	Aug 30, 1991	Jan	CAHN

TADALAFIL

	TABLET; ORAL								
	TADALAFIL								
AB1		NOVITIUM PHARMA	5MG		A215949	001	Mar 03, 2023	Feb	NEWA
AB1			10MG		A215949	002	Mar 03, 2023	Feb	NEWA
AB1			20MG		A215949	003	Mar 03, 2023	Feb	NEWA
AB1		UNICHEM	2.5MG		A209250	001	Mar 26, 2019	Jan	CTEC
AB1			5MG		A209250	002	Mar 26, 2019	Jan	CTEC
AB1			10MG		A209250	003	Mar 26, 2019	Jan	CTEC
AB1			20MG		A209250	004	Mar 26, 2019	Jan	CTEC

TAMOXIFEN CITRATESOLUTION;ORAL
SOLTAMOX

+! MAYNE PHARMA COMMRCLEQ 20MG BASE/10ML N021807 001 Oct 29, 2005 Feb CAHN

TASIMELTEONCAPSULE;ORAL
TASIMELTEONAB APOTEX 20MG A211607 001 Dec 20, 2022 Jan CAHN
AB MSN 20MG A211654 001 Jan 12, 2023 Jan NEWATAVABOROLESOLUTION;TOPICAL
TAVABOROLE

>A> AB ZYDUS LIFESCIENCES 5% A212294 001 Apr 10, 2023 Mar NEWA

TAZAROTENEGEL;TOPICAL
TAZAROTENE>A> AB SOLARIS PHARMA CORP 0.05% A213644 001 Mar 20, 2023 Mar NEWA
>A> AB 0.1% A213644 002 Mar 20, 2023 Mar NEWATECHNETIUM TC-99M MERTIATIDE KITPOWDER;INTRAVENOUS
TECHNETIUM TC 99M MERTIATIDE KIT

+! JUBILANT DRAXIMAGE N/A N216820 001 Jan 30, 2023 Jan NEWA

TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

TENOFOVIR ALAFENAMIDE

>A> AB LUPIN LTD EQ 25MG BASE A214226 001 Mar 30, 2023 Mar NFTG
VEMLIDY
>D> +! GILEAD SCIENCES INC EQ 25MG BASE N208464 001 Nov 10, 2016 Mar CFTG
>A> AB +! EQ 25MG BASE N208464 001 Nov 10, 2016 Mar CFTGTENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

AB REYOUNG PHARM 300MG A211337 001 Mar 02, 2023 Feb NEWA

TERIFLUNOMIDE

TABLET;ORAL

TERIFLUNOMIDE

AB AMNEAL PHARMS CO 7MG A209613 001 Sep 28, 2018 Feb CMFD
AB 14MG A209613 002 Sep 28, 2018 Feb CMFD
AB APOTEX 7MG A209601 001 Nov 02, 2018 Jan CMFD
AB 14MG A209601 002 Nov 02, 2018 Jan CMFD
AB AUROBINDO PHARMA 7MG A209638 001 Oct 26, 2018 Jan CMFD
AB 14MG A209638 002 Oct 26, 2018 Jan CMFD
>A> AB BIOCON PHARMA 7MG A209639 001 Mar 13, 2023 Mar NEWA
>A> AB 14MG A209639 002 Mar 13, 2023 Mar NEWA
>A> AB HETERO LABS LTD V 7MG A209598 001 Mar 13, 2023 Mar NEWA
>A> AB 14MG A209598 002 Mar 13, 2023 Mar NEWA
AB MSN 7MG A209623 001 Apr 24, 2019 Feb CMFD
AB 14MG A209623 002 Apr 24, 2019 Feb CMFD
AB MYLAN 7MG A209702 001 Feb 28, 2020 Feb CMFD
AB 14MG A209702 002 Feb 28, 2020 Feb CMFD
AB SOLA PHARMS 14MG A209677 001 Jun 17, 2020 Feb CMFD
AB TEVA PHARMS USA 7MG A209700 001 Sep 04, 2018 Feb CMFD
AB 14MG A209700 002 Sep 04, 2018 Feb CMFD
AB ZYDUS PHARMS 7MG A209668 001 Nov 30, 2018 Jan CMFD
AB 14MG A209668 002 Nov 30, 2018 Jan CMFDTESTOSTERONEGEL;TRANSDERMAL
ANDROGEL+ @ BESINS HLTHCARE 1.62% (20.25MG/1.25GM PACKET) N022309 002 Sep 07, 2012 Feb CAHN
+ @ 1.62% (40.5MG/2.5GM PACKET) N022309 003 Sep 07, 2012 Feb CAHN
+ @ 25MG/2.5GM PACKET N021015 001 Feb 28, 2000 Feb CAHN
+ @ 50MG/5GM PACKET N021015 002 Feb 28, 2000 Feb CAHN

GEL, METERED;NASAL
NATESTO

+!	ACERUS	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jan CHRS
+		5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jan CRLD

GEL, METERED;TRANSDERMAL
ANDROGEL

AB	+!	BESINS HLTHCARE	1.62% (20.25MG/1.25GM ACTUATION)	N022309	001	Apr 29, 2011	Feb CAHN
	+	@	12.5MG/1.25GM ACTUATION	N021015	003	Sep 26, 2003	Feb CAHN
AB		TESTOSTERONE					
AB		ENCUBE	1.62% (20.25MG/1.25GM ACTUATION)	A208620	001	Apr 10, 2019	Jan CAHN

TESTOSTERONE CYPIONATEINJECTABLE;INJECTION
TESTOSTERONE CYPIONATE

>A>	AO	XIROMED	100MG/ML	A215351	001	Apr 13, 2023	Mar NEWA
>A>	AO		200MG/ML	A215351	002	Apr 13, 2023	Mar NEWA

TETRABENAZINETABLET;ORAL
TETRABENAZINE

@	SUN PHARM	12.5MG	A206129	001	Aug 17, 2015	Jan DISC
@		25MG	A206129	002	Aug 17, 2015	Jan DISC

THEOPHYLLINETABLET, EXTENDED RELEASE;ORAL
THEOPHYLLINE

>A>	AB	AMNEAL	300MG	A216276	001	Mar 20, 2023	Mar NEWA
>A>	AB		450MG	A216276	002	Mar 20, 2023	Mar NEWA
	AB	LEADING	300MG	A214950	001	Jan 30, 2023	Jan NEWA
	AB		450MG	A214950	002	Jan 30, 2023	Jan NEWA

THIAMINE HYDROCHLORIDEINJECTABLE;INJECTION
THIAMINE HYDROCHLORIDE

AP		CAPLIN	100MG/ML	A215692	001	Mar 06, 2023	Feb NEWA
>D>		@ DR REDDYS	100MG/ML	A080571	001		Mar CMFD
>A>	AP		100MG/ML	A080571	001		Mar CMFD
>D>		@	200MG/ML	A080571	002		Mar CMFD
>A>		!	200MG/ML	A080571	002		Mar CMFD

THIORIDAZINE HYDROCHLORIDETABLET;ORAL
THIORIDAZINE HYDROCHLORIDE

@	CHARTWELL RX	10MG	A088131	001	Aug 30, 1983	Jan CAHN
@		15MG	A088132	001	Aug 30, 1983	Jan CAHN
@		25MG	A088133	001	Aug 30, 1983	Jan CAHN
@		50MG	A088134	001	Aug 30, 1983	Jan CAHN
@		100MG	A088135	001	Nov 20, 1984	Jan CAHN
@		150MG	A088136	001	Sep 17, 1986	Jan CAHN
@		200MG	A088137	001	Sep 17, 1986	Jan CAHN

THIOTHIXENECAPSULE;ORAL
THIOTHIXENE

AB		RISING	1MG	A071093	002	Jun 23, 1987	Feb CAHN
AB			2MG	A071093	003	Jun 23, 1987	Feb CAHN
AB			5MG	A071093	004	Jun 23, 1987	Feb CAHN
AB			10MG	A071093	001	Jun 23, 1987	Feb CAHN

TIMOLOLSOLUTION/DROPS;OPHTHALMIC
BETIMOL

+!	THEA PHARMA	EQ 0.25% BASE	N020439	001	Mar 31, 1995	Jan CTEC	
+!		EQ 0.5% BASE	N020439	002	Mar 31, 1995	Jan CTEC	
		TIMOLOL					
	@	AKORN	EQ 0.25% BASE	A205309	001	Sep 30, 2016	Jan DISC
	@		EQ 0.5% BASE	A205309	002	Sep 30, 2016	Jan DISC

TIMOLOL MALEATE

		SOLUTION, GEL FORMING/DROPS;OPHTHALMIC						
		TIMOLOL MALEATE						
>A>	AB	EUGIA PHARMA	EQ 0.5% BASE	A213540	001	Mar 23, 2023	Mar	NEWA
	AB	GLAND PHARMA LTD	EQ 0.5% BASE	A214645	002	Feb 14, 2023	Feb	NEWA
		SOLUTION/DROPS;OPHTHALMIC						
		TIMOLOL MALEATE						
		@ AKORN	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Jan	DISC

TIROFIBAN HYDROCHLORIDE

		SOLUTION;INTRAVENOUS						
		AGGRASTAT						
AP	+	MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N020913	002	May 17, 2002	Jan	CFTG
		TIROFIBAN HYDROCHLORIDE						
AP		NEXUS PHARMS	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	A213947	001	Feb 07, 2023	Jan	NFTG

TOBRAMYCIN

		SOLUTION/DROPS;OPHTHALMIC						
		AKTOB						
		@ AKORN	0.3%	A064096	001	Jan 31, 1996	Feb	DISC

TOBRAMYCIN SULFATE

		INJECTABLE;INJECTION						
		TOBRAMYCIN SULFATE						
AP		HAINAN POLY	EQ 1.2GM BASE/VIAL	A217029	001	Feb 01, 2023	Jan	NEWA

TOFACITINIB CITRATE

		TABLET;ORAL						
		TOFACITINIB CITRATE						
>A>		@ MICRO LABS	EQ 5MG BASE	A209738	001	Mar 13, 2023	Mar	DISC
>A>	AB	ZYDUS PHARMS	EQ 5MG BASE	A209829	001	Mar 13, 2023	Mar	NEWA
		XELJANZ						
>D>	+	PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012	Mar	CFTG
>A>	AB	+	EQ 5MG BASE	N203214	001	Nov 06, 2012	Mar	CFTG

TOPIRAMATE

		CAPSULE, EXTENDED RELEASE;ORAL						
		TOPIRAMATE						
>A>	AB1	ACTAVIS LABS FL	25MG	A206210	001	Mar 10, 2023	Mar	NEWA
>A>	AB1		50MG	A206210	002	Mar 10, 2023	Mar	NEWA
>A>	AB1		100MG	A206210	003	Mar 10, 2023	Mar	NEWA
>A>	AB1		200MG	A206210	004	Mar 10, 2023	Mar	NEWA
	AB1	PAR PHARM	200MG	A205976	001	Mar 01, 2023	Feb	NEWA
	AB1	ZYDUS	25MG	A207382	001	Nov 24, 2017	Jan	CAHN
	AB2		25MG	A208949	001	Nov 29, 2022	Jan	CAHN
	AB1		50MG	A207382	002	Nov 24, 2017	Jan	CAHN
	AB2		50MG	A208949	002	Nov 29, 2022	Jan	CAHN
	AB1		100MG	A207382	003	Nov 24, 2017	Jan	CAHN
	AB2		100MG	A208949	003	Nov 29, 2022	Jan	CAHN
	AB2		150MG	A208949	004	Nov 29, 2022	Jan	CAHN
	AB2		200MG	A208949	005	Nov 29, 2022	Jan	CAHN
	AB1	ZYDUS PHARMS	200MG	A216167	001	Feb 09, 2023	Jan	NFTG
		TROKENDI XR						
	AB1	+! SUPERNUS PHARMS	200MG	N201635	004	Aug 16, 2013	Jan	CFTG

TOPOTECAN HYDROCHLORIDE

		SOLUTION;INTRAVENOUS						
		TOPOTECAN HYDROCHLORIDE						
>A>		@ DASH PHARMS	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A206074	001	Nov 24, 2017	Mar	CAHN
>D>		@ MYLAN LABS LTD	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A206074	001	Nov 24, 2017	Mar	CAHN

TRAMETINIB DIMETHYL SULFOXIDE

>A>		SOLUTION;ORAL						
>A>		MEKINIST						
>A>	+	NOVARTIS	EQ 0.05MG BASE/ML	N217513	001	Mar 16, 2023	Mar	NEWA

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

AB	AUROBINDO PHARMA	50MG	A204852	001	Feb 05, 2020	Jan	CAHN
AB		100MG	A204852	002	Feb 05, 2020	Jan	CAHN
AB		150MG	A204852	003	Feb 05, 2020	Jan	CAHN
AB		300MG	A204852	004	Feb 05, 2020	Jan	CAHN

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS

TREPROSTINIL

AP	DR REDDYS	1MG/ML	A210214	001	May 22, 2020	Feb	CMFD
AP		2.5MG/ML	A210214	002	May 22, 2020	Feb	CMFD
AP		5MG/ML	A210214	003	May 22, 2020	Feb	CMFD
AP		10MG/ML	A210214	004	May 22, 2020	Feb	CMFD

TRETINOIN

CREAM;TOPICAL

RETIN-A

AB	+! BAUSCH	0.025%	N019049	001	Sep 16, 1988	Jan	CAHN
----	-----------	--------	---------	-----	--------------	-----	------

TRIAMCINOLONE ACETONIDE

OINTMENT;TOPICAL

TRIAMCINOLONE ACETONIDE

AT	GLASSHOUSE PHARMS	0.05%	A214532	001	Jan 27, 2023	Jan	NEWA
----	-------------------	-------	---------	-----	--------------	-----	------

TRIAMTERENE

CAPSULE;ORAL

TRIAMTERENE

@ EYWA

50MG

A214768	001	Jul 06, 2022	Jan	DISC
---------	-----	--------------	-----	------

@

100MG

A214768	002	Jul 06, 2022	Jan	DISC
---------	-----	--------------	-----	------

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

TRIENTINE HYDROCHLORIDE

>D>	BX	MSN	250MG	A211134	001	May 22, 2019	Mar	CTEC
>A>	AB		250MG	A211134	001	May 22, 2019	Mar	CTEC

>A> TROFINETIDE

>A> SOLUTION;ORAL

>A> DAYBUE

>A>	+!	ACADIA PHARMS INC	200MG/ML	N217026	001	Mar 10, 2023	Mar	NEWA
-----	----	-------------------	----------	---------	-----	--------------	-----	------

UBROGEPANT

TABLET;ORAL

UBRELVY

+ ABBVIE

50MG

N211765	001	Dec 23, 2019	Jan	CAHN
---------	-----	--------------	-----	------

+!

100MG

N211765	002	Dec 23, 2019	Jan	CAHN
---------	-----	--------------	-----	------

URSODIOL

CAPSULE;ORAL

URSODIOL

@ MYLAN

300MG

A090530	001	Feb 17, 2010	Jan	DISC
---------	-----	--------------	-----	------

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	CHARTWELL RX	EQ 500MG BASE	A090216	001	May 24, 2010	Jan	CAHN
AB		EQ 1GM BASE	A090216	002	May 24, 2010	Jan	CAHN

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALCYTE

>A>	AB	+!	CHEPLAPHARM	50MG/ML	N022257	001	Aug 28, 2009	Mar	CAHN
-----	----	----	-------------	---------	---------	-----	--------------	-----	------

>D>	AB	+!	HOFFMANN LA ROCHE	50MG/ML	N022257	001	Aug 28, 2009	Mar	CAHN
-----	----	----	-------------------	---------	---------	-----	--------------	-----	------

VALGANCICLOVIR HYDROCHLORIDE

>A>	AB		APPCO	50MG/ML	A216317	001	Apr 11, 2023	Mar	NEWA
-----	----	--	-------	---------	---------	-----	--------------	-----	------

TABLET;ORAL

VALCYTE

>A>	AB	+!	CHEPLAPHARM	EQ 450MG BASE	N021304	001	Mar 29, 2001	Mar	CAHN
-----	----	----	-------------	---------------	---------	-----	--------------	-----	------

>D>	AB	+!	HOFFMANN LA ROCHE	EQ 450MG BASE	N021304	001	Mar 29, 2001	Mar	CAHN
-----	----	----	-------------------	---------------	---------	-----	--------------	-----	------

VALPROIC ACID

SYRUP;ORAL
VALPROIC ACID

>D>	@	WOCKHARDT BIO AG	250MG/5ML	A070868	001	Jul 01, 1986	Mar	CAHN
>A>	@	XTTRIUM LABS INC	250MG/5ML	A070868	001	Jul 01, 1986	Mar	CAHN

VALSARTAN

SOLUTION;ORAL
VALSARTAN

!	NOVITIUM PHARMA	20MG/5ML	A214102	001	Nov 02, 2021	Jan	CHRS
---	-----------------	----------	---------	-----	--------------	-----	------

VANCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION
VANCOMYCIN HYDROCHLORIDE

AP	HIKMA	EQ 1GM BASE/VIAL	A203300	002	Aug 11, 2020	Jan	CMFD
----	-------	------------------	---------	-----	--------------	-----	------

POWDER;INTRAVENOUS, ORAL
VANCOMYCIN HYDROCHLORIDE

+	!	ZHEJIANG NOVUS PHARM	EQ 500MG BASE/VIAL	N210274	001	Jan 20, 2023	Jan	NEWA
+	!		EQ 1GM BASE/VIAL	N210274	002	Jan 20, 2023	Jan	NEWA
+	!		EQ 5GM BASE/VIAL	N210274	003	Jan 20, 2023	Jan	NEWA
+	!		EQ 10GM BASE/VIAL	N210274	004	Jan 20, 2023	Jan	NEWA

VARENICLINE TARTRATE

TABLET;ORAL
VARENICLINE TARTRATE

AB	APOTEX	EQ 0.5MG BASE	A201962	001	Jan 25, 2023	Jan	NEWA
AB		EQ 1MG BASE	A201962	002	Jan 25, 2023	Jan	NEWA
AB	PAR PHARM INC	EQ 0.5MG BASE	A201785	001	Aug 11, 2021	Jan	CTEC
AB	!	EQ 1MG BASE	A201785	002	Aug 11, 2021	Jan	CTEC

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDE

>A>	AB	NOSTRUM PHARMS LLC	EQ 37.5MG BASE	A200430	001	Apr 04, 2023	Mar	NEWA
>A>	AB		EQ 75MG BASE	A200430	002	Apr 04, 2023	Mar	NEWA
>A>	AB		EQ 150MG BASE	A200430	003	Apr 04, 2023	Mar	NEWA

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

@	CHARTWELL RX	EQ 25MG BASE	A077515	001	Jun 13, 2008	Jan	CAHN
@		EQ 37.5MG BASE	A077515	002	Jun 13, 2008	Jan	CAHN
@		EQ 50MG BASE	A077515	003	Jun 13, 2008	Jan	CAHN
@		EQ 75MG BASE	A077515	004	Jun 13, 2008	Jan	CAHN
@		EQ 100MG BASE	A077515	005	Jun 13, 2008	Jan	CAHN

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

>A>	AB	AJANTA PHARMA LTD	EQ 37.5MG BASE	A214691	001	Apr 12, 2023	Mar	NEWA
>A>	AB		EQ 75MG BASE	A214691	002	Apr 12, 2023	Mar	NEWA
>A>	AB		EQ 150MG BASE	A214691	003	Apr 12, 2023	Mar	NEWA
>A>	AB		EQ 225MG BASE	A214691	004	Apr 12, 2023	Mar	NEWA

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CALAN SR

>D>	AB	+	!	PFIZER	120MG	N019152	003	Mar 06, 1991	Mar	DISC
>A>		+	@		120MG	N019152	003	Mar 06, 1991	Mar	DISC
>D>	AB	+	!		240MG	N019152	001	Dec 16, 1986	Mar	DISC
>A>		+	@		240MG	N019152	001	Dec 16, 1986	Mar	DISC

VERAPAMIL HYDROCHLORIDE

>A>	AB	CADILA PHARMS LTD	120MG	A206173	003	Nov 14, 2022	Mar	NEWA
>D>	AB	GLENMARK GENERICS	120MG	A090700	001	Aug 03, 2011	Mar	CHRS
>A>	AB	!	120MG	A090700	001	Aug 03, 2011	Mar	CHRS
>D>	AB		240MG	A078906	001	Sep 17, 2009	Mar	CHRS
>A>	AB	!	240MG	A078906	001	Sep 17, 2009	Mar	CHRS

VIGABATRIN

FOR SOLUTION;ORAL
VIGABATRIN

>D>	AA	ACCORD HLTHCARE	500MG/PACKET	A214425	001	Nov 13, 2020	Mar	DISC
>A>		@	500MG/PACKET	A214425	001	Nov 13, 2020	Mar	DISC
	AA	ZYDUS	500MG/PACKET	A214671	001	Mar 02, 2023	Feb	NEWA

VILAZODONE HYDROCHLORIDETABLET; ORAL
VIIBRYD

AB	+	ABBVIE	10MG	N022567	001	Jan 21, 2011	Jan CAHN
AB	+		20MG	N022567	002	Jan 21, 2011	Jan CAHN
AB	+		40MG	N022567	003	Jan 21, 2011	Jan CAHN

VORICONAZOLEINJECTABLE; INTRAVENOUS
VORICONAZOLE

AP		EUGIA PHARMA	200MG/VIAL	A212162	001	Feb 02, 2023	Jan NEWA
>A>	AP	UBI	200MG/VIAL	A211264	001	Mar 09, 2023	Mar NEWA
>A>	AP	XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	Mar CDFR
>D>		POWDER; INTRAVENOUS					
>D>		VORICONAZOLE					
>D>	AP	XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	Mar CDFR

VUTRISIRAN SODIUMSOLUTION; SUBCUTANEOUS
AMVUTTRA

+	!	ALNYLAM PHARMS INC	EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML)	N215515	001	Jun 13, 2022	Feb CPOT
+	!		25MG/0.5ML (25MG/0.5ML)	N215515	001	Jun 13, 2022	Feb CAIN

XENON XE-129 HYPERPOLARIZEDGAS; INHALATION
XENOVIEW

+	!	POLAREAN	N/A	N214375	001	Dec 23, 2022	Jan NEWA
---	---	----------	-----	---------	-----	--------------	----------

>A> ZAVEGEPANT HYDROCHLORIDE>A> SPRAY, METERED; NASAL
>A> ZAVZPRET

>A>	+	!	PFIZER	EQ 10MG BASE/SPRAY	N216386	001	Mar 09, 2023	Mar NEWA
-----	---	---	--------	--------------------	---------	-----	--------------	----------

ZILEUTONTABLET, EXTENDED RELEASE; ORAL
ZILEUTON

AB	!	RISING	600MG	A204929	001	Mar 17, 2017	Jan CHRS
	+	@	CHIESI	N022052	001	May 30, 2007	Jan DISC

ZOLMITRIPTANSPRAY; NASAL
ZOMIG

AB	+	AMNEAL	2.5MG/SPRAY	N021450	003	Sep 16, 2013	Jan CAHN
AB	+	!	5MG/SPRAY	N021450	004	Sep 30, 2003	Jan CAHN

ACETAMINOPHEN; IBUPROFEN

TABLET; ORAL

ACETAMINOPHEN AND IBUPROFEN

L PERRIGO CO

250MG; 125MG

A214836 001 Feb 28, 2023 Feb NEWA

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 5MG; 120MG

A212409 001 Mar 08, 2023 Feb NEWA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION; TOPICAL

SOLUPREP

>D>

>D> +! 3M HEALTH CARE 2%; 70%

N208288 001 Aug 08, 2018 Mar CTNA

>A> SOLUPREP S

>A> +! 3M HEALTH CARE 2%; 70%

N208288 001 Aug 08, 2018 Mar CTNA

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

COREPHARMA

25MG; 220MG

A211830 001 Aug 22, 2019 Feb CAHN

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

>A> GUARDIAN DRUG

EQ 20MG BASE

A216149 001 Mar 15, 2023 Mar NEWA

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

MARKSANS PHARMA

10MG

A217543 001 Mar 08, 2023 Feb NEWA

20MG

A217543 002 Mar 08, 2023 Feb NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ GRANULES

600MG; 60MG

A216082 001 Aug 22, 2022 Feb DISC

@

1.2GM; 120MG

A216082 002 Aug 22, 2022 Feb DISC

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

>A> AUROBINDO PHARMA LTD 200MG; 30MG

A213565 001 Mar 10, 2023 Mar NEWA

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

@ GRANULES

2MG; 125MG

A215981 001 Aug 29, 2022 Feb DISC

LORATADINE

CAPSULE; ORAL

LORATADINE

>A> AUROBINDO PHARMA

10MG

A211900 001 Mar 24, 2023 Mar NEWA

NALOXONE HYDROCHLORIDE

SPRAY, METERED; NASAL

NARCAN

>A> +! EMERGENT 4MG/SPRAY

N208411 001 Nov 18, 2015 Mar CMKT

NAPROXEN SODIUM

CAPSULE; ORAL

NAPROXEN SODIUM

@ STRIDES PHARMA

EQ 200MG BASE

A215472 001 Aug 17, 2022 Feb DISC

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

@ AKORN	EQ 0.1% BASE	A204532	001	Jan 10, 2017	Jan DISC
@	EQ 0.2% BASE	A204723	001	Dec 05, 2017	Jan DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 3 MARCH 2023

NO MARCH 2023 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MARCH 2023 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	>A> 8748382	Oct 03, 2027	U-2009			
	>A> 8748382	Oct 03, 2027	U-3543			
	>A> RE49444	Apr 28, 2031	U-2009			
	>A> RE49444	Apr 28, 2031	U-3543			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	>A> 7855211	Dec 15, 2029	DS DP U-2132			
	>A> 7855211	Dec 15, 2029	DS DP U-2135			
	>A> 7855211	Dec 15, 2029	DS DP U-2251			
	>A> 7855211	Dec 15, 2029	DS DP U-3241			
	>A> 7855211	Dec 15, 2029	DS DP U-3242			
	>A> 7855211	Dec 15, 2029	DS DP U-3243			
	>A> 7855211	Dec 15, 2029	DS DP U-3265			
	>A> 7855211	Dec 15, 2029	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	>A> 7855211	Dec 15, 2029	DS DP U-2132			
	>A> 7855211	Dec 15, 2029	DS DP U-2135			
	>A> 7855211	Dec 15, 2029	DS DP U-2251			
	>A> 7855211	Dec 15, 2029	DS DP U-3241			
	>A> 7855211	Dec 15, 2029	DS DP U-3242			
	>A> 7855211	Dec 15, 2029	DS DP U-3243			
	>A> 7855211	Dec 15, 2029	DS DP U-3265			
	>A> 7855211	Dec 15, 2029	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	>A> 7855211	Dec 15, 2029	DS DP U-2132			
	>A> 7855211	Dec 15, 2029	DS DP U-2135			
	>A> 7855211	Dec 15, 2029	DS DP U-2251			
	>A> 7855211	Dec 15, 2029	DS DP U-3241			
	>A> 7855211	Dec 15, 2029	DS DP U-3242			
	>A> 7855211	Dec 15, 2029	DS DP U-3243			
	>A> 7855211	Dec 15, 2029	DS DP U-3265			
	>A> 7855211	Dec 15, 2029	DS DP U-3546			
<u>ABROCITINIB - CIBINOO</u>						
N 213871 001				>A> NPP		Feb 09, 2026
<u>ABROCITINIB - CIBINOO</u>						
N 213871 002				>A> NPP		Feb 09, 2026
<u>ABROCITINIB - CIBINOO</u>						
N 213871 003				>A> NPP		Feb 09, 2026
<u>ACETAMINOPHEN; IBUPROFEN - COMBOGESIC</u>						
N 209471 001	>A> 10532036	Sep 22, 2025	U-3553			
	>A> 11197830	Feb 27, 2039	DP U-3553			
	>A> 11534407	Feb 27, 2039	DP U-3553			
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001				NCE		Dec 12, 2027
				>A> ODE-352		Dec 12, 2029
<u>ALBUTEROL SULFATE; BUDESONIDE - AIRSUPRA</u>						
N 214070 001	9415009	May 28, 2030	U-3509		NP	Jan 10, 2026
<u>ALPELISIB - VIJOICE</u>						
N 215039 001					ODE-396	Apr 05, 2029
<u>ALPELISIB - VIJOICE</u>						
N 215039 002					ODE-396	Apr 05, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALPELISIB - VIJOICE</u>						
N 215039	003				ODE-396	Apr 05, 2029
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081	001	11540981	Feb 07, 2028	DP		
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR</u>						
N 208147	001	11590228	Sep 07, 2036	DP U-3538		
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 5</u>						
N 210526	001	11590081	Sep 24, 2038	DP U-3538		
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 10</u>						
N 210526	002	11590081	Sep 24, 2038	DP U-3538		
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 15</u>						
N 210526	003	11590081	Sep 24, 2038	DP U-3538		
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 20</u>						
N 210526	004	11590081	Sep 24, 2038	DP U-3538		
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360	001	11559559	Dec 18, 2034	U-3514		
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360	002	11559559	Dec 18, 2034	U-3514		
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360	003	11559559	Dec 18, 2034	U-3514		
<u>APALUTAMIDE - ERLEADA</u>						
N 210951	001	10052314	Sep 23, 2033	U-2381	Y	
		10052314	Sep 23, 2033	U-2382	Y	
		9481663	Jun 04, 2033	DS DP U-2237		
		9481663	Jun 04, 2033	DS DP U-2624		
		RE49353	Sep 23, 2033	U-2381		
<u>APALUTAMIDE - ERLEADA</u>						
N 210951	002	10702508	Apr 30, 2038	U-3012		
		10849888	Sep 23, 2033	U-3013		
		8445507	Sep 15, 2030	DS DP U-2237		
		8445507	Sep 15, 2030	DS DP U-2624		
		8802689	Mar 27, 2027	U-2237		
		8802689	Mar 27, 2027	U-2624		
		9388159	Mar 27, 2027	DS DP		
		9481663	Jun 04, 2033	DS DP U-2237		
		9481663	Jun 04, 2033	DS DP U-2624		
		9884054	Sep 23, 2033	U-2237		
		9987261	Mar 27, 2027	DP		
		RE49353	Sep 23, 2033	U-2381		
<u>ATORVASTATIN CALCIUM - ATORVALIO</u>						
N 213260	001	11369567	Jun 07, 2037	DP		
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494	001				NPP	Dec 20, 2025
<u>AZACITIDINE - VIDAZA</u>						
N 050794	001				ODE-399	May 20, 2029
<u>AZACITIDINE - ONUREG</u>						
N 214120	001	11571436	May 14, 2029	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AZACITIDINE - ONUREG</u>						
N 214120 002	11571436	May 14, 2029	DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001 >A>	9737469	Nov 02, 2031	U-3500			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002 >A>	9737469	Nov 02, 2031	U-3500			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 003 >A>	9737469	Nov 02, 2031	U-3500			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	11559637	Jul 21, 2039	DP			
	>A> 11583643	Aug 19, 2041	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	11559637	Jul 21, 2039	DP			
	>A> 11583643	Aug 19, 2041	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
	9533955*PED	Sep 26, 2029				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
	9533955*PED	Sep 26, 2029				
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	11541026	Feb 19, 2040	U-3356			
<u>BEXAGLIFLOZIN - BREZAVVY</u>						
N 214373 001	10533032	Jul 03, 2031	U-2214		NCE	Jan 20, 2028
	10981942	Jun 13, 2031	DS DP			
	7838499	Jan 30, 2029	DS DP U-2214			
	8106021	Aug 22, 2028	U-2214			
	8802637	Aug 22, 2028	DS DP U-2214			
	8987323	May 14, 2032	DS DP			
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001 >A>	11590209	Apr 29, 2041	U-3539			
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144 001 >A>	11596600	Jul 27, 2029	U-2222			
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001					ODE-389	Dec 15, 2028
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	11534414	Nov 05, 2034	DP U-3419			
	11541021	Nov 05, 2034	U-3419			
	11541048	Nov 05, 2034	U-3419			
	>A> 11596627	Nov 05, 2034	U-3419			
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	11554102	Jan 11, 2033	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001 >A>	11576894	Jul 06, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	>A> 11576894	Jul 06, 2030	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	>A> 11576894	Jul 06, 2030	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	>A> 11576894	Jul 06, 2030	DP			
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030 001	11529357	Jan 31, 2040	DP			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Sep 17, 2029	DS DP U-1750		I-904	Dec 16, 2025
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7737142	Sep 17, 2029	DS DP U-3503			
	RE47350	Jul 16, 2029	U-1750			
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
	RE47350	Jul 16, 2029	U-3503			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Sep 17, 2029	DS DP U-1750		I-904	Dec 16, 2025
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7737142	Sep 17, 2029	DS DP U-3503			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	RE49302	Jul 16, 2029	U-2543		I-904	Dec 16, 2025
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	RE49302	Jul 16, 2029	U-2543		I-904	Dec 16, 2025
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CHLOROPROCAINE HYDROCHLORIDE - IHEEZO</u>						
N 216227 001					NP	Sep 27, 2025
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	8143240	Jan 12, 2024	U-2942			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 001	11541002	Jan 31, 2040	DP U-724			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 002	11541002	Jan 31, 2040	DP U-724			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 003	11541002	Jan 31, 2040	DP U-724			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	>A> 11597699	Oct 05, 2026	U-3554		>A> ODE-416	Oct 28, 2029
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					>A> ODE-407	Jul 14, 2029
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					>A> ODE-407	Jul 14, 2029
<u>CYCLOSPORINE - VERKAZIA</u>						
N 214965 001					NP	Jun 23, 2024
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	>A> 11510941	Mar 02, 2039	DP			
	>A> 11510942	Jan 15, 2039	DP U-2752			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	>A> 10028912	Oct 15, 2032	DP U-3149			
	>A> 10028912	Oct 15, 2032	DP U-3150			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	10869869	Aug 30, 2033	U-3185		I-894	Jun 22, 2025
	10869869*PED	Mar 02, 2034			ODE-147	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-1406		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2031		ODE-183	May 04, 2025
	7994185	Jan 20, 2030	DS DP U-2032		PED	Dec 22, 2024
	7994185	Jan 20, 2030	DS DP U-2296		PED	Oct 30, 2025
	7994185*PED	Jul 20, 2030			PED	Nov 04, 2025
	8415345	Jan 20, 2030	DS DP U-1406		PED	Dec 22, 2025
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-2296			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2027			
	8952018*PED	Apr 15, 2031				
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956*PED	Nov 04, 2029				
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	10869869	Aug 30, 2033	U-3185		I-894	Jun 22, 2025
	10869869*PED	Mar 02, 2034			ODE-147	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-1406		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2031		ODE-183	May 04, 2025
	7994185	Jan 20, 2030	DS DP U-2032		PED	Dec 22, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	7994185	Jan 20, 2030	DS DP U-2296		PED	Oct 30, 2025
	7994185*PED	Jul 20, 2030			PED	Nov 04, 2025
	8415345	Jan 20, 2030	DS DP U-1406		PED	Dec 22, 2025
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-2296			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2027			
	8952018*PED	Apr 15, 2031				
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956*PED	Nov 04, 2029				
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001	6900175	May 23, 2028	U-3499			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 001	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 002	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 003	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 004	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 005	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	>A> 8975254	Mar 25, 2033	DS DP U-2605			
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 001					>A> ODE-417	Apr 30, 2028
					>A> ODE-420	Apr 30, 2028
					>A> ODE-421	Apr 30, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825	001				>A> ODE-417	Apr 30, 2028
					>A> ODE-420	Apr 30, 2028
					>A> ODE-421	Apr 30, 2028
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825	002				>A> ODE-417	Apr 30, 2028
					>A> ODE-420	Apr 30, 2028
					>A> ODE-421	Apr 30, 2028
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030	001				>A> ODE-417	Apr 30, 2028
					>A> ODE-418	Apr 30, 2028
					>A> ODE-419	Apr 30, 2028
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030	002				>A> ODE-417	Apr 30, 2028
					>A> ODE-418	Apr 30, 2028
					>A> ODE-419	Apr 30, 2028
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269	001				>A> ODE-417	Apr 30, 2028
					>A> ODE-420	Apr 30, 2028
					>A> ODE-421	Apr 30, 2028
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	001	11564917	Mar 07, 2036	U-1995		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	002	11564917	Mar 07, 2036	U-1995		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	003	11564917	Mar 07, 2036	U-1995		
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354	001	10959996	Mar 07, 2036	U-3055		
		11179386	Mar 15, 2038	DP U-1995		
		11179386	Mar 15, 2038	DP U-3055		
		11311488	Jun 10, 2041	DP U-1995		
		11311488	Jun 10, 2041	DP U-3055		
		11357772	Mar 07, 2036	U-1995		
		11357772	Mar 07, 2036	U-3055		
		11446291	Mar 07, 2036	U-1995		
		11564917	Mar 07, 2036	U-1995		
		8524733	Apr 03, 2031	DS DP		
		9550780	Sep 18, 2033	DS DP U-1995		
		9550780	Sep 18, 2033	DS DP U-3055		
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354	002	10959996	Mar 07, 2036	U-3055		
		11179386	Mar 15, 2038	DP U-1995		
		11179386	Mar 15, 2038	DP U-3055		
		11311488	Jun 10, 2041	DP U-1995		
		11311488	Jun 10, 2041	DP U-3055		
		11357772	Mar 07, 2036	U-1995		
		11357772	Mar 07, 2036	U-3055		
		11446291	Mar 07, 2036	U-1995		
		11564917	Mar 07, 2036	U-1995		
		8524733	Apr 03, 2031	DS DP		
		9550780	Sep 18, 2033	DS DP U-1995		
		9550780	Sep 18, 2033	DS DP U-3055		
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354	003	10959996	Mar 07, 2036	U-3055		
		11179386	Mar 15, 2038	DP U-1995		
		11179386	Mar 15, 2038	DP U-3055		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 003	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11446291	Mar 07, 2036	U-1995			
	11564917	Mar 07, 2036	U-1995			
	8524733	Apr 03, 2031	DS DP			
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 005					NPP	Dec 16, 2025
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 001	11559501	Jan 06, 2042	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 002	11559501	Jan 06, 2042	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 003	11559501	Jan 06, 2042	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 004	11559501	Jan 06, 2042	DP			
<u>DOXEPIN HYDROCHLORIDE - DOXEPIN HYDROCHLORIDE</u>						
A 215408 001					CGT	Aug 16, 2023
<u>ELACESTRANT DIHYDROCHLORIDE - ORSERDU</u>						
N 217639 001	10071066	Oct 10, 2034	U-3524		NCE	Jan 27, 2028
	>A> 10385008	Jan 05, 2038	DS DP			
	>A> 10420734	Oct 10, 2034	U-3524			
	10745343	Jan 05, 2038	U-3523			
	>A> 7612114	Aug 18, 2026	DS DP U-3523			
	8399520	Dec 25, 2023	DS DP U-3523			
<u>ELACESTRANT DIHYDROCHLORIDE - ORSERDU</u>						
N 217639 002	10071066	Oct 10, 2034	U-3524		NCE	Jan 27, 2028
	>A> 10385008	Jan 05, 2038	DS DP			
	>A> 10420734	Oct 10, 2034	U-3524			
	10745343	Jan 05, 2038	U-3523			
	>A> 7612114	Aug 18, 2026	DS DP U-3523			
	8399520	Dec 25, 2023	DS DP U-3523			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	11542239	Jul 23, 2039	DS DP			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	11542239	Jul 23, 2039	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	11542239	Jul 23, 2039	DS DP			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	11564916	Aug 13, 2029	U-3525			
	>A> 11578062	Mar 25, 2031	DP U-3544			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	11564916	Aug 13, 2029	U-3525			
	>A> 11578062	Mar 25, 2031	DP U-3544			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	11564886	Mar 07, 2032	DP U-3531			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	11564886	Mar 07, 2032	DP U-3531			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	11564886	Mar 07, 2032	DP U-3531			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3534			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3534			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3534			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3534			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	8501758	Aug 27, 2030	DS DP			
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407 001	11571398	May 16, 2040	U-3183			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	>A> 11590286	Dec 12, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	>A> 11590286	Dec 12, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003	>A> 11590286	Dec 12, 2026	DP			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 001	>A> 11578044	Oct 19, 2037	DS			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 002	>A> 11578044	Oct 19, 2037	DS			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	11173134	Sep 10, 2035	U-3257			
	11173134	Sep 10, 2035	U-3536			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001				>A> M-289		Jan 27, 2026
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001				ODE-393 PED		Mar 25, 2029 Sep 25, 2029
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	>A> 11590097	Oct 20, 2023	DS DP U-3312			
	>A> 11590097	Oct 20, 2023	DS DP U-3313			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	>A> 11590097	Oct 20, 2023	DS DP U-3312			
	>A> 11590097	Oct 20, 2023	DS DP U-3313			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	>A> 11590097	Oct 20, 2023	DS DP U-3312			
	>A> 11590097	Oct 20, 2023	DS DP U-3313			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	>A> 11590097	Oct 20, 2023	DS DP U-3312			
	>A> 11590097	Oct 20, 2023	DS DP U-3313			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	11554229	Feb 23, 2036	U-2133			
	>A> 11602603	Oct 27, 2028	DP U-2133			
	8327844	Oct 24, 2023	U-2133			
	>A> 8522778	Apr 20, 2024	DP			
<u>FOSDENOPTERIN HYDROBROMIDE - NULIBRY</u>						
N 214018 001					M-286	Oct 27, 2025
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	11529362	Jun 02, 2037	DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	11529362	Jun 02, 2037	DP			
<u>FUTIBATINIB - LYTGObi</u>						
N 214801 001					>A> ODE-410	Sep 30, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 003	>A> 11590246	Jan 17, 2040	DP			
<u>GANAXOLONE - ZTALMY</u>						
N 215904 001					ODE-395	Jun 01, 2029
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 001	>A> 11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 002	>A> 11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYOPEN</u>						
N 212097 003	>A> 11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYOPEN</u>						
N 212097 004	>A> 11590205	Apr 22, 2036	DP U-2742			
<u>GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO</u>						
N 216903 001	10456354	Oct 25, 2038	DP			
	11110054	Oct 25, 2038	DP			
<u>IBREXAFUNGERP CITRATE - BREXAFEMME</u>						
N 214900 001	11534433	Jun 10, 2039	U-3159		I-903	Nov 30, 2025
	11534433	Jun 10, 2039	U-3508			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001					ODE-109	Mar 04, 2023
					ODE-117	May 06, 2023
					ODE-128	Jan 18, 2024
					ODE-152	Aug 02, 2024
					>A> ODE-405	Aug 24, 2029
					PED	Jul 18, 2024
					PED	Feb 02, 2025
					>A> PED	Feb 24, 2030

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552	002				ODE*	Mar 04, 2023
					ODE*	May 06, 2023
					ODE*	Jan 18, 2024
					ODE*	Aug 02, 2024
				>A>	ODE-405	Aug 24, 2029
				>A>	PED	Feb 24, 2030
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	001				ODE*	Mar 04, 2023
					ODE*	May 06, 2023
					ODE*	Jan 18, 2024
					ODE*	Aug 02, 2024
				>A>	ODE-405	Aug 24, 2029
				>A>	PED	Feb 24, 2030
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	002				ODE*	Mar 04, 2023
					ODE*	May 06, 2023
					ODE*	Jan 18, 2024
					ODE*	Aug 02, 2024
				>A>	ODE-405	Aug 24, 2029
				>A>	PED	Feb 24, 2030
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	003				ODE*	Mar 04, 2023
					ODE*	May 06, 2023
					ODE*	Jan 18, 2024
					ODE*	Aug 02, 2024
				>A>	ODE-405	Aug 24, 2029
				>A>	PED	Feb 24, 2030
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	004				ODE*	Mar 04, 2023
					ODE*	May 06, 2023
					ODE*	Jan 18, 2024
					ODE*	Aug 02, 2024
				>A>	ODE-405	Aug 24, 2029
				>A>	PED	Feb 24, 2030
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003	001	10106548	Jun 03, 2033	DS DP	>A> ODE-405	Aug 24, 2029
		10106548*PED	Dec 03, 2033		>A> PED	Feb 24, 2030
		10125140	Jun 03, 2033	DS DP		
		10125140*PED	Dec 03, 2033			
		10478439	Jun 03, 2031		U-3422	
		10478439*PED	Dec 03, 2031			
		10961251	Jun 03, 2033	DP		
		10961251*PED	Dec 03, 2033			
		7514444	Dec 28, 2026	DS DP		
		7514444*PED	Jun 28, 2027			
		8008309	Nov 13, 2027	DS DP		
		8008309*PED	May 13, 2028			
		8497277	Dec 28, 2026		U-3422	
		8497277*PED	Jun 28, 2027			
		8697711	Dec 28, 2026	DS DP		
		8697711*PED	Jun 28, 2027			
		8735403	Dec 28, 2026	DS DP		
		8735403*PED	Jun 28, 2027			
		8754091	Dec 28, 2026	DP		
		8754091*PED	Jun 28, 2027			
		8957079	Dec 28, 2026	DS DP		
		8957079*PED	Jun 28, 2027			
		9181257	Dec 28, 2026	DS		
		9181257*PED	Jun 28, 2027			
		9296753	Oct 30, 2033	DS		
		9296753*PED	Apr 30, 2034			
		9725455	Jun 03, 2033	DS		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	11564916	Aug 13, 2029	U-3530			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	11564916	Aug 13, 2029	U-3528			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	11564916	Aug 13, 2029	U-3528			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003	11564916	Aug 13, 2029	U-3528			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	11564916	Aug 13, 2029	U-3527			
	>A> 11578062	Mar 25, 2031	DP U-3545			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	11564916	Aug 13, 2029	U-3527			
	>A> 11578062	Mar 25, 2031	DP U-3545			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	11564916	Aug 13, 2029	U-3529			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	11564916	Aug 13, 2029	U-3529			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	11564916	Aug 13, 2029	U-3526		>A> ODE-408	Sep 02, 2029
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	11564916	Aug 13, 2029	U-3526		>A> ODE-408	Sep 02, 2029
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 003	11564916	Aug 13, 2029	U-3526		>A> ODE-408	Sep 02, 2029
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	>A> 11191766	Apr 04, 2037	U-2471			
	>A> 11484535	Apr 04, 2037	U-2470			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	>A> 7423050	Mar 27, 2024	DS DP U-1719			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	>A> 7423050	Mar 27, 2024	DS DP U-1719			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 003	>A> 7423050	Mar 27, 2024	DS DP U-1719			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001					>A> ODE*	Aug 28, 2026
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 002					>A> ODE*	Apr 07, 2024
					>A> ODE*	Aug 28, 2026
					>A> PED	Oct 07, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215973 001	10071985	Aug 17, 2037	DS DP			
	10654827	Aug 17, 2037			U-3507	
	11267799	Aug 16, 2038	DS			
	9951043	Feb 28, 2034	DS DP		U-3507	
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215974 001	10071985	Aug 17, 2037	DS DP			
	10654827	Aug 17, 2037			U-3507	
	11267799	Aug 16, 2038	DS			
	9951043	Feb 28, 2034	DS DP		U-3507	
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	11090386	Feb 23, 2036			U-3519	
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	11090386	Feb 23, 2036			U-3519	
<u>LEVOKETONAZOLE - RECORLEV</u>						
N 214133 001					ODE-385	Dec 30, 2028
<u>LEVOLEUCOVORIN - KHAPZORY</u>						
N 211226 001	11541012	Mar 25, 2039	DP			
<u>LEVOLEUCOVORIN - KHAPZORY</u>						
N 211226 002	11541012	Mar 25, 2039	DP			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001	11571328	Sep 07, 2040	DP			
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001	11534395	Jan 26, 2036	DP		U-2764	
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	>A> 11596599	May 03, 2033			U-2985	
<u>LUMASIRAN SODIUM - OXLUMO</u>						
N 214103 001					>A> ODE-415	Oct 06, 2029
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	>A> 9907794	May 26, 2026	DP			
	>A> 9907794*PED	Nov 26, 2026				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	>A> 9907794	May 26, 2026	DP			
	>A> 9907794*PED	Nov 26, 2026				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	>A> 9907794	May 26, 2026	DP			
	>A> 9907794*PED	Nov 26, 2026				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	>A> 9907794	May 26, 2026	DP			
	>A> 9907794*PED	Nov 26, 2026				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	>A> 9907794	May 26, 2026	DP			
	>A> 9907794*PED	Nov 26, 2026				
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001					ODE-388	Nov 23, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998	001				ODE-398	Apr 28, 2029
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998	002				ODE-398	Apr 28, 2029
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998	003				ODE-398	Apr 28, 2029
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998	004				ODE-398	Apr 28, 2029
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196	001				ODE-392	Feb 17, 2029
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196	002				ODE-392	Feb 17, 2029
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196	003				ODE-392	Feb 17, 2029
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296	001	>A> 11590095	Mar 18, 2036	U-1384		
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787	001	>A> 11590286	Dec 12, 2026	DP		
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862	001	>A> 11590286	Dec 12, 2026	DP		
<u>NALOXONE HYDROCHLORIDE - ZIMHI</u>						
N 212854	001	11571518	Jun 14, 2041	DP U-3515		
		11571518	Jun 14, 2041	DP U-3516		
		11571518	Jun 14, 2041	DP U-3517		
<u>NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE (AUTOINJECTOR)</u>						
N 215457	001	>A> 11590286	Dec 12, 2026	DP		
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718	001	11559523	Nov 18, 2030	DP U-3522		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734	002	11547758	Apr 18, 2027	U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734	003	11547758	Apr 18, 2027	U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734	004	11547758	Apr 18, 2027	U-1029		
<u>NIMODIPINE - NYMALIZE</u>						
N 203340	002	11517563	Apr 16, 2038	DP	Y	
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860	001	11511252	Sep 21, 2029	DP		
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628	001	>A> 11602508	Jan 30, 2038	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628	002	>A> 11602508	Jan 30, 2038	DP		
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628	003	>A> 11602508	Jan 30, 2038	DP		
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498	001	>A> 11583539	Nov 12, 2041		U-3186	
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498	002	>A> 11583539	Nov 12, 2041		U-3186	
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498	003	>A> 11583539	Nov 12, 2041		U-3186	
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498	004	>A> 11583539	Nov 12, 2041		U-3186	
<u>OLUTASIDENIB - REZLIDHIA</u>						
N 215814	001				NCE >A> ODE-413	Dec 01, 2027 Dec 01, 2029
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816	001	>A> 7553828	Jun 02, 2024	DS		
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817	001	>A> 7553828	Jun 02, 2024	DS		
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718	001	>A> 11091430	Apr 20, 2029		U-3552	>A> NCE
		>A> 8124799	Dec 03, 2029	DS		Feb 28, 2028
		>A> 8440854	Apr 20, 2029	DP		
		>A> 8993640	Apr 24, 2033	DS DP		
		>A> 9670147	Apr 20, 2029	DS		
		>A> 9701709	Apr 24, 2033	DS DP		
<u>PACRITINIB CITRATE - VONJO</u>						
N 208712	001				ODE-397	Feb 28, 2029
<u>PAFOLACIANINE SODIUM - CYTALUX</u>						
N 214907	001				I-905 ODE-390	Dec 16, 2025 Nov 29, 2028
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014	001				>A> M-288	Feb 08, 2026
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171	001	>A> 10035822	Nov 15, 2033	DS	>A> NCE	May 14, 2026
		>A> 10125171	Aug 02, 2033	DS	>A> NP	Feb 22, 2026
		>A> 10875893	Nov 15, 2033	DS	U-3540	
		>A> 11292815	Nov 15, 2033	DS DP	U-3540	
		>A> 7888323	Dec 04, 2027	DS		
		>A> 7989589	Dec 04, 2027	DS		
		>A> 8168584	Apr 07, 2027		U-3540	
		>A> 8168584	Apr 07, 2027		U-3542	
		>A> 9056076	Oct 25, 2026		U-3540	
		>A> 9169307	Nov 18, 2027	DS	U-3541	
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736	001				>A> ODE-404	Aug 26, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736	002				>A> ODE-404	Aug 26, 2029
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736	003				>A> ODE-404	Aug 26, 2029
<u>PHENOBARBITAL SODIUM - SEZABY</u>						
N 215910	001				>A> ODE-414	Nov 17, 2029
<u>PHENTOLAMINE MESYLATE - CRAVERSE</u>						
N 022159	001	7229630	Jul 31, 2023	DP		
		7575757	Jul 31, 2023	DP		
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
A 216496	001				CGT	Jul 17, 2023
<u>PHENYLEPHRINE HYDROCHLORIDE - IMPHENTIV</u>						
N 203826	004	>A> 11213480	Sep 26, 2036	DP		
		>A> 11471400	Aug 05, 2036	DP		
<u>PHENYLEPHRINE HYDROCHLORIDE - IMPHENTIV</u>						
N 203826	005	>A> 11213480	Sep 26, 2036	DP		
		>A> 11471400	Aug 05, 2036	DP		
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059	001	10342780	Dec 16, 2036	DS DP	>A> NCE	Jan 27, 2028
		10464905	Dec 16, 2036	U-3518	>A> ODE-424	Jan 27, 2030
		10695323	Dec 16, 2036	DS DP U-3518		
		10918622	Dec 16, 2036	U-3518		
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059	002	10342780	Dec 16, 2036	DS DP	>A> NCE	Jan 27, 2028
		10464905	Dec 16, 2036	U-3518	>A> ODE-424	Jan 27, 2030
		10695323	Dec 16, 2036	DS DP U-3518		
		10918622	Dec 16, 2036	U-3518		
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145	001	>A> 8771733	Jun 02, 2030	DS DP U-257		
		>A> 8852632	Jan 28, 2028	DS DP U-257		
<u>RALTEGRAVIR POTASSIUM - ISENTRESS HD</u>						
N 022145	002	>A> 8771733	Jun 02, 2030	DS DP U-257		
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045	002	>A> 8771733	Jun 02, 2030	DS DP U-257		
<u>RELUGOLIX - ORGOVYX</u>						
N 214621	001	>A> 11583526	Sep 29, 2037	U-3020		
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361	002	11564912	Feb 26, 2029	U-3511		
		11564912	Feb 26, 2029	U-3512		
<u>RIPRETINIB - QINLOCK</u>						
N 213973	001	11529336	Aug 12, 2040	U-3382		
		11534432	Aug 12, 2040	U-3442		
		11576903	Dec 30, 2040	DP		
		11576904	Aug 12, 2040	U-3537		
		>A> 11612591	Dec 30, 2040	DP		
<u>RISDIPLAM - EVRYSDI</u>						
N 213535	001	11534444	Oct 04, 2038	U-1943	ODE-400	May 27, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RYKINDO</u>						
N 212849 001	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
<u>RISPERIDONE - RYKINDO</u>						
N 212849 002	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
<u>RISPERIDONE - RYKINDO</u>						
N 212849 003	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
<u>RISPERIDONE - RYKINDO</u>						
N 212849 004	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001					M-285 PED	Dec 19, 2025 Jun 19, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002					M-285 PED	Dec 19, 2025 Jun 19, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003					M-285 PED	Dec 19, 2025 Jun 19, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004					M-285 PED	Dec 19, 2025 Jun 19, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005					M-285 PED	Dec 19, 2025 Jun 19, 2026
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	11510923	Sep 04, 2040	U-3505			
	11571425	May 20, 2031	DP			
	>A> 11590136	May 20, 2031	U-3229			
	>A> 11590136	May 20, 2031	U-3404			
	>A> 11590137	Sep 04, 2040	U-3505			
	>A> 11590138	Jun 10, 2040	U-3551			
	>A> 11602536	May 05, 2041	U-3550			
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	>A> 11602522	Sep 04, 2035	DP U-3169			
	>A> 11602522	Sep 04, 2035	DP U-3302			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001					>A> ODE-409 >A> ODE-412	Sep 21, 2029 Sep 21, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMO</u>						
N 213246	002				>A> ODE-409 >A> ODE-412	Sep 21, 2029 Sep 21, 2029
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756	001	>A> 7425637	Mar 13, 2024	DS		
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756	002	>A> 7425637	Mar 13, 2024	DS		
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256	001				NPP	Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256	002				NPP	Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256	003				NPP	Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256	004				NPP	Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256	005				NPP	Dec 23, 2025
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793	001				ODE-402	Jun 16, 2029
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845	001				M-287	Jan 31, 2026
<u>SIROLIMUS - FYARRO</u>						
N 213312	001				ODE-386	Nov 22, 2028
<u>SIROLIMUS - HYFTOR</u>						
N 213478	001				ODE-391	Mar 22, 2029
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860	001	11154521	Oct 17, 2036	DP		
		11202767	Oct 17, 2036		U-3502	
		11433041	Oct 17, 2036	DP		
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860	002	11154521	Oct 17, 2036	DP		
		11202767	Oct 17, 2036		U-3502	
		11433041	Oct 17, 2036	DP		
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860	003	11154521	Oct 17, 2036	DP		
		11202767	Oct 17, 2036		U-3502	
		11433041	Oct 17, 2036	DP		
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860	004	11154521	Oct 17, 2036	DP		
		11202767	Oct 17, 2036		U-3502	
		11433041	Oct 17, 2036	DP		
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860	005	11154521	Oct 17, 2036	DP		
		11202767	Oct 17, 2036		U-3502	
		11433041	Oct 17, 2036	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860 006	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYL BUTYRATE; TAURURSODIOL - RELYVRIO</u>						
N 216660 001	11583542	Jul 27, 2040	DP		>A> ODE-411	Sep 29, 2029
<u>SODIUM THIOSULFATE - PEDMARK</u>						
N 212937 001					ODE-384	Sep 20, 2029
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	11160779	Mar 19, 2040	U-3521			
	>A> 11439597	Sep 05, 2037	DP			
	11560354	Mar 06, 2039	DP U-3520			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	11160779	Mar 19, 2040	U-3521			
	>A> 11439597	Sep 05, 2037	DP			
	11560354	Mar 06, 2039	DP U-3520			
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001	>A> 10512620	Aug 18, 2038	U-2769			
	>A> 10512620	Aug 18, 2038	U-3547			
	>A> 10799138	Apr 05, 2039	U-3125			
	>A> 10799138	Apr 05, 2039	U-3549			
	>A> 11583216	Aug 21, 2039	U-3549			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 002	10519146	May 21, 2038	DS DP			
	11236091	May 20, 2040	DS DP U-3306			
	11426404	Aug 11, 2040	U-3306			
<u>SPARSENTAN - FILSPARI</u>						
N 216403 001	>A> 9993461	Mar 29, 2030	U-3269		>A> NCE >A> ODE-389	Feb 17, 2028 Feb 17, 2030
<u>SPARSENTAN - FILSPARI</u>						
N 216403 002	>A> 9993461	Mar 29, 2030	U-3269		>A> NCE >A> ODE-389	Feb 17, 2028 Feb 17, 2030
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709 001					>A> ODE-403	Jul 14, 2029
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709 002					>A> ODE-403	Jul 14, 2029
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223 001					>A> ODE-403	Jul 14, 2029
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223 002					>A> ODE-403	Jul 14, 2029
<u>TAPINAROF - VTAMA</u>						
N 215272 001	>A> 11590088	Nov 13, 2039	U-2625			
	>A> 11597692	Nov 13, 2038	DS DP			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	11566011	Feb 12, 2035	DS DP			
<u>TASIMELTEON - HETLIOZ LO</u>						
N 214517 001	11566011	Feb 12, 2035	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	>A> 8410088	Jan 23, 2034	DS DP			
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209549 001					>A> PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209549 002					>A> PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209601 001					>A> PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209601 002					>A> PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209613 001					>A> PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209613 002					>A> PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209663 001					>A> PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209663 002					>A> PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209668 001					>A> PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209668 002					>A> PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209690 001					>A> PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209690 002					>A> PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209700 001					>A> PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209700 002					>A> PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209710 001					>A> PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209710 002					>A> PC	Sep 08, 2023
<u>TERLIPRESSIN ACETATE - TERLIVAZ</u>						
N 022231 001					>A> ODE-406	Sep 14, 2029
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	11564933	Apr 12, 2039	U-1103			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	11564933	Apr 12, 2039	U-1103			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	11564933	Apr 12, 2039	U-1103			
<u>TESTOSTERONE UNDECANOATE - TLANDO</u>						
N 208088 001	11559530	Nov 28, 2037	U-1500			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	6821987	Apr 26, 2024	DS DP U-3100			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987	Apr 26, 2024	DS DP U-3100			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034			ODE-148	Jun 22, 2024
	7378423	May 29, 2027	DS DP		ODE-182	Apr 30, 2025
	7378423*PED	Nov 29, 2027			ODE-183	May 04, 2025
	8580304	Jan 28, 2032	DP		PED	Dec 22, 2024
	8580304*PED	Jul 28, 2032			PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-1712		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2020		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034			ODE-148	Jun 22, 2024
	7378423	May 29, 2027	DS DP		ODE-182	Apr 30, 2025
	7378423*PED	Nov 29, 2027			ODE-183	May 04, 2025
	8580304	Jan 28, 2032	DP		PED	Dec 22, 2024
	8580304*PED	Jul 28, 2032			PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-1712		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2020		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	9399021*PED	Jul 28, 2032				
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034			ODE-148	Jun 22, 2024
	7378423	May 29, 2027	DS DP		ODE-182	Apr 30, 2025
	7378423*PED	Nov 29, 2027			ODE-183	May 04, 2025
	8580304	Jan 28, 2032	DP		PED	Dec 22, 2024
	8580304*PED	Jul 28, 2032			PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-1712		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2020		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
<u>TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR</u>						
N 215760 001					ODE-401	Apr 28, 2029
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	11529352	Jul 23, 2039	U-3504			
<u>TROFINETIDE - DAYBUE</u>						
N 217026 001	>A> 11370755	Aug 03, 2040	DS DP		>A> NCE	Mar 10, 2028
	>A> 9212204	Jan 27, 2032	U-3556			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	11207324	Apr 27, 2038	U-3510		I-906	Jan 19, 2026
					>A> ODE-422	Jan 19, 2030
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	11207324	Apr 27, 2038	U-3510		I-906	Jan 19, 2026
					>A> ODE-422	Jan 19, 2030
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	11524964	Oct 17, 2036	U-3371			
	11535624	Oct 17, 2036	U-3255			
	11535625	Oct 17, 2036	U-3298			
<u>UPADACITINIB - RINVOO</u>						
N 211675 002	11535626	Oct 17, 2036	U-3298			
<u>VANCOMYCIN - VANCOMYCIN</u>						
N 213895 001	>A> 11517609	Nov 06, 2035	U-282			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	>A> 11590128	Sep 06, 2033	U-3548			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	>A> 11590128	Sep 06, 2033	U-3548			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	>A> 11590128	Sep 06, 2033	U-3548			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001					ODE-387	Nov 19, 2028
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002					ODE-387	Nov 19, 2028
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003					ODE-387	Nov 19, 2028
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001					ODE-394	Dec 17, 2028
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 002					ODE-394	Dec 17, 2028
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001					ODE-394	Dec 17, 2028
<u>VUTRISIRAN SODIUM - AMVUTTRA</u>						
N 215515 001					>A> ODE-212	Jun 13, 2029
<u>XENON XE-129 HYPERPOLARIZED - XENOVUE</u>						
N 214375 001	10583205	Feb 20, 2035	DP		NCE	Dec 23, 2027
	11052161	Dec 29, 2035	DP			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	U-1745		I-817	Jan 19, 2026
	10570139	Apr 22, 2034	U-2145		>A> ODE-274	Jan 19, 2030
	10570139	Apr 22, 2034	U-2537			
	10570139	Apr 22, 2034	U-2666			
	10570139	Apr 22, 2034	U-3063			
	10570139	Apr 22, 2034	U-3486			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
	11591340	Aug 15, 2037	U-1745			
	11591340	Aug 15, 2037	U-2145			
	11591340	Aug 15, 2037	U-2537			
	11591340	Aug 15, 2037	U-2666			
	11591340	Aug 15, 2037	U-3063			
	11591340	Aug 15, 2037	U-3486			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
<u>ZAVEGEPANT HYDROCHLORIDE - ZAVZPRET</u>						
N 216386 001	>A> 7220862	Jan 21, 2024	DS DP			
	>A> 7314883	Dec 05, 2023			U-3555	
	>A> 8481546	Oct 07, 2031	DS DP		U-3555	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZINC SULFATE MONOHYDRATE - ZINC SULFATE</u> A 216145 001					CGT	Aug 14, 2023

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 43rd Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm